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Novel quaternary pyridinium compounds useful in inhibit-
ing acetylcholinesterase in mammals of the general struc-
ture: 
and 
or pharmaceutically acceptable salts thereof, where R, is 
pentafluorophenyl. phenyl monosubstituted with K. phenyl 
disubstituted with K. phenyl trisubstituted with K. or naph-
thyl; ~ is H. C1~ alkyl. phenyl. pentafluorophenyl, phenyl 
mono. di, or trisubstituted with K. C1~ alkyl with an 
attached phenyl group. C1~ alkyl with an attached phenyl 
group mono. di, or trisubstituted with K; K is halogen. 
COOH. OH. CN. N02 • NH2• C1~ alkyl, C1~ fluorinated 
alkyl, C1~ alkoxy. C1~ alkylamine. C1~ alkyl--0-CO-. 
C1~ alkyl-CO-NH-. C1~ alkyl-NH-CO-NH-. 
C1~ alkyl-NH-CO-O-. C1~ alkyl-NH-CO-, or 
(C1~ alkylhN-CO-; Xis OH. C1~ alkyl-NH-C0-
0-. (C1~ alkylh-N-CO-O-, C1~ fluoroalkyl-
NH-CO-. or (C1~ fluoroalkyl)2-NH-CO-O-; and 
B is H or C1~ alkyl. 
1 Claim, No Drawings 
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1 
PYRIDINIUM COMPOUNDS 
This is a divisional of copending application Ser. No. 
08/193,217 filed on Feb. 8. 1994. 
2 
herein by reference). The negative charge on this mono ester 
repels nucleophiles which are required to dephosphonylate 
the enzyme. 
Other approaches to OP antidotes have dealt with changes 
STATEMENT OF GOVERNMENT INTEREST 
This invention was made with Government support under 
Contract No. DAMD17-85-C-5143 awarded by the U.S. 
Anny Medical Research and Development Command. The 
Government has certain rights in the invention. 
5 in the heteroaromatic ring system in order to improve the 
reactivation of OP-inhibited acetylcholinesterase (Bedford. 
C. D .• Harris. R. N .• ill. Howd. R. A., Goff. D. A .• Koolpe. 
G. A.. Petesch. M.. Koplovitz. L. Sultan. W. E.. and 
Musallam. H. A., J. Med. Chem. 1989, 32. 504; Bedford. C. 
10 D .• Harris, R. N .. Howd, R. A., Goff. D. A .• Koolpe. G. A.. Petesob. M .• Miller. A.. Nolen. H. W .• fil Musallam.. H. A.. 
Pick. R. 0 .. Jones. D. E., Koplovitz. L. and Sultan. W. E .• J. 
Med. Chem. 1989, 32.493; Benschop, H.P .. Van der Berg. G. 
R., Van der Hooidonk. C .. Delong. L. P. A.. Kientz. C. E .• 
Berends. F .• Kepner, L. A.. Meeter. E .. and Visser. R. P. L. 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
15 S., J. Med. Chem. 1979. 22. 1306; Grifantini, M .• Martelli. This invention relates to a novel class of quaternary pyridinium compounds useful for selectively inhibiting ace-
tylcholinesterase (ACHE) and to their use as nerve agent 
antidotes and prophylactics. We have found that certain 
quaternary pyridinium derivatives can offer in vivo protec-
tion against the nerve agents Soman (GD) and Tabun (CA) 20 
and therefore they can also offer protection against other 
organophophate poisons. We have also found that certain 
quaternary pyridinium derivatives can effectively increase 
the rate of survival of experimental animals exposed to the 
nerve agents GD and GA and therefore they can also serve 25 
as antidotes against other organophosphate poisons. All of 
the active pyridinium compounds are good ACHE inhibitors 
S .• and Stein. M. L.. J. Med. Chem. 1973. 16, 937. incor-
porated herein by reference). 
OCII=NOH 
CJ- I 
CH3 
2-PAM Chloride 
ID-6 
in vitro and therefore they can also be used to treat condi-
tions where a cholinergic deficit leading to pathology can be 
ameliorated by administration of an anticholinesterase 30 
agent. All of the pyridinium compounds described herein 
can have additional beneficial effects in living organisms by 
virtue of their resemblance to the natural neurotransmitter 
acetylcholine and their ability to act on cholinergic recep-
tors. We have also found that the pyridinium compounds can Since it is difficult to reactivate aged phosphonylated 
be used to treat Alzheimer's disease (senile dementia). 35 AChe. prophylactic treatment with AChe inhibitors may be 
presenile dementia of the Alzheimer's type. Korsakoffs the preferred alternative. AChe is protected from nerve 
agents by preadministration of an AChe carbamylating agent 
syndrome (psychosis). age-related memory impairment, h "d u· · h u· · Th arb te 
multi 'nf d · p .ki · d . D , sue as pyn os gmme or p ysos gmme. ese c ama s 
-1 arct ementla, ar n~oman em~ntia, own. s react covalently with AChe at the active site serine, but the 
syn~o!11e· and postraumatlc dementia (dementia 40 carbamylated enzyme is hydrolyzed quickly to active 
pugilistica). enzyme (30 min.) while phosphonylated AChe requires 
2. Description of the Related Art several hours or days for regeneration of active AChe (Main. 
Development of an effective antidote to organophospho- A. R.. vide supra). Bloc.king ACHE for a short period of time 
rus (OP) nerve agents has been a goal of medicinal chemists allows destruction of the OP agent by uncatalyzed hydroly-
since the development of Tabun in Germany in 1937. OP 4S sis or reaction with enzymes such as carboxylesterase or 
agents react covalently with the active site serine hydroxyl pseudocholine~teras_e (Harris. L. W.: Stitcher, D. L.._ and 
group of acetylcholinesterase (AChE) to form a stable Heyl. W. C .. Life Sci. 1980. 26. 188;>. ~corporated her~m by 
phosphonylesterwhichrequiresupto30daysforhydrolysis reference). Unfortunately. physostigmme 1s very ~oxi~ an.d 
(Main. A. R. In Biology of Cholinergic Function; Goldberg. small doses can be leth:U. Furthermore. physostigmme 1s 
A. M .• Hanin. L, Eds.· Raven Press: New York. 1976' pp. 50 unstable and would rapidly_ decompose m the ~ttlefi~d. 
. ' . ' Both carbamates are effective only when combmed with 
269-353. mcorporated herem by reference). Excess acetyl- eral th dru (H 1 w C H · L w d Sti'tch h 1. 1 d 1 . al sev o er gs ey • . .. ams. . .• an er. ~ o me accu~u ates an ~auses severe neuro og1c D. L.. Drug Chem. Toxicol. 1980. 3. 319. incorporated 
imbalance. resprra~ory par~ys1s. and dea~ (Koelle. G. B. In herein by reference). 
The P?annacologica~ Basis ~f Th:rapeutics; Goo~. L., Other approaches to prophylaxis against OP poisoning 
'."°d Gilman. A .• ~·· MacMillan. New~~~ 1975, P· ~04. ss have involved the use of cyclic organophosphates to tem-
mcorporated herem by reference). pyndimum aldoximes porarily block AChE (Ashani. Y., Leader. H .• Raveh. L.. 
~2-P~ an~ Ill-?· see structures.below) are. currentl~ used Bruckstein. R. and Spiegelstein. M .• J. Med. Chem. 1983. 
10 conjunction with an acetylcholine antagomst (atropme) to 26. 145. incorporated herein by reference). reduction of 
reactivate the phosphonylated serine hydroxyl group of AChE levels by inhibition of choline acetyl transferase 
AChE after poisoning occurs (Leadbeater, L., Inns, R. H.. 60 (Gray. A. P .• Platz, R. D .• Henderson. T. R.. Chang, T. C. P .. 
and Rylands. J. M. Fund. App. Toxicol. 1985, 5. S225. Takahashi. K. and Dretchen. K. L .• J. Med. Chem. 1988. 31. 
incmporated herein by reference). This treatment is ineffec- 807, incorporated herein by reference). and the use of 
tive against GD and GA because theinitially formed enzyme antimuscarinic a-adrenergic agonists (e.g.. clonidine) to 
bound alkyl phosphonate esters undergo rapid aging with block the release of acetylcholine from presynaptic nerve 
loss of the alkoxy side chain to form a negatively charged 6S terminals (Buccafusco. J. J. and Aronstam. R. S .• J. Phar-
phosphonyl mono ester (Wolthuis. 0. L.. Berends, F., and macol. Exp. Ther. 1986. 239. 43. incorporated herein by 
Meeter. E .• Fund. Appl. Toxicol. 1981. 1. 183, incorporated reference). 
5,726,314 
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Many oxime, semicarbazone. hydrazone and acyl hydra-
z one derivatives of 2-formyl-3-hydroxy- l-
methylpyridinium chloride described herein incorporate 
both a nucleophile to displace the phosphonate from the 
serine hydroxyl group of AChE and an additional hydrogen 5 
bonding group (hydroxyl) to neutralize the negative charge 
on the aged phosphonate mono ester. In addition. the parent 
3-hydroxypyridinium derivatives were converted into vari-
ous carbamates since these are pyridostigmine analogs and 
can react covalently with AChE and thus provide protection 1o 
from OP agents. 
Treatment of dementing illnesses such as Alzheimer's 
Disease (AD) represents a significant clinical challenge. 
While several palliative treatments have been attempted, 
pharmacological interventions which enhance central cho- 15 
linergic neurotransmission have often provided limited ben-
eficial effects. However. serious limitations with regard to 
long-term therapy with cholinergic agonists include narrow 
therapeutic windows. tolerance to the beneficial effects. 
severe side effects and unpredictable patient response to 20 
standard dosing regimens. Consequently, there is consider-
able interest in the development of new therapeutic agents 
With greater efficacy and improved selectivity. One 
approach which has proven successful is the development of 
novel compounds based upon the results from studies 25 
employing known pharmacological agents or combinations 
4 
be associated with, or located on, cholinergic fibers project-
ing to the cortical regions which are involved in AD. 
Unfortunately, nicotine, which is an extremely toxic 
substance, is one of the few agonists of the neuronal 
nicotinic receptor that produces central actions following 
peripheral administration. In order to pharmacologically 
exploit central nicotinic receptors it will be necessary to 
develop new centrally acting nicotinic agonists with less 
side effects and toxicity than nicotine. 
A superior approach might be to combine the pharmaco-
logical properties of central AChE inhibition with nicotinic 
receptor activation. In addition to providing two potential 
cognitive enhancing mechanisms to target, the presynaptic 
down-regulation (reduced transmitter release) produced dur-
ing chronic esterase inhibition might be avoided through 
stimulation of nicotinic receptors located on nerve endings 
which normally enhance acetylcholine release. To this end, 
we have synthesized pyridinium compounds, compounds 
designed primarily as specific inhibitors of AChE. These 
compounds are different from other previous centrally-
acting AChE inhibitors used to treat Alzheimer's patients in 
that the molecule retains a permanent positive charge and 
therefore, may exhibit the ability to directly stimulate cho-
linergic receptors as well as inhibit the esterase. The ability 
of these compounds to cross the blood-brain barrier is due to 
their enhanced hydrophobicity. In this invention, we show 
that it is possible to develop centrally-acting drags with 
permanent positive charges. Such compounds exlubit the 
ability to both inhibit cholinesterase and stimulate nicotinic 
of agents. From a therapeutic standpoint, it would be best if 
the same molecule could target multiple sites or act through 
multiple mechanisms. Part of the basis for these concepts 
derives from the nature of the disease itself. 
Post mortem studies of AD have demonstrated a loss of 
markers specific for brain cholinergic neurons. While the 
30 (and/or muscarinic) receptors in the central nervous system. 
BRIEF DESCR1PTION OF THE F1GURES 
cholinergic loss in AD has a clear basis in the known F1G. 1 is a graph showing the effect of of MHP-133 ( 4b) 
amnestic actions of cholinergic (muscarinic) antagonists, it on DMTS performance as a function of dose. Data are 
is known that several other neurotransmitters and related 35 presented for Long (upper panel) and Medium (lower panel) 
growth factors may also be affected. For example, evidence delay intervals. Each value represents mean+S.E.M. from 5 
has been accumulating from a number of studies supporting monkeys. The numbers in the upper panel indicate the 
the existence of functional nicotinic receptors in the brain. numbers of animals contributing data within the doses 
Of recent interest has been its role in normal and pathologic bracketed by the vertical axes. 
cognitive processing. Post mortem brain tissue receptor 40 F1G. 2 is a graph showing the effect of ofMHP-133 (4b) 
binding studies in AD have demonstrated significant abnor-
on DMTS performance as a function of dose. Data are 
malities of the nicotinic cholinergic system. The nucleus presented for Long (filled bars) and Medium (open bars) 
basalis, located in the ventromedial corner of the globus delay intervals. Each value represents mean+S.E.M. from 11 
pallidus, is part of the basal forebrain cholinergic system 45 monkeys. The * indicates a significant increase (P<0/05) 
which provides the major source of extrinsic cholinergic with regard to control (vehicle) performance levels. 
input to the frontal cortex. and is known to be involved in 
neuronal processes mediating cognitive function and inte- F1G. 3 is a graph showing the effect of of MHP-133 ( 4b) 
gration at the highest level. Interestingly, this region is on DMTS performance in 11 monkeys as a function of delay 
known to undergo extensive degeneration in AD. While the interval. "Best Dose" refers to that dose selected (between 
functional role of such nicotinic receptors is unknown. one 50 30-100 µg/kg. inclusive) for each individual animal which 
possibility is that they may serve as a positive feedback provided the best overall (all delays combined) improve-
mechanism for acetylcholine release. using the prototype ment in performance. The * indicates a significant increase 
agonists nicotine. it has been demonstrated that stimulation (P<0/05) with regard to control (vehicle) performance lev-
of central nicotinic receptors produces a significant and els. 
reliable increase in performance of the automated delayed 55 F1G. 4 is a graph showing the effect of 3 doses of of 
matching-to-sample (DMTS) task by both young and aged MHP-133 (4b) on the perfonnance in 4 trials of the Morris 
monkeys (Buccafusco, J. J. and Jackson, W. J .. Beneficial Water Maze task by young mature rats. Each point repre-
effects of nicotine administered prior to a delayed matching- sents the mean+S.E.M. from 10 rats. Latency indicates the 
to-sample task in young and aged monkeys, Neurobiol. time interval between placing the rat in the maze and his 
Aging 12:233-238 (1991)). More recently one of the inven- 60 locating the hidden platform. The * indicates a significant 
tors has demonstrated that muscarinic receptors mediate the decrease (P<0/05) with regard to control (vehicle) latencies. 
enhanced DMTS performance, reflecting the acetylcholine 
releasing action of nicotine (Terry, A. V., Buccafusco, J. J. 
and Jackson, W. J .. Scopolamine reversal of nicotine 
enhanced delayed matching-to-sample performance in 65 
monkeys. Pharmacol. Biochem. Behav. 45:925-929 ( 1993) ). 
The possibility exists, therefore. that nicotinic receptors may 
DEI'AlLED DESCRIPilON OF THE 
INVENTION 
Aldoxime. hydrazone, semicarbazone and acyl hydrazone 
derivatives of 2-formyl-1-substituted pyridinium com-
pounds are good inhibitors of acetylcholinesterase (ACE) 
5,726,314 
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and can displace a nerve agent from the enzyme active site 
or protect the latter from attack by a nerve agent. Therefore 
these structures can be used as antidotes and prophylactics 
against nerve agents or other organophosphate poisons. 
Furthermore. it is possible that the carbamates act first as 
prophylactics against OP poisoning and that the reaction 
products (3-hydroxy derivatives) act as reactivators of phos-
phonylated AChE (see below). Herein we describe one 
instance of this prophylactic/prodrug concept. 
(XOCONR"R"' 
:.... 
+N CH=Nu 
I 
R' 
Prophylactic 
Nu = nucleophile 
ACbE) 
~OH 
~ ~ 
+N CH=Nu 
I 
R' 
Reactivator 
6 
groups mono, di, or trisubstituted with J, C1-6 alkyl with an 
attached naphtyl group mono, di, or trisubstituted with J, 
wherein J is selected from the group consisting of 
halogen. COOH. OH, CN, N02• NH2• C1-6 alkyl. C1-6 
s alkoxy. C1-6 alkylamine, C1-6 alkyl-0-CO-. C1-6 
alkyl-0-CO-NH-. c,-6 alkyl-NH-CO-NH-. 
C1_6 alkyl-NH-C0-0-. C1-6 alkyl NH-CO-. 
(C1_6alkyl)iN-CO-. 
wherein X is selected from the group consisting of OH. 
10 C1-6 alkyl-NH-C0-0-. (C1-6 alkyl)z-N-C0-0-. C1-6 fluoroalkyl-NH-CO-O-. (C1-6 fluoroalkyl) 
2-NH-CO-O-. 
wherein R1 is selected from the group consisting of C1-6 
alkyl. C1-6 alkyl with an attached phenyl group. C1-6 alkyl 
with two attached phenyl groups. C i-6 alkyl with an attached 
15 phenyl group mono. di. or trisubstituted with K. c,-6 alkyl 
with two attached phenyl groups mono, di, or trisubstituted 
with K. cl-6 alkyl with an attached naphtyl group. cl-6 
alkyl with an attached naphtyl group mono. di. or trisubsti-
tuted with K, C1-6 alkyl-T, 
20 wherein T is selected from the group consisting of for-
mula (I) and formula (Il), 
R' Formula I 
I 
-N+-R" 
25 I 
R'" 
In addition to their AChE inhibitory properties. these 
derivatives can act on cholinergic receptors in the nervous 
system either to mimic or to oppose the effects of the natural 30 
neurotransmitter acetylcholine. Therefore these structures 
can also be used in the treatment of conditions such as 
Fonnula II 
Myasthenia Gravis. Alzheimer's disease (senile dementia), wherein R', R", and R"' are selected from the group 
presenile dementia of the Alzheimer's type, Korsakoffs consisting of H, C1-6 alkyl. C1-6 fluoroalkyl, C1-6 alkyl with 
syndrome (psychosis), age-related memory impairment, 
35 
an attached phenyl group, C1-6 alkyl with an attached phenyl 
multi-infarct dementia, Parkinsonian dementia, Down's group mono. di. or trisubstituted with K. C1-6 fluoroalkyl 
syndrome. and postraumatic dementia (dementia pugilistica) with an attached phenyl group mono, di, or trisubstituted 
where a cholinergic deficit leading to pathology can be with K. 
ameliorated by administration of a cholinomimetic or an wherein K is selected from the group consisting of 
anticholinesterase agent. These structures can also act on the 
40 
halogen. COOH. OH. CN. N02. NH2. C1-6 alkyl. C1-6 
di ul d ih . _.., alkoxy, C1-6 alkylamine. C1-6 alkyl-0-CO-. C 1-6 car ovasc ar system to pro uce an ant ypertens1ve c.uect; alkyl-0-CO-NH-. c
1
-6 alkyl-NH-CO-NH-. 
they can be useful in the treatment of glaucoma; they can c
1
-6 alkyl-NH-CO-O-, c,-6 alkyl NH-CO-, (Ci-6 
enhance bowel tone and motility. alkyl)iN-CO-, 
The novel substituted pyridinium derivatives have the wherein Bis selected from the group consisting of H. C i-6 
following structural formulas: 45 alkyl. 
x~ 
~ ~ N+ CH=NOR1 
I 
z 
and 
~x 
A~ 
B N+ CH=NOR1 
I 
z 
with any counterion to make pharmaceutically acceptable 
salts, wherein 
so 
55 
60 
Z is selected from the group consisting of C1-6 alkyl. C1-6 
alkyl with an attached phenyl group. c,-6 alkyl with an 
attached naphtyl group, c,-6 alkyl with two attached phenyl 65 
groups. c,-6 alkyl with an attached phenyl group mono. di, 
or trisubstituted with J. cl-6 alkyl with two attached phenyl 
Alternatively the novel quaternary pyridinium com-
pounds are represented by the following structural formulas: 
and 
with any counterion to make pharmaceutically acceptable 
salts, wherein 
Yis 0 or S. 
wherein R2 is selected from the group consisting of H. 
C1-6 alkyl. phenyl. C1-6 alkyl with an attached phenyl 
5,726,314 
7 
group, C1-6 alkyl with an attached phenyl group mono, di. 
or trisubstituted with K. C1-6 alkyl with an attached naphtyl 
group. C1-6 alkyl with an attached naphtyl group mono, di, 
or trisubstituted with K. 
wherein R3 is selected from the group consisting of H, 5 
C1-6 alkyl. phenyl. C1-6 alkyl with an attached phenyl 
group. C1-6 alkyl with an attached phenyl group mono, di, 
or trisubstituted with K. 
Alternatively the novel quaternary pyridinium com-
pounds are represented by the following structural formulas: 10 
x~ 
~ Jl If 
N + CH=NNH-C-Ri 
I 
z 
and 
15 
8 
n N + CH=NNRsR.s 
I 
z 
and 
~x 
.A Jl B N + CH=NNRsR.s 
I 
z 
with any counterion to make pharmaceutically acceptable 
salts. wherein 
Rs is selected from the group consisting of C1-6 alkyl, 
phenyl. C1-6 alkyl with an attached phenyl group. C1-6 alkyl ~X1 
.A J... ~ 
B N + CH=NNH-C-Ri 
I 
20 with an attached phenyl group mono. di, or trisubstituted 
with K. C1-6 alkyl with an attached naphtyl group. C1-6 
alkyl with an attached naphtyl group mono, di, or trisubsti-
tuted with K. 
z wherein ~ is selected from the group consisting of H. 
25 C1-6 alkyl, phenyl. C1-6 alkyl with an attached phenyl 
group, C1-6 alkyl-with an attached phenyl group mono. di, 
with any counterion to make pharmaceutically acceptable or trisubstituted with K. 
salts. wherein Alternatively the novel quaternary pyridinium com-
X1 is selected from the group consisting of H. OH. C 1-6 pounds are represented by the following structural formulas: 
alkyl-NH-C0-0-. (C1-6 alkylh-N-C0-0-, 30 
C1-6 fluoroalkyl-NH-CO-O-. (C1-6 fluoroalkylh-
NH-CO-O-, 
wherein R4 is selected from the group consisting of C1-6 
alkyl with a pyridinium ring attached through nitrogen, cl-6 
alkyl with a pyridinium ring attached through nitrogen and 35 
mono. di. or trisubstituted with K. C1-6 alkyl with a quino-
linium ring attached through nitrogen and mono, di, or 
trisubstituted with K. C1-6 alkyl with an isoquinoliniumring 
attached through nitrogen and mono. di, or trisubstituted 
with K. C1-6 alkyl-T, 40 
wherein T is selected from the group consisting of for-
mula en and formula <m. 
R' Fonnula I 
Xu 
;:,... N+ I CH=NOH 
I 
z 
and 
r'Xx 
B ;:,... N+ I CH=NOH 
I 
z 
I 
-N+-R" 
I 
R'" 
45 with any counterion to make pharmaceutically acceptable 
salts. 
Formula II 
50 
wherein R'. R". and R"' are selected from the group 
consisting of H. C1-6 alkyl C1-6 fluoroalkyl. C1-6 alkyl with 55 
an attached phenyl group. C1-6 alkyl with an attached phenyl 
Alternatively the novel quaternary pyridinium com-
pounds are represented by the following structural formula: 
group mono. di, or trisubstituted with K. C 1-6 fluoroalkyl with any counterion to make pharmaceutically acceptable 
with an attached phenyl group mono. di, or trisubstituted salts, wherein 
with K. R, is selected from the group consisting of C1-6 alkyl. 
wherein K is selected from the group consisting of 60 phenyl. C1_ 6 alkyl with an attached phenyl group, C1-6 alkyl 
halogen. COOH, OH. CN. N02 • NH2 • C 1-6 alkyl. C1-6 with an attached phenyl group mono. di. or trisubstituted 
alkoxy, C1-6 alkylamine. C 1-6 alkyl-0-CO-. C1-6 with K. C 1-6 alkyl with an attached naphtyl group. C1-6 
alkyl--0-CO-NH-. C1-6 alkyl-NH-CO-NH-, alkyl with an attached naphtyl group mono. di, or trisubsti-
C1-6 alkyl-NH-CO---O-. C1-6 alkyl NH-CO-. (C1-6 tuted with K. -CO-C1-6 alkyl,-CO-C1-6 alkyl with an alkyl)~-CO-. 65 attached phenyl group mono, di. or trisubstituted with K. 
Alternatively the novel quaternary pyridinium com- wherein R8 is selected from the group consisting of H. 
pounds are represented by the following structural formulas: C l-6 alkyl. phenyl. C1-6 alkyl with an attached phenyl 
5,726,314 
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group. C1-6 alkyl with an attached phenyl group mono. di, 
or trisubstituted with K. 
Alternatively the novel quaternary pyridinium com-
pounds are represented by the following structural formula: 
10 
wherein K is selected from the group consisting of 
halogen, COOH, OH. CN, N02• NH2• C1-6 alkyl. C1-6 
fluorinated alkyl. C1-6 alkoxy. C1-6 alkylamine. C 1-6 
alkyl-0-CO-, C1_ 6 alkyl-0-CO-NH-. C1 _ 6 
5 alkyl-NH-CO-NH-. C1-6 alkyl-NH-CO-O-. 
C1-6 alkyl-NH-CO-. (C1-6 alkyl)2N-CO-. 
wherein Bis selected from the group consisting of H. C i-6 
alkyl. Cl N CH=NOR9 
1+ 
z 
Alternatively the novel quaternary pyridinium com-
10 pounds are represented by the following structural formulas: 
with any counterion to make phannaceutically acceptable 
salts. wherein 
~is selected from the group consisting of C1-6 alkyl with 
an attached phenyl group. C1-6 alkyl with two attached 15 
phenyl groups, C1-6 alkyl with an attached phenyl group 
mono, di. or trisubstituted with K. cl-6 alkyl with two 
attached phenyl groups mono, di, or trisubstituted with K. 
cl-6 alkyl with an attached naphtyl group. cl-6 alkyl with 
an attached naphtyl group mono, di. or trisubstituted with K. 20 
Alternatively the novel quaternary pyridinium com-
pounds are represented by the following structural formulas: 
and any counterion to make pharmaceutically acceptable 
salts. wherein 
Rs is is selected from the group consisting of 
pentafluorophenyl. phenyl monosubstituted with K. phenyl 
disubstituted with K. phenyl trisubstituted with K. and 
naphthyl. 
wherein ~ is selected from the group consisting of H. 
25 C1-6 alkyl. phenyl. pentafluorophenyl. phenyl mono. di. or 
trisubstituted with K. cl-6 alkyl with an attached phenyl 
group, C1-6 alkyl with an attached phenyl group mono, di, 
or trisubstituted with K. 
and 
1llis invention describes a method of treating mammalian 
30 dementia consisting of treating a mammal with a therapeu-
tically effective mount of a compound having the following 
structure: 
and any counterion to make pharmaceutically acceptable 
salts, wherein 
35 
Z is selected from the group consisting of C1-6 alkyl. C l-6 40 
alkyl with an attached phenyl group. C1-6 alkyl with an 
attached naphthyl group. cl-6 alkyl with two attached 
phenyl groups. C1-6 alkyl with an attached phenyl group 
mono. di. or trisubstituted with J. C1-6 alkyl with two 
attached phenyl groups mono. di, or trisubstituted with J, 45 
C1-6 alkyl with an attached naphthyl group mono, di, or 
trisubstituted with J. 
x~ 
~ ..l fi N CH=NNH-C-NRz)t3 
I+ 
z 
and 
~x 
~ ).._ fi 
B N CH=NNH-C-NRz)t3 
I+ 
z 
wherein J is selected from the group consisting of and any counted on to make pharmaceutically acceptable 
halogen. COOH. OH. CN, N02• NH2• C1-6 alkyl. C1-6 salts, wherein 
alkoxy. C l-6 alkylamine, C1-6 alkyl-0-CO-. C l-6 50 Z is selected from the group consisting of C1-6 alkyl. C1-6 
alkyl-0-CO-NH-. C1-6 alkyl-NH-CO-NH-. alkyl with an attached phenyl group, C1-6 alkyl with an 
C1_ 6 alkyl-NH-C0-0-. C1-6 alkyl-NH-CO-. attached naphthyl group. C1-6 alkyl with two attached (C1-6 alkyl)iN-CO-, phenyl groups, C1-6 alkyl with an attached phenyl group 
wherein X is selected from the group consisting of OH. mono, di, or trisubstituted with J, C1-6 alkyl with two 
C1_ 6 alkyl-NH-C0-0-, (C1-6 alkyl)2-N-CO- 55 attached phenyl groups mono, di, or trisubstituted with J, 
0-. C 1 _ 6 tluoroalkyl-NH-C0-0-. (CH 1 _ 6 C1-6 alkyl with an attached naphthyl group mono. di, or 
tluoroalkyl)i-NH-CO-O-, trisubstituted with J, 
Y is 0 or S. wherein J is selected from the group consisting of 
wherein R2 is selected from the group consisting of halogen. COOH. OH. CN, N02, NH2• C1-6 alkyl. C1-6 
pentafluorophenyl. phenyl monosubstituted with K. phenyl 60 alkoxy. C 1-6 alkylamine. C1-6 alkyl-0-CO-. C1-6 
disubstituted with K, phenyl trisubstituted with K. and alkyl-0-CO-NH-, C1-6 alkyl-NH-CO-NH-. 
naphthyl. C1-6 alkyl-NH-CO-O-, C1-6 alkyl-NH-CO-. 
wherein R3 is selected from the group consisting of H. (C1-6 alkyl)iN-CO-. 
C1_ 6 alkyl. phenyl. pentaflorophenyl, phenyl mono. di. or wherein Xis selected from the group consisting of OH. 
trisubstituted with K. C1-6 alkyl with an attached phenyl 65 C1-6 alkyl-NH-C0-0-. (C1-6 alkyl)i-N-CO-
group. C1-6 alkyl with an attached phenyl group mono. di, 0-. C 1 _ 6 fl.uoroalkyl-NH-C0-0-. (C 1 _ 6 
or trisubstituted with K. tluoroalkyl)2-NH-CO-O-. 
5,726,314 
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Yis 0 or S, 
wherein R2 is selected from the group consisting of H, 
C l-6 alkyl, phenyl. pentafiuorophenyl, phenyl mono, di. or 
trisubstituted with K, C1-6 alkyl with an attached phenyl 
group, C1-6 alkyl with an attached phenyl group mono. di, 5 
or trisubstituted with K. C l-6 alkyl with an attached naphthyl 
group, naphthyl. C1-6 alkyl with an attached naphthyl group 
mono, di. or trisubstituted with K. 
wherein R3 is selected from the group consisting of H, 
C1-6 alkyl. phenyl, pentaftuorophenyl. phenyl mono, di, or 10 
trisubstituted with K. C l-6 alkyl with an attached phenyl 
group. C1-6 alkyl with an attached phenyl group mono, di. 
or trisubstituted with K. 
wherein K is selected from the group consisting of 
halogen, COOH, OH, CN, N02• NH2 • C1-6 alkyl. C1-6 15 
fluorinated alkyl, C 1-6 alkoxy, C1-6 alkylamine, C1-6 
alkyl-0-CO-. C 1_6 alkyl-0-CO-NH-, C1_6 
alkyl-NH-CO-NH-, C1_6 alkyl-NH--CO-O-, 
C1-6 alkyl-NH-CO-, (C1-6 alkyl)iN--CO-, 
12 
attached through nitrogen and mono, di, or trisubstituted 
with K. C1-6 alkyl-T. 
wherein T is selected from the group consisting of for-
mula (I) and formula (II). 
R' 
R' 
I+ 
-N-R" 
I 
R'" 
+I~ 
-N ) ~CHW-&. 
Fonnula I 
Formula II 
wherein R', R", and R"' are selected from the group 
consisting of H. C1-6 alkyl, C1-6 fluoroalkyl, C1-6 alkyl with 
an attached phenyl group, C1-6 alkyl with an attached phenyl 
group mono, di, or trisubstituted with K. C1-6 fluoroalkyl 
with an attached phenyl group mono, di, or trisubstituted 
with K. 
whereinB is selected from the group consisting ofH, C1-6 20 
alkyl. 
wherein K is selected from the group consisting of 
halogen, COOH, OH, CN. N02• NH2• C1-6 alkyl, C1-6 
fluorinated alkyl, C1-6 alkoxy, C1-6 alkylamine, C 1-6 
25 
alkyl-0-CO-. C1_6 alkyl-0-CO-NH-, C1_6 
alkyl-NH-CO-NH-. C 1-6 alkyl-NH--CO-O-, 
C1-6 alkyl-NH-CO-. (C1-6 alkyl)iN-CO-, 
This invention also describes a method of treating mam-
malian dementia consisting of treating a mammal with a 
therapeutically effective amount of a compound having the 
following structure: 
x~ 
~ .l If 
N CH=NNH-C-R. 
I+ 
z 
and any counterion to make pharmaceutically acceptable 
salts, wherein 
30 
35 
40 
X 1 is selected from the group consisting of H. OH, C l-6 
alkyl-NH--CO-O-. (C1-6 alkyl)i-N--CO-O-, C1-6 
fluoroalkyl-NH--CO-O-, (C1-6 fluoroalkylh-NH- 45 
CO-O-. 
wherein B is selected from the group consisting of H, C l-6 
alkyl. 
This invention also describes a method of treating mam-
malian dementia consisting of treating a mammal with a 
therapeutically effective mount of a compound having the 
following structure: 
(l ~ 
N CH=NNH-C-NR1Rs 
I+ 
z 
and any counterion to make pharmaceutically acceptable 
salts, wherein 
Y is 0 or S. 
Z is selected from the group consisting of C l-6 alkyl. C l-6 
alkyl with an attached phenyl group, C 1-6 alkyl with an 
attached naphthyl group, C1-6 alkyl with two attached 
Y is 0 or S, phenyl groups, C 1-6 alkyl with an attached phenyl group 
Z is selected from the group consisting of C1-6 alkyl, C1-6 mono, di, or trisubstituted with J, C1-6 alkyl with two 
alkyl with an attached phenyl group. C1-6 alkyl with an attached phenyl groups mono. di, or trisubstituted with J, 
attached naphthyl group, C1-6 alkyl with two attached 50 C1-6 alkyl with an attached naphthyl group mono, di, or 
phenyl groups, C1-6 alkyl with an attached phenyl group trisubstituted with J, 
mono. di, or trisubstituted with J, C l-6 alkyl with two wherein J is selected from the group consisting of 
attached phenyl groups mono, di, or trisubstituted with J. halogen. COOH. OH. CN, N02• NH2 • C1-6 alkyl. C1-6 
C1-6 alkyl with an attached naphthyl group mono, di, or alkoxy, C1-6 alkylamine, C1-6 alkyl-0-CO-, C1-6 
trisubstituted with J. 55 alkyl-0-CO-NH-, C 1-6 alkyl-NH-CO-NH-, 
wherein J is selected from the group consisting of C1-6 alkyl-NH--CO-O-. C1-6 alkyl-NH-CO-, (C1-6 
halogen, COOH. OH. CN. N02, NH2• C1-6 alkyl. C1-6 alkyl)iN--CO-, 
alkoxy, C 1-6 alkylamine, C1-6 alkyl-0--CO-. C1-6 R7 is selected from the group consisting of C1-6 alkyl, 
alkyl-0-CO-NH-, C1-6 alkyl-NH-CO-NH-, phenyl, pentafiuorophenyl. phenyl mono. di. or trisubsti-
C1-6 alkyl-NH--CO-O-. C1-6 alkyl-NH-CO-. (C1-6 60 tuted with K. C1-6 alkyl with an attached phenyl group, C1-6 
alkyl):iN-CO-, alkyl with an attached phenyl group mono, di, or trisubsti-
wherein R.i is selected from the group consisting of C1-6 tuted with K. C1-6 alkyl with an attached naphthyl group, 
alkyl with a pyridiniumring attached through nitrogen, C1-6 naphthyl. C1-6 alkyl with an attached naphthyl group mono. 
alkyl with a pyridinium ring attached through nitrogen and di, or trisubstituted with K. 
mono, di, or trisubstituted with K. C1-6 alkyl with a quino- 65 wherein Rs is selected from the group consisting of H, 
linium ring attached through nitrogen and mono, di. or C1-6 alkyl. phenyl. pentafiuorophenyl. phenyl mono, di, or 
trisubstituted with K. C1-6 alkyl with an isoquinoliniumring trisubstituted with K. C1-6 alkyl with an attached phenyl 
5,726.314 
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group, C1--6 alkyl with an attached phenyl group mono, di, 
or trisubstituted with K. 
14 
0-(p-Ethoxycarbonyl benzyl)-N-(3-hydroxy-l-methyl-2-
pyridinemethylene) hydroxylamine chloride. 
0-(p-Methoxybenzyl)-N-( 1.6-dimethyl-3-hydroxy-2-
pyridinemethylene) hydroxylarnine chloride. 
0-(p-Dimethylarninocarbonyloxy benzyl)-N-(l.6-dimethyl-
3-hydroxy-2-pyridinemethylene) hydroxylamine chlo-
ride. 
wherein K is selected from the group consisting of 
halogen, COOH, OH. CN. N02• NH2• C1--6 alkyl. C1_ 6 
fluorinated alkyl. C1--6 alkoxy, C1--6 alkylamine, Cl-6 5 
alkyl-0-CO-, C1_6 alkyl-0-CO-NH-, C1_ 6 
alkyl-NH-CO-NH-, C1--6 alkyl-NH-CO-O-, 
C1_ 6 alkyl-NH-CO-, (C1--6 alkyl)2N-CO-. 0-(p-Propylaminocarbonyl benzyl)-N-( 1,6-dimethyl-3-
hydroxy-2-pyridinemethylene) hydroxylarnine chloride. 
10 0-Benzyl-N-[3-(N',N'-dimethylcarbamoyl)hydroxy-1-
methyl-2-pyridinemethylene]hydroxylamine chloride 
(2a). 
The following compounds are representative of the inven-
tion: 
0-Benzyl-N-( l-methyl-2-pyridinemethylene) hydroxy-
lamine chloride (la). 
0-( Diphenylmethyl)-N-( 1-methyl-2-pyridinemethylene) 
hydroxylamine chloride. 0-[2-( l-Methyl-1-piperidinium)ethyl]-N-[3-(N' ,N' -dimethy lcarbamoyl)hydroxy-1-meth yl-2-0-(p-Chlorobenzyl)-N-( 1-methyl-2-pyridinemethylene) 
hydroxylamine chloride. 
0-(p-Methoxybenzyl)-N-(l-methyl-2-pyridinemethylene) 
hydroxylamine chloride. 
15 pyridinemethylene ]hydroxylamine dichloride. 
0-( 1-N aphtylmethyl)-N-( 1-methyl-2-pyridinemethylene) 
hydroxylamine chloride. 
0-(2-(Trimethylammonium)ethyl]-N-[3-(N' ,N' -
dimethylc arbamoyl)hydroxy-1-meth yl-2-
pyridinemethylene]hydroxylamine dichloride. 
0-Benzyl-N-[3-(N' ,N' -diethylcarbamoyl)hydroxy- l-
0-(2-Methyl- l-naphtylmethyl)-N-( l-methyl-2-
pyridinemethylene) hydroxylamine chloride. 
20 methyl-2-pyridinemethylene]hydroxylarnine chloride. 
0-Benzyl-N-[3-(N',N'-difluoroethylcarbamoyl)hydroxy-1-
methyl-2-pyridinemethylene]hydroxylarnine chloride. 
0-Diphenylmethyl-N-(3-hydroxy-1-methyl-2-
pyridinemethylene) hydroxylamine iodide. 
0-(2,3 ,4-Trimethoxybenzyl)-N-( l-methyl-2-
pyridinemethylene) hydroxylamine chloride. 
0-(3.3-Diphenylpropyl)-N-( 1-methyl-2-pyridinemethylene) 
hydroxylamine chloride. 
O-Benzyl-N-(3-hydroxy-1-methyl-2-pyridinemethylene) 
hydroxylamine chloride (lb). 
25 0-Benzyl-N-[3-(N' ,N'-dimethylcarbamoyl)hydroxy-1,6-
dimethyl-2-pyridinemethylene ]hydroxylamine chloride. 
O-Benzyl-N-[3-(N',N'-diethylcarbamoyl)hydroxy-1,6-
dimethyl-2-pyridinemethylene]hydroxylarnine chloride. 
0-Benzyl-N-[3-(N' ,N'-difluoroethylcarbamoyl)hydroxy-1. 
0-( l-Naphtylmethyl)-N-(3-hydroxy-l-methyl-2-
pyridinemethylene) hydroxylarnine chloride. 
0-(2-Methyl- 1 -naphtylmethyl)-N-(3-hydroxy- 1 -methyl-
2-pyridinemethylene) hydroxylarnine chloride. 
0-(2,3.4-Trimethoxybenzyl)-N-(3-hydroxy-1-methyl-2-
pyridinemethylene) hydroxylarnine chloride. 
0-(3,3-Diphenylpropyl)-N-(3-hydroxy-1-methyl-2-
pyridinemethylene) hydroxylarnine chloride. 
30 6-dimethyl-2-pyridinemethylene ]hydroxylamine chlo-
ride. 
0-(Diphenylmethyl)-N-[3-(N',N'-dimethylcarbamoyl) 
hydroxy-1-methyl-2-pyridinemethylene ]hydroxylamine 
chloride (2b ). 
0-( 1-N aphtylmethy 1)-N-( l ,6-dimethyl-3-hydroxy-2-
pyridinemethylene) hydroxylamine chloride. 
0-(2-Methyl-1-naphtylmethy 1)-N-( 1,6-dimethyl-3-
hydroxy-2-pyridinemethylene) hydroxylamine chloride. 
35 0-(Diphenylmethyl)-N-[3-(N'-isopropylcarbamoyl) 
hydroxy-1-methyl-2-pyridinemethylene ]hydroxylamine 
chloride. 
O-Methyl-N-(3-hydroxy-1-methyl-2-pyridinemethylene) 40 
hydroxylamine chloride (le). 
0- Meth y 1-N -( 1, 6-dimeth y 1-3 -hydroxy- 2-
pyridinemethylene) hydroxylarnine chloride. 
O-(Diphenylmethyl)-N-[3-(N'-(2-fluoroethyl)carbamoyl] 
hydroxy-1-methyl-2-pyridinemethylene ]hydroxylarnine 
chloride. 
0-(Diphenylmethyl)-N-[3-(N'.N'-dimethylcarbamoyl) 
hydroxy-1,6-dimethyl-2-pyridinemethylene] 
hydroxylarnine chloride. 
0-(Diphenylmethyl)-N-[ l .6-dimethyl-3-(N'-
isopropylcarbamoyl)hydroxy-2-pyridinemethylene] 
hydroxylamine chloride. 
0-(Diphenylmethyl)-N- [3-(N' -(2-fl uoroethyl)carbamoyl] 
hydroxy-1,6-dimethyl-2-pyridinemethylene] 
hydroxylamine chloride. 
50 0-(p-Methoxybenzyl)-N-[3-(N' .N'-dimethylcarbamoyl) 
hydroxy-1-methyl-2-pyridinemethylene ]hydroxylamine 
chloride (2c). 
0-(2-( l-Methyl-1-piperidinium] ethyl]-N-(3-hydroxy-l-
methyl-2-pyridinemethylene) hydroxylamine dichloride. 45 
0-(2-(Trimethylammonium)ethyl]-N-(3-hydroxy-1-methyl-
2-pyridinemethylene) hydroxylarnine dichloride. 
0-(p-Chloro benzyl )-N-(3-hydroxy- l-methyl-2-
pyridinemethylene) hydroxylarnine chloride (ld). 
0-(p-Cyanobenzyl)-N-(3-hydroxy-1-methyl-2-
pyridinemethylene) hydroxylarnine chloride. 
0-(2-Hydroxy-4-nitrobenzyl)-N-(3-hydroxy- l-methyl-2-
pyridinemethylene) hydroxylamine chloride. 
0-(p-Carboxybenzyl)-N -(3-hydroxy- l-methyl-2-
pyridinemethylene) hydroxylarnine chloride. 
0-(p-Chlorobenzyl)-N-( 1.6-dimethyl-3-hydroxy-2-
pyridinemethylene) hydroxylarnine chloride. 
0-(p-Cyanobenzyl)-N-( l ,6-dimethyl-3-hydroxy-2-
pyridinemethylene) hydroxylarnine chloride. 
0-(2-Hydroxy-4-nitrobenzyl)-N-(l,6-dimethyl-3-hydroxy-
2-pyridinemethylene) hydroxylarnine chloride. 
O-(p-Methoxybenzyl)-N-(3-hydroxy- l-methyl-2-
pyridinemethylene) hydroxylarnine chloride (le). 
0-(p-Dimethylaminocarbonyloxy benzyl)-N-(3-hydroxy-l-
methyl-2-pyridinemethylene) hydroxylamine chloride. 
0-(p-Propylaminocarbonyl benzyl)-N-(3-hydroxy-1-
methyl-2-pyridinemethylene) hydroxylamine chloride. 
0-(p-Methoxybenzyl)-N- [3-(N' ,N'-dime thy lcarbamoy l) 
hydroxy-1-ethyl-2-pyridinemethylene ]hydroxylamine 
55 chloride. 
0-(p-Methoxybenzyl)-N-[3-(N' ,N' -dimethylcarbamoyl) 
hydroxy-l-benzyl-2-pyridinemethylene]hydroxylamine 
bromide. 
0-(p-Methoxybenzyl)-N-[3-(N' ,N'-dimethy lcarbamoyl) 
60 hydroxy-1,6-dimethyl-2-pyridinemethylene] 
hydroxylamine chloride. 
0-(p-Methoxybenzyl)-N-[3-(N' ,N' -dimethylcarbamoyl) 
hydroxy-1-ethy 1-6-methy 1-2-pyridinemethylene] 
hydroxylamine chloride. 
65 0-(p-Methoxybenzyl) -N-[3-(N' ,N'-dimethylcarbamoyl) 
hydroxy-1-benzyl-6-methyl-2-pyridinemethylene] 
hydroxylamine bromide. 
5,726.314 
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0-(p-Methoxybenzy 1)-N-[3-(N' .N'-dime thy lcarbamoyl) 0-(p-M ethoxybenzyl)-N-[5-(N' .N' -dimethylcarbamoyl) 
hydroxy-1-( 1-naphtylmethy 1 )-2-pyridinemethy lene] hydroxy-1-benzyl-2-pyridinemethylene ]hydroxylamine 
hydroxylamine chloride. bromide. 
0-(p-Methoxybenzyl)-N-[3-(N'.N'-dimethylcarbamoyl) 0-(p-Methoxybenzyl)-N-[5-(N'.N'-dimethylcarbamoyl) 
h ydrox y-1-( 2-me thyl-1-n aph tylmethyl )-2- 5 hydroxy-1-( 1-naphtylmethyl)-2-pyridinemethylene] 
pyridinemethylene ]hydroxylamine chloride. hydroxylamine chloride. 
0-(p-Methoxybenzyl)-N-[3-(N'.N'-dimethylcarbamoyl) 0-(p-Methoxybenzyl)-N-[5-(N'.N'-dimethylcarbamoyl) 
hydroxy-1-diphenylmethyl-2-pyridinemethylene] h ydroxy-1-( 2-me thy 1-1- naph ty lmeth y 1)-2-
hydroxylamine chloride. pyridinemethylene]hydroxylamine chloride. 
0-(p-Methoxybenzy 1)-N-[ 3-(N' .N' -dimethylcarbamoy 1) 
10 
0-(p-Methoxybenzyl)-N-[5-(N' .N' -dimethylcarbamoyl) 
hydroxy- 1-( 2-hy dr oxy-4-nitro benz yl )-2- hydroxy-1-diphenylmethyl-2-pyridinemethylene] 
pyridinemethylene]hydroxylamine chloride. hydroxylamine chloride. 
0-(p-Methoxybenzyl)-N-[3-(N' .N' -dimethylcarbamoyl) 0-(p-Methoxybenzyl)-N-[ 5-(N' ,N'-dime thy lcarbamoy 1) 
hydroxy-1-(p-carboxy benzyl)-2-pyridinemethylene] h ydroxy-1-( 2-h ydroxy-4-nitro benzyl )-2-
hydroxylamine chloride. pyridinemethylene]hydroxylamine chloride. 
0-(p-Methoxybenzyl)-N-[3-(N'.N'-dimethylcarbamoyl) l5 0-(p-Methoxybenzyl)-N-[5-(N'.N'-dimethylcarbamoyl) 
hydroxy-1-(p-cy anobenzyl )-2-pyridi nemethy lene] hydroxy-1-(p-carboxy benzyl)-2-pyridinemethylene] 
hydroxylamine chloride. hydroxylamine chloride. 
N-[5-(N'.N'-Dimethylcarbamoyl)hydroxy-1-methyl-2- 0-(p-Methoxybenzyl)-N-[5-(N'.N'-dimethylcarbamoyl) 
pyridinemethylene ]hydroxylamine chloride (2d). hydroxy-1-(p-cy anobenzyl)-2-pyridinemethy lene] 
N-[3-(N' .N'-Dimethylcarbamoyl)hydroxy-1-methyl-2- 20 hydroxylamine chloride. 
pyridinemethylene ]hydroxylamine chloride. 0-Benzyl-N-( l-benzyl-3-hydroxy-2-pyridinemethy lene) 
N-[3-(N'.N'-Dimethylcarbamoyl)hydroxy-1,6-dimethyl-2- hydroxylamine bromide. 
pyridinemethylene ]hydroxylamine chloride. 0-Benzyl-N-( 1-benzy 1-5-hydroxy-2-pyridinemethy lene) 
0-( l-Naphtylmethyl)-N-(5-hydroxy-1-methyl-2- hydroxylamine bromide. 
pyridinemethylene) hydroxylamine chloride. 25 2-[[(Aminocarbonyl)hydrazono)methyl]-3-hydroxy-1-
0-(2-Methyl-1-naphtylmethyl)-N-(5-hydroxy-1-methyl-2- methyl pyridinium chloride (3a). 
pyridinemethylene) hydroxylamine chloride. 2-[ [ ( Aminocarbony I )hydrazono ]methyl ]-5-h ydroxy-1-
0-(2.3.4-Trimethoxybenzyl)-N-(5-hydroxy-1-methy l-2- methyl pyridinium chloride. 
pyridinemethylene) hydroxylamine chloride. 2[[ (Aminothiocarbonyl)hydrazono ]methyl)-3-hydroxy-1-
0-(3,3-Dipheny lpropyl)-N-( 5-hydroxy-1-methy l-2- 30 methyl pyridinium chloride. 
pyridinemethylene) hydroxylamine chloride. 2-[[(Aminothiocarbonyl)hydrazono]methyl]-5-hydroxy-1-
0-Methyl-N-(5-hydroxy-1-methyl-2-pyridinemethylene) methyl pyridinium chloride. 
hydroxylamine chloride. 2-Hydrazonomethyl-3-hydroxy-1-methyl pyridinium chlo-
0-(p-Chlorobenzyl)-N-(5-hydroxy-l-methyl-2- ride. 
pyridinemethylene) hydroxylamine chloride. 35 2-Hydrazonomethyl-3-hydroxy-1.6-dimethyl pyridinium 
0-(p-Cyanobenzyl)-N-(5-hydroxy-1-methyl-2- chloride. 
pyridinemethylene) hydroxylamine chloride. 2-Hydrazonomethyl-5-hydroxy-1-methyl pyridinium chlo-
0-(2-Hydroxy-4-nitro benzyl)-N-(5-hydroxy-1-methyl-2- ride. 
pyridinemethylene) hydroxylamine chloride. 1-Methyl-2-(3-hydroxy-1-methyl-2-pyridinemethylene) 
0-(p-Carboxy benzyl)-N-(5-hydroxy-1-methyl-2- 40 hydrazine chloride. 
pyridinemethylene) hydroxylamine chloride. 1-M ethyl-1-phe n yl-2-( 3 -h y droxy-1-meth yl-2-
0-(p-Methoxybenzyl)-N -(5-hydroxy-1-methyl-2- pyridinemethylene) hydrazine chloride. 
pyridinemethylene) hydroxylamine chloride. l, l-Diphenyl-2-(3-hydroxy-1-methyl-2-pyridinemethylene) 
0-(p-Dimethylaminocarbonyloxy benzyl)-N-(5-hydroxy-1- hydrazine chloride. 
methyl-2-pyridinemethylene) hydroxylamine chloride. 45 1-(2 ,4-Dinitrophenyl )-2-( 3-hy droxy-1-meth yl-2-
0-(p-Propylaminocarbonyl benzyl)-N-(5-hydroxy-1- pyridinemethylene) hydrazine chloride. 
methyl-2-pyridinemethylene) hydroxylamine chloride. 1-Naphtyl-2-(3-hydroxy-1-methyl-2-pyridinemethylene) 
0-(p-Ethoxycarbonyl benzyl)-N-(5-hydroxy-1-methyl-2- hydrazine chloride. 
pyridinemethylene) hydroxylamine chloride. 1-Methyl-2-(5-hydroxy-1-methyl-2-pyridinemethylene) 
O-Benzyl-N-[5-(N',N'-dimethylcarbamoyl)hydroxy-1- so hydrazine chloride. 
methyl-2-pyridinemethylene]hydroxylamine chloride. 1-Methyl-1-phenyl-2-(5-hydroxy-1-methyl-2-
0-Benzyl-N-[5-(N' ,N'-diethylcarbamoyl)hydroxy-1- pyridinemethylene) hydrazine chloride. l 1-Diphenyl-2-
methyl-2-pyridinemethylene]hydroxylamine chloride. (5-hydroxy-1-methyl-2-pyridinemethylene) hydrazine 
0-Benzyl-N-[5-(N ,N' -difiuoroethylcarbamoyl)hydroxy-1- chloride. 
methyl-2-pyridinemethylene)hydroxylamine chloride. 55 1-(2.4- Dinitrophenyl)-2-(5-hydroxy-1-methy 1-2-
0-(Diphenylmethyl)-N-[5-(N' -isopropylcarbamoyl) pyridinemethylene) hydrazine chloride. 
hydroxy-1-methyl-2-pyridinemethylene ]hydroxylamine 1-N aphty 1-2-(5-hydroxy-1-methy 1-2-pyridinemethylene) 
chloride. hydrazine chloride. -Methyl-2-( 1.6-dimethyl-3-hydroxy-
0-(Diphenylmethyl)-N-[ 5-[N' -(2-fluoroethyl)carbamoyl] 2-pyridinemethylene) hydrazine chloride. 
hydroxy-1-methyl-2-pyridinemethylene]hydroxylarnine 60 1-Methyl- l-phenyl-2-( l ,6-dimethyl-3-hydroxy-2-
chloride. pyridinemethylene) hydrazine chloride. 
0-(p-Methoxybenzyl)-N-[5-(N'.N'-dimethylcarbamoyl) 1.1-Diphe nyl-2-( 1. 6-dimethyl-3-hydroxy-2-
hydroxy-1-methyl-2-pyridinemethylene ]hydroxylamine pyridinemethylene) hydrazine chloride. 
chloride. 3-Hydroxy-1-methyl-2-[ ( (N-phenylaminocarbonyl) 
0-(p-Methoxybenzyl)-N-[ 5-(N' .N'-dimethylcarbamoyl) 65 hydrazonolmethyl]pyridinium chloride (3b ). 
hydroxy-1-ethyl-2-pyridinemethylene ]hydroxylamine 1.6-Dimethyl-3-hydroxy-2-[ [ (N-pheny laminocarbonyl) 
chloride. hydrazonolmethyl]pyridinium chloride. 
5,726314 
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S-Hydroxy-1-methyl-2-[ [ (N-phenylaminocarbonyl) 
hydrazonolmethyl]pyridinium chloride. 
3-Hydroxy-1-methyl-2-[[(N-phenylaminothiocarbonyl) 
hydrazono ]methyl]pyridinium chloride. 
2-[[(N.N-Diphenylaminocarbonyl)hydrazono]methyl]-3- 5 
hydroxy-1-methyl pyridinium chloride. 
1.6-Dimethyl-3-hydroxy-2-[[(N-phenylaminothiocarbonyl) 
hydrazonolmethyl]pyridinium chloride. 
1.6-Dimethyl-2-[[(N,N-diphenylaminocarbonyl)hydrazono] 
methyl]-3-hydroxy pyridinium chloride. 10 2-[[(N.N-Dimethylaminothiocarbonyl)hydrazono]methyl] 
3-hydroxy-1-methyl pyridinium chloride. 
2-[ [ (N-Ethylaminothiocarbonyl)hydrazono ]methyl]-3-
hydroxy-1-methyl pyridinium chloride. 
3-Hydroxy-1-methyl-2-[[(N-naphtylaminocarbonyl) 
hydrazono]methyl]pyridinium chloride. 15 
2-[[[N-(l-Chloro-2-naphtyl)amino carbonyl]hydrazono] 
methyl]-3-hydroxy-1-methyl pyridinium chloride. 
S-Hydroxy-1-methyl-2-[[(N-phenylaminothiocarbonyl) 
hydrazonolmethyl]pyridinium chloride. 
2- [[ (N .N-Diphenylaminocarbonyl)hydrazono ]methyl]-S- 20 
hydroxy-1-methyl pyridinium chloride. 
2-[ [ (N.N-Dimethylaminothiocarbonyl)hydrazono ]methyl]-
S-hydroxy-1-methyl pyridinium chloride. 
2-[[(N-Ethylaminothiocarbonyl)hydrazono]methyl]-5-
hydroxy-1-methyl pyridinium chloride. 
S-Hydroxy-1-methyl-2-[[(N-naphtylaminocarbonyl) 
hydrazono]methyl]pyridinium chloride. 
25 
2-[ [ [ N-( l-Chloro-2-naphtyl)amino car bony l]hydrazono] 
methyl]-S-hydroxy-1-methyl pyridinium chloride. 
1-Methyl-2-[ [ (N-phenylaminocarbonyl)hydrazono ]methyl] 30 
pyridinium chloride (3d). 
2-[ [ (Aminocarbonyl)hydrazono ]methyl)-3-(N .N-
dimethylcarbamoyl)hydroxy-1-methyl pyridinium chlo-
ride (4a). 
2-[ [ (Aminocarbonyl)hydrazono ]methyl]-3-(N ,N- 35 
dimethylcarbamoyl)hydroxy-1.6-dimethyl pyridinium 
chloride. 
2-[ [(Aminocarbonyl)hydrazono ]methyl]-5-(N ,N-
dimethylcarbamoyl)hydroxy-1-methyl pyridinium chlo-
ride. 
3-(N.N-Dimethylcarbamoyl)hydroxy-l-methyl-2-([(N-
phenylaminocarbonyl) hydrazono]methyl]pyridinium 
chloride (4b). 
40 
S-(N.N-Dimethylcarbamoyl)hydroxy-1-methyl-2-[[(N-
phenylaminocarbonyl) hydrazono ]methyl]pyridinium 45 
chloride. 
2-(3-Hydroxy-1-methyl-2-pyridinemethylene )-1-[2-( 1-
pyridinium)acetyl]hydrazine dichloride (Sa). 
2-(1.6-Dimethyl-3-hydroxy-2-pyridinemethylene)-1-[2-(l-
pyridinium)acetyl]hydrazine dichloride. 
2-(5-Hydroxy-1-methy 1-2-pyridinemethylene )-1-[2-( 1-
pyridinium)acetyl]hydrazine dichloride. 
2-(3-Hydroxy-1-methy 1-2-pyridinemethylene )-1-(2-
(trimethylammonium)acetyl]hydrazine dichloride. 
50 
1-[2-( 4-Chloro-1-pyridinium)acetyl)-2-(3-hydroxy-1- 55 
methyl-2-pyridinemethylene) hydrazine dichloride. 
2-( l ,6-Dimethyl-3-hydroxy-2-pyridinemethylene )-1-[2-
(trimethylammonium)acetyl]hydrazine dichloride. 
18 
2-(3-Hydroxy-1-methyl-2-pyridinemethylene )-1-(2-( 1-
methyl-piperidinium)acetyl]hydrazine dichloride. 
2-(S-Hydroxy-1-methyl-2-pyridinemethylene )-1-[2-
(trimethylammonium)acetyl]hydrazine dichloride. 
1-[2-( 4-Chloro- l-pyridinium)acetyl]-2-( S-hydroxy-1-
methyl-2-pyridinemethylene) hydrazine dichloride. 
1-(2-(3-Carboxy-1-isoquinolinium) acetyl]-2-(S-hydroxy-1-
methyl-2-pyridinemethylene) hydrazine dichloride. 
1-[2-(2-Carboxy-4-methoxy-1-quinolinium)acetyl]-2-(5-
hydroxy-1-methyl-2-pyridinemethylene) hydrazine 
dichloride. 
2-(5-Hydroxy-1-methyl-2-pyridinemethylene )-1-(2-(3-
hydroxy-1-pyridinium)acetyl ]hydrazine dichloride. 
2-(5-Hydroxy-1-methyl-2-pyridinemethylene )-1-[2-( 1-
methyl-1-piperidinium)acetyl ]hydrazine dichloride. 
2-( 1-Methyl-2-pyridinemethylene )-1-[2-(l-pyridinium) 
acetyl]hydrazine dichloride (Sb). 
0-B en zyl-N -( 1.6- dimethyl-3-h ydroxy-2-
pyridinemethylene) hydroxylamine chloride. 
1-( 1-Methyl-3-(N .N-dimethylcarbamoyloxy)-2-
pyri dylme thy I ene )-4-(2 .6-dichlorophen yl) 
diazinecarboxamide Iodide. 
1-( 1-Methyl-3-(N .N-dimethylcarbamoyloxy)-2-
pyridylmethylene )-4-( 4-methoxyphenyl) diazinecarboxa-
mide Iodide. 
1-(1 -Methyl-3-(N.N-dimethylcarbamoyloxy)-2-
pyridylmethylene )-2-(2.4.6.trichlorophenyl) diazane 
Iodide. 
1-( 1-Methyl-3-(N .N-dimethylcarbamoyloxy)-2-
pyridylmethylene )-4-( 4-chlorophenyl) diazanecarboxam-
ide Iodide. 
1-( 1-Methyl-3-(N .N-dimethylcarbamoyloxy)-2-
pyridylmethylene)-4-(2.6-dimethylphenyl) diazanecar-
boxamide Iodide. 
1-( 1-Methyl-3-(N .N-dimethylcarbamoyloxy)-2-
pyridylmethy lene )-4-(2.6-difluorophenyl) diazinecar-
boxamide Iodide. 
1-( 1-Methyl-3-(N .N-dimethylcarbamoyloxy)-2-
pyridylmethylene )-4-(2-ethoxyphenyl) diazanecarboxa-
mide Iodide. 
1-( 1-Methyl-3-(N .N-dimethylcarbamoyloxy)-2-
pyridylmethylene)-2-(4-flurophenyl) diazane Iodide. 
1-( 1-Methyl-3-(N ,N-dimethylcarbamoyloxy)-2-
pyridylmethylene )-4-(3-nitrophenyl)diazanecarboxamide 
Iodide. 
( 1-methyl-3-(N .N-dimethylcarbamoyloxy)-2-
pyridylmethylene)-4-(2.6-dichlorophenyl) diazinecar-
boxamide Iodide. 
1-( 1-Methyl-3-(N .N-dimethylcarbamoyloxy)-2-
p yr id y 1 methylene )-4-( 4-bromophe nyl) 
diazanecarboxamide Iodide. 
It has been found that the novel pyridinium compounds of 
this invention are good acetylcholinesterase inhibitors in 
vitro as shown in Tables I and II. The pyridinium compounds 
also have good activity in vivo as prophylactics and anti-
dotes against nerve agent poisoning as shown in Tables 
ill-Vl 
Competitive Inhibition of Acetylcholinesterase. The 
reversible inhibition studies on electric eel and human 2-( L6-Dimethyl-3-hydroxy-2-pyridinemethylene )-1-[2-( 4-
chloro-1-pyridinine )acetyl]hydrazine dichloride. 
1-[2-(3-Carboxy-1-isoquinolinium)acetyl]-2-(3-hydroxy-1-
methyl-2-pyridinemethylene) hydrazine dichloride. 
1-[2-(2-Carboxy-4-methoxy-1-quinolinium)acetyl]-2-(3-
hydroxy-1-methyl-2-pyridinemethylene) hydrazine 
dichloride. 
2-(3-Hydroxy-1-methyl-2-pyridinemethylene )-1-[2-(3-
hydroxy-1-pyridinium)acetyl]hydrazine dichloride. 
60 erythrocyte AChE were performed at 25°±1° C. in pH 7 .6. 
O. lM phosphate buffer containing 4% ethanol using S-acetyl 
thiocholine as a substrate (Ellman. G. L.. Courtney. D .• 
Andres, V .. and Featherstone, R. M .. Biochem. Pharmacol. 
1961. 7. 88). For analysis of AChE inhibitory potency. 
65 electric eel AChE was dissolved in buffer. Human erythro-
cyte AChE was dissolved in a 0.0 lM borate buffer (pH 10.2) 
containing 0.01 % protease free bovine serum albumin. S,S'-
5,726,314 
19 20 
by the aldoximes 2a-e in the E.I complex. Also. the 
3-hydroxyl group does not negatively infiuence binding as 
with the 3-hydroxy aldoximes which further indicates that 
binding of the semicarbazones is different from the 
5 aldoximes. 
Dithiobis(2-nitrobenzoic acid) (DTNB) and 
S-acetylthiocholine were prepared in phosphate buffer. All 
inhibitor solutions were also dissolved in phosphate buffer; 
some required the addition of 95% ethanol. Increasing 
absorbance during substrate hydrolysis was monitored on a 
Varian DMS-90 spectrometer. Duplicate studies were per-
formed on separate days using fresh solutions. No time 
dependent inhibition was observed over a period of at least 
one hour. Using three different substrate concentrations and 
four inhibitor concentrations. a Dixon plot (I/activity vs. 10 
inhibitor cone.) was made and the Kr values determined. The 
Kr value is the dissociation constant of the enzyme-inhibitor 
complex. Inhibitors with lower Kr values are more potent. In 
the case of poor inhibitors an IC,0 was determined by 
plotting AChE activity vs inhibitor concentration. Only 15 
values between 10% and 90% inlubition were used. The 
exact procedure is as follows. 
First. 20 µL of S-acetylthiocholine (0.075M) and 100 µL 
of DTNB (0. lOM) were mixed together with phosphate 
buffer. Inhibitor was then added and the solution mixed well. 20 
Next, 50 µL, of electric eel AChE (1.5 units/mL) was added 
and the solution mixed again. With human enzyme, 20 µL of 
Inhibitory data with acetylcholinesterase with halogen 
substituted semicarbazones and hydrazones are shown in the 
following table. 
TABlE 
Kinetic Coostmtts for the Reversible Inhibition of Electric Eel 
Acety!cho~. 
Inln"bitor Concenlr.ltion (mM) % Jnlnbition 
( l -methyl-3-{N,N-dimethy!carbamoyloxy )-2-pyridyl.methylene )-2-
(2,4,6,tricblorophenyl)diazane iodide 
0.45 82 
0.35 75 
0.15 48 
( l-methyl-3-{N,N-dimethylcarbamoyloxy )-2-pyridylmethylenc )-4-(2,6-
dich!orophenyl)diazanecarboxamide iodide 
032 ~ 
a 2 units/mL stock solution was added. Increasing absor- Irreversible Inhibition of Acetylcholinesterase. The irre-
bance was monitored at 412 run. Controls were used for each versible inhibition studies of electric eel and human eryth-
run in the case of inhibitors that absorb highly at 412 run. 25 rocyte AChE were performed at 25°±1° C. in O. lM phos-
Hydrolysis rates of all inlubitors were negligible. Total phate buffer. Inhibitor and enzyme were incubated in a 
volume and organic solvent, if any, was kept constant. buffer solution of 1.0 mL total volume and 100 µL aliquots 
Aldoximes (la,b,d,e) showed pure competitive inhibition were taken at 1 min intervals. The aliquots were added to 
of AChE whereas the semicarbazones (3a,b, 4b) and acyl freshly prepared assay solutions containing 20 µL of 
hydrazones (5a. 5b) showed mixed-type inhibition of AChE 30 S-acetylthiocholine, 100 µL of DTNB. and 2280 µL of 
(linear. noncompetitive). Results are summarized in Table 1 buffer. Increasing absorbance was monitored at 412 run. 
The 3-hydroxy substituted aldoximes did not inhibit Pseudo first order inhibition constants were determined by 
either enzyme well, but did show some selectivity for the measuring the enzymatic activity of acetylcholinesterase 
electric eel enzyme. The 3-hydroxy derivative of 2-PAM after incubating the enzyme with inhibitor for various time 
was also tested and did not inhibit either enzyme at con- 35 periods. Second order inhibition rate constants kobs/[I] are 
centrations up to 1 mM. Addition of a benzyl group to the reported in Table 11 Inhibitors with higher kobs/[I] values 
aldoxime of 3-hydroxy-2-PAM (lb) improves binding and are more potent. Half-lives for inactivation ranged from 10.8 
lb has an IC,0 of 500 µM with electric eel ACHE. The min for 4a to about 9 see for 2c. The kobs/[I] for 2c was 
methylaldoxime le did not inhibit either enzyme at concen- estimated at >llO.OOOM-1s-1 because its rapid inactivation 
trations up to 1 mM. Without the 3-hydroxy substituent, 40 of AChE made it difficult to accurately determine its inhibi-
tighter binding occurs and Kr values of 40 µM and 100 µM tory potency. Compounds 2a-c are novel analogs of 2-PAM 
were observed with eel and human enzymes respectively for that also incorporate a dimethylcarbamyl substituent that 
the benzyl aldoxime la. reacts covalently with AChE. Compounds 2a and 2c have 
The bis-pyridinium acyl hydrazones 5a-b were the tight- greater anti AChE activity in vitro with human AChE than 
est binding reversible inhibitors with 5a having Kr values of 45 either pyridostigmine or physostigmine. A notable selectiv-
10 and 20 µM with electric eel and human erythrocyte ity for the human enzyme was observed for all of the 
ACHE. respectively. However. 3-hydroxy substitution did carbamates. The semicarbazone 4a inactivated AChE very 
not have the same effect on acyl hydrazones as with the slowly. In contrast. the phenyl substituted semicarbazone 
aldoximes. In this case a 3-hydroxy group improved the carbamate 4b was not a time dependent inhibitor of AChE 
binding to ACHE. The complex kinetics of 5b indicate at 50 over a period of 1.5 hours, unlike all other carbamates tested. 
least two different binding modes for this inhibitor. At Both compounds have similar K1 values with electric eel 
concentrations up to 75 µM. 5b acts as a noncompetitive AChE; 4a has a K1 of 100 µM and 4b has a K1 of 85 µM. A 
inhibitor. However, at higher concentrations. 5b is an Kr for the human enzyme could not be determined for 4a 
uncompetitive inhibitor. Only noncompetitive kinetics were because of its rapid inactivation of AChE at inhibitor con-
observed for 5a. 55 centrations exceeding 10 times the enzyme concentration: 
All of the semicarbazones (3a,b, 4b) also exhibited non- Animal Studies-Pretreatment Activity. All animal stud-
competitive kinetics. In addition, multiple binding was ies were carried out at Battelle. Inc .• in Columbus, Ohio. The 
observed and compound 3b had two distinct K1 values of 30 results of in vivo mouse evaluations against GD for the 
µM and 340 µM with electric eel ACHE. Addition of a compounds tested as intramuscular (i.m.) or oral pretreat-
phenyl group to give the semicarbazone 3b resulted in a 60 ment agents are given in Tables ill and IV respectively and 
decrease of the IC,0 to 240 µM with the human enzyme. were obtained as follows. Male ICR mice from Charles 
From the kinetic results, it appears that binding in a hydro- River (20 to 30 g average weight) were treated With three 
phobic pocket near the active site is the most important different doses of the pyridinium test compound i.m. 15 or 
interaction for the semicarbazones. Compound 4b is the 60 min, or by gavage 30 or 120 min before challenge with 
most indicative of this trend. Unlike all other carbamates, it 65 a dose of 2xLDso of GD (LDs0 =98 µg/kg without atropine. 
is not a time dependent inhibitor indicating that its position LDso=l30 µglkg with 11.2 mg/kg of atropine). The 24 h 
near the active site serine is not equivalent to that occupied LDso of the test compounds administered i.m. or orally were 
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detennined using 5-7 dose groups with 5 animals per dose. 
As a negative reference treatment, saline was administered 
instead of the test compound. As a positive control for 
survival. pyridostigmine (0.1 mg/kg. i.m.; 0.82 mgfkg. 
orally) was administered to a separate group of animals. All 5 
pretreatment groups received atropine sulfate (11.2 mgfkg) 
and 2-PAM (25 mg/kg) i.m. exactly 10 seconds after GD 
challenge. using a total dose volume of 0.5 m1/kg body 
weight All animals were allocated to pretreatment cells in a 
randomized block design. Groups of ten mice were used in 10 
each experiment and survivors in each group were noted 
after 24 h. The 24-hour survival of animals pretreated with 
each dose of the pyridinium test compound was compared 
with the 24-hour survival observed in the negative reference 
pretreatment group. A survival difference of at least four is 15 
required to identify improved efficacy of the candidate over 
that observed with the negative reference pretreatment. 
Compounds 2a-d. 4a-b. 5a-b were excellent pretreatment 
agents, affording significant protection against a dose of 
2xLDso of GD. In all cases saline solution was used as the 20 
baseline standard (all mice die) and pyridostigmine as the 
positive control for survival (80-100% of the mice survive). 
Carbamate derivatives 2a-2d showed 70 to 90% survival 
rates at selected doses. After 15 min pretreatment with 
compound 2a. 2b, or 2d 90% of mice survive a challenge of 25 
2xLDso of GD at comparable fractions of the LDso's for 
these compounds (1155 LD50 of 2a. 1/72 LDso of 2b. 1167 
LD50 of 2d). On the other hand, compound 2c afforded a 
70% survival rate under the same conditions but at a V16,700 
fraction of its LD50• Carbamate sernicarbazones 4a and 4b 30 
and the acyl hydrazones 5a and 5b were also very good i.m. 
pretreatment agents. Carbamate semicarbazone 4a was 
exceptionally good as a pretreatment agent Acyl hydrazones 
5a and 5b were also excellent pretreatment agents but their 
effective doses were much closer to their toxic doses than 35 
was the case with 4a. Except for 4a, all remaining pretreat-
ment agents were more effective when given 15 min prior to 
Soman challenge. The decrease in efficacy at 60 min may be 
due to transformation of the drags to inactive metabolites 
and/or clearance from the animal. It was most noticeable for 40 
acyl hydrazones 5a and 5b, which are doubly charged and 
can be excreted more rapidly. All seven pretreatment agents 
offered comparable or better protection against GD than the 
positive control. pyridostigmine. 
Carbamate derivatives 2a-2c and carbamate semicarba- 45 
zone 4b showed excellent activity in the oral pretreatment 
studies. They afforded 80-100 survival rates at 120 min 
prior to nerve agent challenge while pyridostigmine alone 
allowed no survival. In contrast to its good activity in the 
i.m. studies, bis-pyridinium acyl hydrazone 5a was not good 50 
as an oral pretreatment agent. This may be due to fast 
clearance from the animal requiring higher doses that 
approach the toxic dose. 
Oximes la-lf and semicarbazones 3b. 3c and 3d were 
inactive in the i.m. pretreatment assay. In the case of 55 
substituted oxime derivatives a 3-hydroxy substituent sig-
nificantly reduces drag toxicity (la> lb). On the other hand 
increasing the steric bulk of the oxyimino substituent 
increases drug toxicity (lb>lc). 
Animal Studies-Reactivator Activity. The results of in 60 
vivo mouse evaluations against GD and GA for the com-
pounds tested as OP reactivators are given in Tables V and 
VI and were obtained as follows. Male ICR mice from 
Charles River (20 to 30 g average weight) were treated with 
the pyridinium test compound at three different doses 65 
administered i.m. 10 seconds after challenge with 2xLDso of 
GD or GA (aqueous solution containing 0.9% NaCl). The 
22 
test compound was always given simultaneously with atro-
pine sulfate (11.2 mg/kg). As a negative reference treatment 
group, atropine sulfate (11.2 mg/kg) and 2-PAM (25 mgfkg) 
were given without the pyridinium test compound (no mice 
survive). As a positive control for survival. HI-6 (9.6 mg/kg) 
was administered with atropine sulfate (11.2 mg/kg) to a 
separate group of animals. All injections were administered 
i.m. using a dose volume of 0.5 mLJkg body weight. All 
animals were allocated to treatment cells in a randomized 
block design. Groups of ten mice were used in each experi-
ment and survivors in each group were noted after 24 h. The 
24-hour survival of animals injected with each dose of test 
compound was compared to the 24-hour survival observed 
in the negative reference treatment cell. A survival difference 
of at least four is required to identify improved efficacy of 
the candidate over that observed with the reference treat-
ment. An alternate procedure used on some compounds was 
the adjunct efficacy test: the pyridinium test compound was 
always given simultaneously with atropine sulfate (11.2 
mg/kg) and 2-PAM (25 mg/kg). The rest of the procedure is 
as described above. 
Carbamate oxime derivatives 2a. 2b. semicarbazone 3a, 
carbamate semicarbazone 4b and bis-pyridinium acyl hydra-
zones 5a and 5b showed significant activity as GD reacti-
vators (fable V). The last two also showed significant 
activity as GA reactivators (Table VI). 2-PAM was used as 
the baseline standard while the positive control used HI-6 as 
the reactivator. Carbamate oximes 2a and 2b afforded 50% 
and 70% survival rates respectively at a dose 1/16 of their 
LD50's. They were also the most toxic of the five derivatives 
that showed activity as OP reactivators. The greater inhibi-
tion of AChE displayed by 2a compared to 2b is matched by 
its greater toxicity. A 62 fold increase in k,,,,j[I] accompa-
nied by a 44 fold increase in toxicity indicates that in the 
case of irreversible inhibitors a compromise must be reached 
between the degree of inhibition that affords protection from 
the OP agent and that which prevents the enzyme from 
performing its physiological role. It is noteworthy that 2a 
and 2b must be acting as prodrugs of the actual OP reacti-
vator since they do not possess a nucleophile themselves that 
can displace the OP from the active site of AChE. In the 
semicarbazone series. a 3-hydroxy substituent increases in 
vivo activity (3a >>3c). Semicarbazone 3a afforded 70% 
survival rate at 1/2!5 of its LDso when given 10 seconds after 
a challenge of 2xLDso of Soman. Sernicarbazone 3a was 
also an excellent reactivator when tested in the adjunct 
assay: it afforded 90% survival rate when administered 
along with 2-PAM (25 mg/kg) 10 seconds after Soman 
challenge. This combination of drugs was more effective 
than HI-6 in counteracting Soman intoxication. Carbamate 
semicarbazone 4b afforded 50% survival rate at 1/16 of its 
LD50 when given 10 sec after a challenge of 2xLD50 of 
Soman. Bis-pyridinium acyl hydrazone 5a was an excellent 
GD reactivator. It afforded 90% survival rate at a dose of 73 
mm.ol/kg (approx. Vs LDso) when given 10 seconds after 
Soman challenge. 
1\vo hydroxy 2-PAM derivatives (lf. lg) were prepared 
and tested for comparison with 2-PAM and with the other 
substituted oxime derivatives reported in this study. The 
parent 2-PAM is not an effective reactivator against Soman 
due to rapid "aging" of the inhibited AChE. Adding a 
hydroxy substituent to the 3 or 5 position of 2-PAM resulted 
in no improvement in reactivating ability concurrent with a 
small increase in toxicity. In addition, these derivatives were 
not significantly better than 2-PAM in the pretreatment 
assay. The carbamate of 5-hydroxy-2-PAM chloride. com-
pound 2d. incoiporates the structural features of pyridostig-
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mine and 2-PAM. It afforded 90% survival rate at a dose 1/61 a delay interval lasting 0-120 sec. Following the delay 
of its LD50 when given 15 or 60 minutes prior to Soman interval, two choice keys (positioned below and to either 
challenge. side of the stimulus key). but not the sample key. were then 
Summary-Animal Studies. The in vivo activity illuminated. One of the two choice keys was the same color 
described herein for some of the novel pyridinium com- 5 as the sample key had been prior the delay. while the other 
pounds of this invention can be summarized as follows: (incorrect) choice key was one of the two remaining colors. 
eight compounds (2a-2d. 4a. 4b. 5a. 5b) were effective i.m. If the monkey matched (i.e .. pressed the choice key which 
prophylactics against GD; four compounds (2a-2c, 4b) were was the same color as the sample key had been). that 
effective oral prophylactics against GD; six compounds (2a. response was rewarded with a 300 mg banana flavored food 
2b, 3a. 4b, 5a. 5b) were good in vivo reactivators against 10 pellet. A non-corrective procedure was employed. thus 
GD; two compounds (Sa. 5b) were good in vivo reactivators incorrect responses were followed by a completely new trial. 
against CA; five compounds (2a. 2b. 4b. 5a, 5b) were both Following both correct and incorrect responses there was an 
excellent prophylactics and good reactivators against GD. inter-trial interval of 3 sec. Monkeys exhibit individual 
Compounds 4a and 3a form a set in which an excellent capabilities to maintain matching performance following 
prophylactic (4a) is transformed by AChE into a good OP 15 various delay intervals. and the longest delay chosen for a 
reactivator (3a). Structural requirements for prophylactic particular monkey is that which consistently allows correct 
activity are a carbamate moiety and/or a second quaternary matching at just above chance levels (approximately 60% 
center. Since carbamates may act as prodrugs for the actual correct). In general, the length of delay interval is adjusted 
reactivators (i.e. 3a and 4a). the latter structural requirements until four levels of performance difficulty are found: 1) the 
also apply for AChE reactivators in addition to semicarba- 20 least difficult 0 delay (mean=85-100% correct); 2) a short 
zones having a free OH group in the pyridine ring. delay interval (means ranging from 75-85% correct); 3) a 
Monkey Cognition/Memory Studies. The cohort of mon- medium delay interval (means ranging from 65-75% 
keys for this study included the following macaques: 4 aged correct) and 4) a long delay interval representing each 
male rhesus (macaca mulatta). 1 young mature male rhesus, animal's limit in tenns of DMTS performance (55-65% 
1 aged female rhesus, 2 young mature male pigtails (macaca 25 correct). Baseline data was obtained following the i.m. 
nemestrina). 3 young mature female pigtails. and 1 young administration of vehicle (sterile normal saline). Drags were 
mature female cynomolgous (maeaca fasciculafis). The administered i.m. (gastrocnemius muscle) in a volume of 0.3 
young mature animals were 8-15 years old and the aged ml. At 10 min after drug or vehicle injection. testing panels 
animals were 21-45 years old. The animals were originally were attached to the front of the animal's home cage and the 
obtained from commercial suppliers or as reproductive culls. 30 trials immediately initiated. A minimum drug "washout" 
All of these animals had participated in previous drug period of 2 days was allowed between sessions in which a 
studies involving short-term administration of low doses of drug was administered. Generally. vehicle was administered 
agents affecting cognition/memory. They were allowed to on Monday. drug wad administered on Tuesday and 
wash out any prior drug effects for at least 4 weeks prior to Thursday, and on Wednesday and Friday animals were 
this study. The monkeys were housed in individual stainless 35 tested. but no drug or vehicle was administered. After drag 
steel cages located in the Medical College of Georgia administration. a return to baseline performance was estab-
Animal Behavior Center, an A.A.A.L.A.C.-approved facility lished in each animal before again administering drug. 
designed for the care and maintenance .of non-human pri- Rat Behavioral Studies. Male, outbred Wtstar rats weigh-
mates. At certain times when animals are not tested routinely ing 250-300 g were obtained from Harlan. Sprague-Dawley 
(during quarantine after arrival or during washout periods 40 (Indianapolis, Ind.) and housed separately in our animal care 
from drug studies) they were allowed access to an enclosed facility for 1 week prior to experimentation. At the time of 
outdoor exercise facility on an individual basis. Both cages the experiment the 40 animals were randomly assigned to 
and exercise facilities contained perch bars and play objects. one of 4 treatment groups, a saline vehicle group, or a 50 or 
The animals were maintained on water (unlimited) and 100 or 200 µg/kg 4b group. Vehicle (1 ml/kg body weight) 
standard laboratory monkey chow supplemented with fruits 45 was administered i.p. 30 min prior to testing in the Morals 
and vegetables. The animals were maintained on a feeding Water Maze apparatus. The apparatus consisted of a water 
schedule such that approximately 15% of their normal daily (room temperature )-filled tub 1.2 m in diameter. A mount-
( except weekends) food intake was derived from reinforce- ing platform was fixed in place and slightly submerged in the 
ment food pellets (commercial composition of standard north-west quadrant of the tub. The platform was similar in 
monkey chow and banana flakes) obtained during experi- 50 hue to the inner surface of tub so as to make it difficult to 
mental sessions. The remainder was made available follow- visualize. The tub was always maintained in the same 
ing each test session. On weekends the animals were fed orientation with respect to visual cues placed on the walls. 
twice per day. When not participating in testing sessions. the etc .• around the testing room. Rats were tested by placing the 
animals were permitted to watch television programs to animal in the water facing away from the platform. Four 
permit psychological well being. Also, monkeys received 55 consecutive trials were administered with 10 min between 
human visual contact and attention each day. especially just trials. In each successive trial the rats were placed first in the 
after testing sessions. These protocols for maintenance and south quadrant of the tub, followed by the north, east and 
testing of the animals received prior approval by the Insti- west quadrants. The time required for the rat to find (place 
tutional Committee on Animal Use for Research and Edu- at least 2 paws) the platform was monitored to the nearest 
cation. 60 0.1 sec. All rats found the platform in at least 90 sec. 
DMTS (delayed matching to sample) testing took place For nicotinic receptor binding assays. rats were decapi-
with the animals in their home cage with the room darkened tated and the brain was removed and dissected over ice. 
and the computer and operator isolated from the subjects. Cerebral cortical tissue was homogenized (teflon-glass) in 
Daily sessions consist of 96 trials. Trials begin by illumi- ice cold 50 mM Tris-HCl buffer containing 120 mM NaCl. 
nation of a sample key with one of three colored discs. 65 5 mM KCl. 1 mM MgC12, and 2 mM CaC12 (pH 7.0). The 
Monkeys were trained to depress the illuminated sample key tissue homogenate was centrifuged at 17 .000 ipm (37 ,223 g) 
and this action terminated illumination of the sample key for for 20 min at 0° C. The pellet was washed twice by 
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centrifugation and resuspended in fresh buffer. The Bio-Rad 
protein assay was used to determine the protein concentra-
tion of homogenates with methylated bovine albumin as the 
standard. [3H]cytisine was used to determine nicotinic 
receptor binding parameters according to the method 5 
described by Pabreza et al .. [Pabreza, L. A .• Dhawasn S. and 
Kellar. K. J. [3H]cytsine binding to nicotinic cholinergic 
receptors in brain. Mol. Pharmacol. 39: 9-12(1991)] with 
some modification. [3H]cytisine (2 nM) was incubated with 
1 of 10 concentrations from 0.001 to 100 µM nicotine, 10 
Drug 
4b 
26 
TABLE-continued 
Comparison of Comparison of Cortical 
Nirotinic Receptor Binding Parameters as 
Measured by !3HJCytisine Displacement 
IC,0 CuMl 
High Affinity Site Low Affinity Site 
23.394 2,630.0 
carbachol or 4b and with 0.525 mg protein in a final volume E-ac--hval_ue_re_pre_sen--t.sthe-mean--o-f-3-expenmen--. _t.s_pe_rformed ___ in_du_p_lic ___ ate-.-
of0.25 ml at 2° C. for75 min; 10 µM (-)-nicotine was used cH3 
to determine nonspecific binding. Separation of bound from I 
free ligand was accomplished by rapid filtration (Brandel ~ N -CH3 
Cell Harvester. Gaithersburg. Md.) under reduced pressure 15 l 
(20-25 inch Hg) through glass fiber filter paper and by ex ~ 
washing with ice-cold washing buffer (fris-HCI (50 mM) o I 
4x4 ml). Filter strips were pre-soaked in 0.05% polyethyl- N+ N...._ ll ~ 
eneimine for 2 hr. Following the filtration, filters were N°""' 
placed in 7-ml polypropylene scintillation vials and 4.5 ml 20 ~H3 H H 
of Scintillation fluid was added. The radioactivity was 
measured in a scintillation. spectrophotometer. The frac-
tional specific binding of [3H]cytisine in the presence of 
unlabeled ligand was analyzed using a nonlinear curve 
fitting program (fable Curve. Jandel Scientific. Corte 25 
Madera. Calif.) which fits the data to either one or two 
classes of binding sites and assists in determining whether 
the two-site model is better than the one-site fit of the data. 
The resulting IC50 values represent the mean of 3 separate 
binding experiments which were performed in duplicate. 30 
Data derived from the more than 2 treatment groups were 
analyzed using one- or two-way analysis of variance 
(ANOVA) with repeated measures. In cases where signifi-
cant differences were found or to compare only 2 treatment 
groups. Student's t-test was employed to determine which 35 
group means differed. Means were considered to be statis-
tically significant at the p<0.05 level. Statistical comparisons 
for all behavioral studies were made on the baseline data. 
In the first series of experiments, 4b was compared with 
the nicotinic agonists nicotine and carbachol for the ability 40 
to displace [3H]cytisine from binding sites on membranes 
derived from rat cerebral cortex. The results of the experi-
ment are presented in the following Table. Nicotine specific 
fractional binding was fit to a one-site model and exhibited 
the greatest potency. Carbachol also was fit to a one-site 45 
model and exhibited about 18 fold less potency than nico-
tine. In contrast. 4b binding fit well to a two-site model in 
which the high affinity binding was about 600 fold less 
potent than nicotine and about 30 fold less potent than 
carbachol. Thus. 4b appears to possess significant, albeit 50 
weak affinity for neuronal nicotinic receptors. In contrast. 
Structure of 3-(N ,N-Dimethylcarbamoyl)hydroxy-1-
methyl-2-[[(N-phenylaminocarbonyl)hydrazono ]methyl] 
pyridiniumchloride (MHP-133, 4b) or l-(l-methyl-3-(N.N-
dimethylcarbamoyloxy)-2-pyridylmethylene)4-(phenyl) 
diazanecarboxamide chloride. 
In an initial series of experiments employing 4b in mon-
keys performing the DMTS task we examined a broad range 
of doses between 1.25 and 150 µg/kg. i.m. in 5 monkeys in 
an ascending series. The cohort employed in this series 
consisted of 4 aged male rhesus and 1 young mature male 
pigtail. The dose-response relationship for medium and long 
delay intervals is depicted in FlG. 1. 4b produced a graded 
increase in performance of the DMTS task. particularly at 
long delay intervals (0 delay and short delay intervals were 
not affected) up to 60 µg/kg. A second peak of activity. 
particularly at medium delay . occurred at 100 µg/kg. 
However. above 70 µglkg 2 animals would not complete 
their sessions. and above 150 µg/k:g. a third animal failed to 
complete his sessions. When an animal fails to complete a 
session while on drag regimen it often signifies the onset of 
some untoward effect which interferes with task perfor-
mance. The 3 animals who failed to achieve the highest 
doses were from the aged group. and occasionally aged 
animals will not complete sessions even in the absence of 
drags. We were able to repeat the 100 µg/kg dose in one of 
these animals several months later. and this animal had no 
difficulty completing his sessions, and exhibited no apparent 
deleterious effect of the dose. 
In the second series, an additional 7 animals were tested 
with an ascending regimen of 3 doses of 4b. 30. 60 and 100 
µg/kg. corresponding to the doses which appeared to provide 
the greatest improvement in the initial study. One of these 
was the aged male rhesus mentioned above who was in the 
the related carbamate cholinesterase inhibitor, physostig-
mine (which is a tertiary amine at physiological pH) exhib-
ited no selective binding to nicotinic receptors, even at mM 
concentrations (data not shown). 
TABLE 
Comparison of Comparison of Cortical 
Nirotinic Receptor Binding Parameters as 
Measured by !3H!Cytisine Displacement 
55 original study. and who did not receive doses higher than 70 
µg/kg. Of these 7 animals, one aged male rhesus was a 
non-responder, who did not improve performance signifi-
cantly at any of the 3 doses. The possibility existed that this 
particular animal may have responded to one or more doses 
Drug 
Nicotine 
Carbachol 
High Affinity Site 
0.0396 
0.6988 
ICM (UM) 
Low Affinity Site 
60 other than the 3 employed. however. this possibility was not 
explored and the data for this animal was omitted from 
further analysis. Examination of the individual data indi-
cated that there was no apparent differences between the 
responsiveness to 4b between animals segregated into 
65 gender, species or age groups. However. these individual 
groups were too small to permit rigorous statistical analysis. 
Data were combined for performance at 30. 60 and 100/µgt 
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kg for all 11 animals of the entire study (omitting the 1 rather than decrease acetylcholine release from brain tissue 
non-responder) and the results presented in FIG. 2. The derived from Alzheimer's patients (Nilsson. L.. Nordberg. 
improvement observed to the 3 doses was essentially similar A.. Hardy, J .. Wester. P. and Winblad, B .• Physostigmine 
to that observed in the initial study. One difference was that restores 3H-acetylcholine efflux from Alzheimer brain slices 
the improvement in performance obtained to 100 µg/kg in 5 to normal level. J. Neural Trans. 67:275-285 (1986); 
the initial study for medium delay intervals was not main- Nilsson. L.. Adem. A.. Hardy, J., Winblad. B. and Nordbcrg. 
tained in the larger group. Also. while the dose exhibiting A .• Do tetrahydroaminoacridine (fHA) and physostigmine 
greatest improvement in the initial study appeared to be the restore acetylcholine release in Alzheimer brains via nico-
60 µg/kg dose. in the larger group. improvement appeared to tinic receptors?, J. Neural Transm. 70:357-368 (1987).). It 
be greatest for the 30 and 100 µg/kg doses. Interestingly. 10 is not clear why the muscarinic inhibitory circuit is not 
while performance at long delay intervals for the 60 µglkg activated under these circumstances, however. it is known 
dose in the larger group did not improve to statistically that in neuromuscular tissue. presynaptic facilitation by 
significant levels. it appears that some of the improvement physostigmine (cholinesterase inhibitor) is mediated 
was shifted from long delay to medium delay intervals (FIG. through pre synaptic nicotinic receptors. Also. when the 
2). Performance was also analyzed during testing on the day 15 nicotinic 'system is fully operative. the muscarinic inhibi-
following each administration of 4b. There was no signifi- tory system is much less effective. H this were true for 
cant improvement noted on the day following drag admin- central cholinergic neurons, it could explain the apparently 
istration for any of the doses and for any of the delay inactive status of the muscarinic inhibitory feedback system 
intervals (data not shown). There was also no significant in Alzheimer's tissue. 
effect produced by 4b on choice latencies (time interval 20 One study has indicated that the facilitatory action of 
between sample illumination and key press). cholinesterase inhibitors on acetylcholine release in Alzhe-
For each responder in the study a most effective or "best imer's Disease tissue is blocked by nicotinic antagonists 
dose" was selected. For the 7 animals involved in the second such as mecamylamine. While these relationships may seem 
phase this involved 1 of the 3 doses employed. For the 5 circumstantial, they do help to explain the findings of one of 
animals involved in the initial phase, only doses between 30 25 the inventors and those of others that central nicotinic 
and 100 µg/kg were considered. Thus. the average increase antagonists such as mecamylamine produce significant and 
in DMI'S performance at best dose should be considered a severe memory difficulties in animal models (Dills, S. L. and 
conservative estimate since only doses from this restricted Berry. C. A. Effect of cholinergic drugs on passive avoidance 
range were employed. For the cohort. 5 of the animals' best in the mouse. J. Pharmacol. Exper. Ther. 158:279-285 
dose was 30 µg/kg. 1 was 50 µg/kg. 2 was 60 µg/kg. 1 was 30 (1967); Chiappeta. L. and Jaravik. M. E .. Comparison of 
70 µg/kg and 2 was 100 µg/kg. Thus. the average best dose learning impairment and activity depression produced by 
was 54±8 µg/kg. The data for average change in DMrS two classes of cholinergic blocking agents, Arch. Int. 
performance for best dose is depicted in FIG. 3. Although Pharmcodyn. Therap. 179: 161-166 (1969); Goldberg. M. 
there was a statistically significant improvement in overall E., Sledge. K.. Hefner, M. and Robichaud, R. C., Learning 
performance (all delay intervals combined), there was a 35 impairment after three classes of agents which modify 
delay-dependent increase in performance with the greatest cholinergic function. Arch. Int. Pharmacodyn. 193:226-235 
and only statistically significant improvement observed for (1971); Blozovski, D .• Deficits in passive avoidance learn-
long delay intervals. In fact. at long delay intervals, ing in young rats following mecamylamine injections in the 
improvement averaged 18 percentage points above baseline. hippocampo-entorhinal area. Exper. Brain Rex. 50:442-448 
Expressed as percent of baseline DMfS performance, the 40 (1983)) and in man (Stolerman, I. P .• Goldfarb. T., Fink. R. 
improvement for this group after 4b administration averaged and Jarvik. M. E .• Influencing cigarette smoking with nico-
32.2%. tine antagonists. PsychopharmacoL (Berlin) 28:247-259 
In the final series. 4 groups of young mature rats were (1973)). 
tested in the Morris Water Maze apparatus. Rats which These findings underlie the rationale for the present 
received saline (vehicles) prior to testing exhibited a steep 45 invention, that is, to develop a drug that exhibits both 
learning curve. Performance (platform finding) required nicotinic activity and AChE inhibition and thus could pro-
about 64 sec on average for the initial trial and this decreased duce significantly improved memory enhancement with 
to only about 20 see by the fourth trial. 4b did not signifi.- respect to that produced by either nicotine or an AChE 
cantly affect the first or second trial latencies, but the 50 and inhibitor alone. In fact, it has been known since 1966 that 
100 µg/kg doses produced an increase in the slope of the so physostigmine can facilitate the pharmacological actions of 
learning curve. This was particularly evident on the third nicotine (Armitage, A. K .• Milton. A. S. and Morrison, c. F.. 
trial. Effects of nicotine and some nicotine-like compounds 
Animal Studies-Discussion. While the neurochemical injected into the cerebral ventricles of the cat, Br. J. Phar-
basis for the use of cholinesterase inhibitors is generally mac. 27:3~5 (1966)). This has been attributed to the 
ascribed to their ability to increase synaptic levels of 55 ability of nicotine to cause acetylcholine release and through 
acetylcholine, this class of compounds when administered physostigmine's ability to prevent acetylcholine degradation 
on a chronic basis often results in tolerance to their (Balfour, D. J. K.. The effects of nicotine on brain neu-
pharmacological, biochemical and toxic actions. Such tol- rotransmitter systems, Pharmac. Ther. 16:269--282 (1982)). 
erance occurs in two phases, acute and chronic. The latter The delayed matching-to-sample (DMrS) task allows the 
phase is usually associated with postsynaptic muscarinic 60 measurement of abilities which are relevant to human aging. 
receptor down-regulation. The more acute phase is associ- such as attention. strategy formation. reaction time in com-
ated with a decrease in acetylcholine biosynthesis and plex situations and memory for recent events. A similar 
release which is mediated either through activation of version of this task has been employed to demonstrate 
presynaptic muscarinic inhibitory feedback receptors, or cognitive impairment in Alzheimer's disease (AD) patients 
through the high intra-terminal concentration of acetylcho- 65 (Irle. E .• Kessler, J. and Markowitsch. H.J .. Primate learning 
line achieved. Interestingly. two recent reports concur in tasks reveal strong impairments in patients with presenile or 
their findings that cholinesterase inhibitors may increase senile dementia of the Alzheimer type. Brain Cogn. 6:429 
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( 1987) ). It is of interest to note that different classes of 
memory enhancing agents do not all produce selective 
effects at long delay intervals. The a2-adrenergic agonist 
clonidine improves DMfS perfonnance to the greatest 
extent at mediwn delays while the ACHE inhibitor physos- 5 
tigmine acts more evenly across short, medium and long 
delays (Terry. A. V .• Jackson, W. J. and Buccafusco. J. J .. 
Effects of concomitant cholinergic and adrenergic stimula-
tion on learning and memory performance by young and 
aged monkeys. Cerebral Cortex 3:304-312 (1993)). Both 10 
clonidine and nicotine improve performance for at least 24 
hr after administration, whereas physostigmine evokes 
responses only on the day of administration. 
In the present invention. 4b appears to be more nicotine-
like since it appears to affect mainly the long delay intervals. 15 
On the other hand. nicotine evokes an enhancement of 
DMfS performance which is still measurable 24 hr after the 
injection (Buccafusco. J. J. and Jackson, W. J., Beneficial 
effects of nicotine administered prior to a delayed matching-
to-sample task in young and aged monkeys. Neurobiol. 20 
Aging 12:233-238 (1991)). The improvement in perfor-
mance to 4b is relegated to the day of administration. Thus. 
4b appears to exhibit characteristics of both physostigmine 
and nicotine in the DMfS task. which fits well with the 
hypothesis that the drug may enhance memory function 25 
through both AOIE inhibition and nicotinic receptor stimu-
lation. 
A second feature of this hypothesis was that combining 
nicotinic stimulation with AOIE inhibition should result in 
a synergistic action on memory performance. Dose-response 30 
studies employing physostigmine or nicotine alone gener-
ally produce improvements of 5-10% points. and generally 
increases of this magnitude occur for but one dose in the 
series. In the present invention 4b produced a robust increase 
in DMfS performance up to 14% points over 2-3 doses. 35 
Thus. 4b may exhibit a wider therapeutic response window 
than either physostigmine or nicotine. The drug improves 
memory performance in both young and aged monkeys and 
in young rats tested in the Morris Water Maze. It was 
interesting that rats and monkeys received mnemonic benefit 40 
from similar doses despite the differences in the route of 
administration and the nature of the task. n is clear, however, 
that the effect of the drug at long delay intervals in the 
DMfS task. is more consistent with a selective action of the 
drug on problems that are most taxing to memory. The drug 45 
does not act as a stimulant. increasing lever pressing activity. 
since choice latencies in the DMfS paradigm were not 
affected. 
Summary. In summary. 4b is a novel ACHE inhibitor 
which produces dramatic improvement in memory so 
performance. particularly for the most taxing challenges to 
recall. The drug is centrally-active while retaining a perma-
nent positive charge at physiological pH. Its acetylcholine-
like structure may impart some nicotinic activity which adds 
or perhaps synergizes with its AChE inhibiting activity to 55 
produce its mnemonic stimulating action. 
Drug Delivery. For the prophylaxis of OP poisoning and 
for the treatment of OP overdose, Alzheimer's disease 
(senile dementia). presenile dementia of the Alzheimer's 
type. Korsakoffs syndrome (psychosis). age-related memory 60 
impairment. multi-infarct dementia. Parkinsonian dementia. 
Down's syndrome. and postraumatic dementia (dementia 
pugilistica). Myasthenia Gravis. high blood pressure, 
glaucoma. and abdominal distension the pyridinium com-
pounds of the present invention may be administered orally, 65 
topically or parenterally. The term parenteral as used 
includes subcutaneous injection. intravenous, intramuscular, 
30 
intrasternal injection or infusion techniques. The dosage 
depends primarily on the specific formulation and on the 
object of the therapy or prophylaxis. The amount of the 
individual doses as well as the administration is best deter-
mined by individually assessing the particular case. 
The pharmaceutical compositions containing the active 
ingredient may be in a form suitable for oral use. for 
example as tablets. troches. lozenges. aqueous or oily 
suspensions. dispersible powders or granules. emulsions. 
hard or soft capsules or syrups or elixirs. Dosage levels of 
the order to 0.2 mg to 140 mg per kilogram of body weight 
per day are useful in the treatment of above-indicated 
conditions ( 10 mg to 7 gins per patient per day). The amount 
of active ingredient that may be combined with carrier 
materials to produce a single dosage form will vary depend-
ing upon the host treated and the particular mode of admin-
istration. 
For injection. the therapeutic amount of pyridinium com-
pounds of the present invention will normally be in the 
dosage range from 0.2 mg to 140 mg/kg of body weight 
Administration is made by intravenous. intramuscular or 
subcutaneous injection. Accordingly. pharmaceutical com-
positions for parenteral administration will contain in a 
single dosage form about 10 mg to 7 gms of pyridiniwn 
compound of the present invention. In addition to the active 
ingredient. these pharmaceutical compositions will usually 
contain a buffer. e.g. a phosphate buffer which keeps the pH 
in the range from 3.5 to 7 and also sodiwn chloride, mannitol 
or sorbitol for adjusting the isotonic pressure. 
A composition for topical application can be formulated 
as an aqueous solution. lotion. jelly or an oily solution or 
suspention. A composition in the form of an aqueous solu-
tion is obtained by dissolving the pyridinium compounds of 
the present invention in aqueous buffer solution of pH 4 to 
8.5 and if desired, adding a polymeric binder. An oily 
formulation for topical application is obtained by suspend-
ing the pyridinium compounds of the present invention in an 
oil. optionally with the addition of a swelling agent such as 
aluminiwn stearate and/or a surfactant 
Synthetic Methods. All common chemicals and solvents 
were reagent grade or better. The purity of each compound 
was checked by 1H NMR. mass spectroscopy. thin-layer 
chromatography ('ILC). and elemental analysis. Results are 
consistent with the proposed structures. Melting points were 
obtained on a Biichi capillary melting point apparatus and 
are uncorrected. 1H NMR spectra were recorded with a 
Varian Gemini 300 MHz NMR spectrometer; chemical 
shifts are reported in parts per million (d) from an internal 
tetramethylsilane standard. Mass spectra were recorded on a 
Varian Mat l 12s spectrometer. Elemental analyses were 
performed by Atlantic Microlab in Atlanta. Georgia. 
3-Hydroxy-2-pyridine carboxaldehyde (Stempel. A. and 
Buzzi. E. C .. J. Am. Chem Soc. 1949, 71. 2969; Ginsburg. 
S. and Wilson, I. B .. J. Am Chem Soc. 1957. 79, 481. 
incorporated herein by reference) was prepared from 
3-hydroxy-2-hydroxymethyl pyridine by oxidation using 
manganese dioxide (Demerseman, P .• Kiffer. D .. Debussche. 
L .• Lion. C .. Royer. R.. and S. Roumanou, H., Eur. J. Med. 
Chem 1988. 23. 63. incorporated herein by reference). 
Girard's reagent "P" (1-(carboxymethyl)pyridinium 
chloride). 4-phenylsemicarbazide. and 3-hydroxy-6-methyl-
2-pyridinemethanol were purchased from Aldrich Chemical 
Company. 
The oxime. hydrazone. semicarbazone and acyl hydra-
zone derivatives described herein were prepared using stan-
dard methodology. Many different 0-substituted hydroxy-
lamines can be prepared by known procedures (Grochowski. 
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E. and Jurczak. J .. Synthesis 1976, 682; Schumann. E. L., O-Benzyl-N-(l-methyl-2-pyridinemethylene) 
Heinzelman. R. V., Greig, M. E .• and Veldkamp, W., J. Med. hydroxylamine iodide. Methyl iodide (14.3 mL. 0.23 mol) 
Chem. 1964, 7, 329, incorporated herein by reference) to was added to a solution of O-Benzyl-N-(2-
afford the various substituted oximes described herein. Sev- pyridinemethylene) hydroxylamine (11.3 g. 0.05 mol) in 75 
eral substituted hydrazines are commercially available (i.e. 5 mL of acetonitrile. The resulting mixture was heated in a 
methylhydrazine, 1.1-dimethylhydrazine, 1. 1- pressure vessel at 65° C. for 24 h. The solvent was removed 
diphenylhydrazine, from Aldrich Chemical Co.) and others in vacuo and the residue was triturated with acetone to afford 
can be synthesized by standard methodology (i.e. Hoffman the product as a light orange solid (17.2 g. 92%), m.p. 
degradation of ureas. reduction of N-nitroso compounds. 1250_70 c. (dee.). 1H NMR (Me2SO-~) d: 4.36 (s. 3H). 
reduction of diazonium salts) to afford the hydrazone deriva- 5 38 ( 2H) 7 36-7 49 ( 5H) 09 1 ) 8 
tives described herein. Several substituted semicarbazides 10 • s. · · · m. · 8· (t. H ' -36 ( d. lH). 
· 11 -1 bl ( · 4 1 3 8.55 (t. lH). 8.84 (s. lH). 9.00 (d. lH). are commerc1a y avai a e i.e. -pheny - -
thiosemicarbazide. 4.4-diphenylsemicarbazide. 4.4- O-Benzyl-N-(l-methyl-2-pyridinemethylene) hydroxy-
dimethyl- 3-thio s emicarbazide. 4-e thy 1-3- lamine chloride. Silver chloride (freshly prepared from 14.6 
thiosemicarbazide) and others can be synthesized by g AgN03 and excess cone. HCl) was added to a solution of 
standard methodology (reduction of N-nitro ureas). Com- 15 16.2 g (0.05 mol) of 0-Benzyl-N-(l-methyl-2-
mercially available Girard's reagent ••r• ((carboxymethyl) pyridinemethylene)hydroxylamine iodide in 800 mL H20. 
trimethylammonium chloride hydrazide) can be used instead The suspension was vigorously stirred with a mechanical 
of Girard's reagent "P" to obtain 2-(trimethylammoniwn) stirrer for 4 hat room temperature. The yellow precipitate 
acetyl hydrazine derivatives similar to 5a and 5b. Other was filtered off and the filtrate was concentrated to dryness 
hydrazides for the synthesis of various acyl hydrazones 20 and coevaporated several times with acetone. Traces of 
described herein can be made by known methodology solvent are removed by evaporation at 50° C. in a rotary 
(Vogel. A. I.. in A Textbook of Practical Organic Chemistry; evaporator at 0.8 mm Hg overnight. The yellow solid that 
Longman Group Limited: London, 1972; pp.976-978, remains (11.63 g) is recrystallized from EtOH/acetone with 
incorporated herein by reference). which involves the reac- scratching to obtain 8.1 g (68%) of analytically pure product 
tion between an amine and ethyl chloroacetate, followed by 25 as beige microscopic needles; m.p. 145°-6° C. (dee.). Anal. 
reaction with hydrazine hydrate. Conversion of the 3 or Calcd. for C14H1,ClN20 x H20: C. 61.87; H, 5.93; N, 
5-hydroxy moiety into a carbamate was accomplished using 10.31; Cl. 13.05. Found: C. 61.94; H. 5.94; N, 10.31; CI. 
N.N-dimethylcarbamyl chloride. Other N.N-disubstituted 13.10. 1H NMR (Me2SO-dJ d: 4.38 (s, 3H), 5.38 (s. 2H). 
carbamates can be made by reaction between commercially 7.36-7.48 (m. 5H). 8.09 (t, lH). 8.35 (d, lH). 8.55 (t, lH). 
available triphosgene and a disubstituted amine, followed by 30 8.86 (s. lH), 9.08 (d. lH). 
reaction with the 3 or 5-hydroxy pyridine derivative. O-(Diphenylmethyl)-N-(l-methyl-2-pyridinemethylene) 
N-monosubstituted carbamates can be prepared by reaction hydroxylamine chloride O-(p-chlorobenzyl)-N-(l-methyl-2-
of the free 3-0H group on the pyridine ring and any of pyridinemethylene) hydroxylamine chloride 0-(p-
numerous isocyanates that are commercially available. In methoxybenzyl)-N-(l-methyl-2-pyridinemethylene) 
the case of fluorinated derivatives, the synthesis of the 35 hydroxylamine chloride 0-(1-naphtylmethyl)-N-(l-methyl-
appropiate fluoroalkylamine (some are commercially 2-pyridinemethylene) hydroxylamine chloride 0-(2-methyl-
available) is required, followed by reaction with phosgene to 1-naphtylmethyl)-N-( 1-methyl-2-pyridinemethylene) 
generate the desired isocyanate. Quaternization of the pyri- hydroxylamine chloride, 0-(2.3,4-trimethoxybenzyl)-N-(1-
dine nitrogen was carried out using methyl iodide in a sealed methyl-2-pyridinemethylene) hydroxylamine chloride. and 
glass pressure vessel and was followed by anion exchange 40 0-(3.3-diphenylpropyl)-N-(1-methyl-2-pyridinemethylene) 
using a biphasic mixture of silver chloride and the methio- hydroxylamine chloride can be made by the same procedure 
dide in acetonitrile/water. Other salts of the pyridinium replacing 0-benzyl hydroxylamine in the above example 
compounds described herein can be inade in similar fashion, respectively with 0-( diphenylmethyl) hydroxylamine. 0-(p-
by methathesis involving the silver salt of the desired chlorobenzyl) hydroxylamine, 0-(p-methoxybenzy) 
counterion and the methiodide formed in the initial alkyla- 45 hydroxylamine, 0-(1-naphtylmethyl) hydroxylamine, 0-(2-
tion of the pyridine nitrogen. The usefulness of this proce- methyl-1-naphtylmethyl) hydroxylamine, 0-(2,3.4-
dure has been studied with 2-PAM derivatives (Koodritzer, trimethoxybenzyl) hydroxylamine, and 0-(3,3-
A. A .. Ellin. R. I., and Edberg. L. J .. J. Pharrn. Sci. 1961. 50. diphenylpropyl) hydroxylamine. 
109. incorporated herein by reference). EXAMPIE 2 
The following examples are given to illustrate the inven- 50 
tioo and are not intended to limit it in any manner: Preparation of O-Benzyl-N-(3-hydroxy-1-methyl-2-
pyridinemethylene)hydroxylamine chloride (lb). 
EXAMPLE 1 O-Benzyl-N-(3-hydroxy-2-pyridinemethylene) hydroxy-
Prepar a ti on of 0-Benzyl-N -( 1-methyl-2- lamine. A solution ofO-benzyl hydroxylamine was prepared 
pyridinemethylene) Hydroxylamine Chloride (la). 55 by dissolving 2 g of sodiwn hydroxide (0.05 mol) and 8 g 
O-Benzyl-N-(2-pyridioemethylene) hydroxylamine. of 0-benzyl hydroxylamine hydrochloride (0.05 mol) in 50 
0-Benzylhydroxylamine hydrochloride (12.77 g. 0.08 mol) mL of 50% ethanol-water. To this solution was added 6.15 
was added to a solution of NaOH (3.2 g. 0.08 mol) in 80 mL g of 2-formyl-3-hydroxypyridine (0.05 mol). The mixture 
1: 1 Et0H/H20. Pyridine-2-carbaldehyde (7 .6 mL. 0.08 mol) was stirred for 3 h at room temperature. The precipitate was 
was added to this solution and the resulting mixture was 60 then filtered and air dried to yield 10.3 g (90.3%) of pure 
stirred at room temperature for 10 h. Excess water was product; m.p. 64°-65° C. 1H NMR (CDC13) d: 9.72 (s. lH. 
removed under vacuum and the residue was fractionally OH); 8.37 (s, lH. CH N); 8.13 (d of d. J=2H. J=4Hz. lH); 
distilled under reduced pressure (14 mm Hg). The product 7.33 (m. 7H); 5.17 (s, 2H, CH2). Anal. Calcd. for 
was obtained as a yellow oil in the fraction distilling at C13H 12N20 2: C. 68.41; H, 5.30; N. 12.27. Found: C. 68.34; 
85°-90 ° C. (11.3 g. 67%). 1H NMR (Me2S0-<4) d: 5.25 (s. 65 H. 5.32; N. 12.21. 
2H). 7.24 (t. lH). 7.32-7.44 (m. 5H). 7.66 (t. lH). 7.78 (d. O-Benzyl-N-(3-hydroxy-1-methyl-2-pyridinemethylene) 
lH). 8.23 (s. lH). 8.58 (d. lH). hydroxylamine chloride. 0-Benzyl-N-(3-hydroxy-2-
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pyridinemethylene) hydroxylamine (2.65 g. 11.6 mmol) was was added to a solution of O-methyl-N-(3-hydroxy-2-
placed in a pressure tube together with 7 g of methyl iodide pyridinemethylene) hydroxylamine ( 4.83 g. 32 mmol) in 20 
and 40 ml.. of a 2:3 mixture of EtOWWater. The reaction mL of acetonitrile. The reaction mixture was heated in a 
mixture was heated at 65° C. for 20 h and the solvent was pressure glass bottle at 70° C. for 20 hand then concentrated 
then removed in vacuo. The residue was triturated with 5 to dryness in vacuo. The resulting yellow solid was triturated 
acetone to afford 2.50 g (58%) of product as greenish with acetone and filtered to yield 7.72 g (82%) of product 
crystals; m.p. 247° C. (dee.). The methiodide salt (4.90 g. which was used in the next step without further purification. 
13.2 mmol) was dissolved in 22 mL of a 1:1 mixture of O-Methyl-N-(3-hydroxy-l-methyl-2-pyridinemethylene) 
acetonitrile and water and freshly made AgCl was then hydroxylamine chloride. The methiodide obtained in the 
added (from 4.0 g AgN03 and excess cone. HCl. washed 10 previous step (7:72 g. 26 mmol) was dissolved in 230 mL of 
well with water). Additional water (15 mL) was added to this H20. Freshly made AgCl (7 .6 g. 53 mmol) was added to this 
suspension and the resulting mixture was stirred at room solution and the resulting suspension was stirred at room 
temperature for 40 min. The silver iodide was removed by temperature for 15 h. The reaction mixture was filtered and 
filtration and the filtrate was concentrated to dryness in the filtrate was concentrated to dryness in vacuo. The white 
vacuo to yield a residue that was triturated with acetone. The 15 solid that resulted was triturated with warm ( 40° C.) acetone 
solid that resulted was washed well with acetone and dried and filtered to yield 4.35 g (83%) of product; m.p. 186°-7° 
to yield 3.61 g (98%) of product as white crystals; m.p.146° C. (dee.). 1H NMR (DMSO-~) d: 8.62 (d. lH. J=6.0 Hz); 
C. 1H NMR (DMSO-d6) o: 8.58 (d, lH. J=5.0 Hz). 8.55 (s, 8.48 (s. lH); 8.31 (d. lH. J=8.5 Hz); 7.93 (d of d. lH. J=6.0 
lH). 8.20 (d. lH, J=7.3 Hz), 7.90 (d of d, lH). 7.42 (m. SH), Hz. J=8.5 Hz). Anal. Calcd for C8H11N2Cl02: C. 47.41; H. 
5.34 (s. 2H), 4.27 (s, 3H). Anal. Calcd. for C14HisN2 20 5.47; N. 13.83; Cl. 17.50. Found: C. 47.47; H. 5.49; N. 
0 1 ci.., Hp: C. 56.65; H. 5.78; N. 9.43; Cl. 11.94. Found: C. 13.76; Cl. 17.43. 
56.65; H. 5.79; N. 9.40; Cl. ll.88. O-Methyl-N-(5-hydroxy-1-methyl-2-pyridinemethylene) 
0-( 1-Naphtylmethyl)-N-(3-hydroxy-1-methyl-2- hydroxylamine chloride can be made by the same procedure 
pyridinemethylene) hydroxylamine chloride, 0-(2-methyl- replacing 3-hydroxy-2-pyridine aldehyde in the above 
1-naphtylmethyl)-N-(3-hydroxy-1-methyl-2- 25 example with 2-formyl-5-hydroxy pyridine. 0-[2-(1-
pyridinemethylene) hydroxylamine chloride. 0-(2,3.4- Methyl-1-piperidinium]ethyl]-N-(3-hydroxy-l-methyl-2-
trime th ox y be nz y l )-N -( 3 -h y dr ox y- l -methyl-2- pyridinemethylene) hydroxylamine dichloride and 0-(2-
pyridinemethylene) hydroxylamine chloride. and 0-(3.3- (trimethyl ammonium)ethyl]-N-(3-hydroxy-1-methyl-2-
diphe nylpropyl)-N -( 3-h ydrox y-1-me thyl- 2- pyridinemethylene) hydroxylamine dichloride can be made 
pyridinemethylene) hydroxylamine chloride can be made by 30 by the same procedure replacing methoxyamine in the above 
the same procedure replacing 0-benzyl hydroxylamine in example with: 0-[2-(l-piperidine)ethyl] hydroxylamine and 
the above example respectively with 0-(1-naphtylmethyl) 0-[2-(dimethylamino)ethyl] hydroxylamine. 
hydroxylamine, 0-(2-methyl-1-naphtylmethyl) 
hydroxylamine, 0-(2.3.4-trimethoxybenzyl) EXAMPIE 4 
hydroxylarnine. and 0-(3.3-diphenylpropyl) hydroxy- 35 Preparation O-(p-Chlorobenzyl)-N-(3-hydroxy-1-methyl-2-
lamine. 0-(1-Naphtylmethyl)-N-(5-hydroxy-1-methyl-2- pyridinemethylene) hydroxylamine chloride (ld). 
pyridinemethylene) hydroxylamine chloride, 0-( 2-methyl-
l- naph tylmethyl)-N -( 5-hy droxy-1-me thy 1-2- 0-(p-Chlorobenzyl)hydroxylamine hydrochloride. The 
pyridinemethylene)hydroxylamine chloride, 0-(2.3.4- hydroxylamine hydrochloride was prepared by hydrazinoly-
trimethoxybenzyl )-N-(5-hydroxy-1-methyl-2- 40 sis of the corresponding benzyloxyphthalimide. The phthal-
pyridinemethylene) hydroxylamine chloride. and 0-(3.3- imide (15 g. 0.051 mol) was dissolved in DMF (75 mL) and 
diphenylpropyl)-N-( 5-hy droxy-1-methyl-2- MeOH (260 mL) and warmed to 60° C. The solution was 
pyridinemethylene) hydroxylamine chloride can be made by treated with hydrazine monohydrate (5.7 g. 0.11 mol) and 
the same procedure substituting 3-hydroxy-2-pyridine car- allowed to cool to room temperature for 3 h. The mixture 
baldehyde for 2-formyl-5-hydroxy pyridine. 45 was acidified to pH 2 with 2N HCl and filtered The filtrate 
was evaporated to dryness and treated with 2N NaOH (75 
EXAMPIE 3 ml..). The oily product was extracted with ether. and the 
Preparation of O-Methyl-N-(3-hydroxy-1-methyl-2- combined ether extracts were washed with H20. dried over 
pyridinemethylene)hydroxylamine chloride (le). anhydrous K2C03• and concentrated in vacuo. The resulting 
O-Methyl-N-(3-hydroxy-2-pyridinemethylene) hydroxy- 50 oil was treated with ethereal hydrogen chloride to precipitate 
lamine. NaOH (l.62 g. 0.04 mol) was added to a solution of the product as a white solid. Recrystallization from EtOH 
methoxyamine hydrochloride (3.4 g. 0.04 mol) in 30 ml of gave the pure hydroxylamine hydrochloride as shiny white 
H20. 3-Hydroxy-2-pyridine carboxaldehyde (5.0 g. 0.04 plates (9.5 g. 96%), m.p. 235° C. [lit m.p. 245° C.; 
mol) was added to the clear solution. followed by 15 mL of Schumann. E. L .. Heinzelman, R. V .• Greig. M. E .. and 
EtOH.Thereactionmixturewasstirredatroomtemperature ss Veldkamp, W .. J. Med. Chem. 1964. 7. 329]. 1H NMR 
for 15 hand concentrated in vacuo to a minimum volume (CDCl3) d: 7.23(s, 4H); 5.00(s, 2H). 
(approx. 5 ml..). Water ( 15 mL) was added to this residue and 0-(p-Cyanobenzyl)hydroxylamine hydrochloride. 0-(2-
the resulting solution was extracted with EtOAc (4x20 mL). Hydroxy-4-nitrobenzyl) hydroxylamine hydrochloride. and 
The organic extract was dried (MgS04), filtered and con- 0-(p-Carboxy benzyl)hydroxylamine hydrochloride can be 
centrated in high vacuum to a yellow oil that crystallizes 60 made by the same procedure replacing 
upons cooling in a bath of isopropanol-dry ice to yield 4.83 p-chlorobenzyloxyphtalimide respectively with 
g (79%) of product as a white solid; m.p. 186°-7° C. (dee). p-cyanobenzyloxyphtalimide, 2-hydroxy-4-
1H NMR (CDC13) d: 9.82 (s. lH); 8.35 (s. lH); 8.21 (d of nitrobenzyloxyphtalirnide. and p-carboxybenzyl oxyphtal-
d. lH, J=l.5 Hz. J=4.5 Hz); 7.30(dof d. lH. J=l.5 Hz. J=8.5 imide. 
Hz); 7.19 (d of cl, lH. J=4.5 Hz. J=8.5 Hz). 65 O-(p-Chlorobenzyl)-N-{3-hydroxy-2-pyridinemethylene) 
O-Methyl-N-(3-hydroxy-1-methyl-2-pyridinemethylene) hydroxylarnine. 0-( 4-Chlorobenzyl) hydroxylamine hydro-
hydroxylamine iodide. Methyl iodide (8.9 mL. 0.14 mol) chloride (9.75 g. 50 mmol) was neutralized with NaOH (2.0 
5,726,314 
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g. 50 mmol dissolved in 20 mL H20). Ethanol (20 mL) was and Schumann et at, 1964, vide supra) was added to a 
added to solubilize the resulting hydroxylamine. 3-Hydroxy- solution of NaOH ( 1.2 g, 29 mmol) in 15 mL H20. 
2-pyridinealdehyde (6.2 g, 50 mmol) dissolved in H20 (150 3-Hydroxy-2-pyridine carbaldehyde (3.6 g. 29 mmol) was 
mL) was added and the mixture heated on a steam bath for then added. followed by 15 mL of 95% EtOH and 10 mL of 
30 min. The solution was cooled to room temperature. The 5 acetone. The reaction mixture was stirred at room tempera-
od ct talli d t l ng pale Yellow needles The ture for 4 h and was then poured over 400 mL of crashed ice. pr u crys re ou as o · de 
mixture was filtered to isolate the pure product ( 12.5 g. A beige solid comes out of solution upon scratching the si s 
of the beaker. It was filtered. washed with water and dried to 96%). m.p. 890_900 C. iH NMR(CDCl3) d: 9.67 (s. lH); yield 7.03 g (93%) of product; m.p. 79o_g1 o C. iH NMR 
8.33 (s. lH); 7.33-7.13 (m. 7H); 5.17 (s. 2H). Anal. Calcd. l d 9 85 ( lH) 8 38 ( lH) 8 19 (d fd lH) 7 36 (CDC 3) : . s. ; . S, ; • 0 • ; • 
for C13H11N202Cl: C,59.43; H. 4.23; NJ0.67; Cl. l3.49. 10 (d of d. 2H); 7.28 (d of d, lH); 7.18 (d of d, lH); 6.93 (d of 
Found: C. 59.43; H. 4.26; N, 10.64; Cl. 13.56. d. 2H); 5.15 (s. 2H); 3.82 (s. 3H). 
0-(p-Chlorob enzy 1)-N-(3-h ydroxy-1-meth Y 1-2- 0-(p-M ethoxybenzyl )-N-(3-hydroxy-1-methyl-2-
pyridinemethylene) hydroxylamine iodide. A solution of pyrid.inemethylene) hydroxylamine chloride. Methyl iodide 
0-(p-chlorobenzyl)-N-(3-hydroxy-2-pyridinemethylene) (7.2 mL. 0.12 mol) was added to a solution of 0-(p-
hydroxylamine (1.0 g. 3.8 mmol) in EtOH (45 mL) was 15 methoxy)benzyl-N-(3-hydroxy-2-pyridinemethylene) 
placed in a glass pressure tube. Methyl iodide (i mL. 16.0 hydroxylamine (3.72 g, 14 mmol) in 60 mL of acetonitrile. 
mmol) was then added, and the tube was sealed tightly. The The resulting mixture was divided into three pressure glass 
tube was heated at 69° C. in an oil bath for 20 h. The solution vessels and heated at 70° C. for 3 days. The solvent was 
was concentrated in vacuo. The oily residue was triturated removed in vacuo and the residue was triturated with 
with acetone to give the crude product as a yellow solid 20 ether/acetone (3:1); after drying. the methiodide weighed 
(1.46 g. 95% ). Recrystallization from acetone gave the pure 4.88 g (85% ). It was dissolved in 500 mL H20 and 300 mL productasashinyyellowsolid(0.8g.52%).m.p.164°-l66° of acetonitrile and freshly made AgCl (2 eq.) was then 
C. 1H NMR (CDClJDMSO-<ii;) d: 8.83-8.67 (m. 2H); added. The suspension was stirred at room temperature for 
8.13-7.67 (m. 2H); 7.33 (s. 4H); 5.00 (s. 2H); 4.43 (s. 3H). 1.5 h and then filtered through Celite. The filtrate was 
Anal. Calcd for C14H14N20 2Cll: C. 41.55; H, 3.49; N, 25 concentrated to dryness in vacuo and the residue was 6.92; Cl. 8.76; L 31.36. Found: C. 41.62; H. 3.53; N, 6.92; triturated with acetone/ether (1:1). The yellow solid was 
0, 8.71; I. 31.28. filtered. washed first with acetone/ether (1:1), then with ether 
0-(p-Chlorobenzyl)-N-(3-hydroxy-1-methyl-2- and dried to yield 3.57 g (97%) of pure product, m.p. 
pyridinemethylene) hydroxylamine chloride. To a solution 183°-184° C. (dee.). 1H NMR (d6-DMSO) d: 8.57 (d, lH. 
of the corresponding pyridinium iodide (1.0 g, 2.47 mmol) 30 J=6.1 Hz); 8.50 (s, lH); 8.19 (d, lH. J=8.2 Hz); 7.88 (d of in CH3CN/H20 (1:1. 15 mL) was added freshly made AgCl d, lH, J=6.1 Hz, J=8.2 Hz); 7.38 (d. 2H. J=8.7 Hz); 6.95 (d, 
(from 0.54 g AgN03 and cone. HCl). The mixture was 2H. J=8.7 Hz); 5.25 (s. 2H); 4.26 (s, 3H); 3.75 (s. 3H). Anal. 
allowed to stir at room temperature for 1.5 h. It was then Calcd. for C15H17ClN20 3 x 0.55 Hp: C, 6.53; H, 5.73; N. 
filtered through a bed of Celite. The solvent was removed in 8.79; Cl.11.13. Found: C, 56.53; H. 5.72; N. 8.79; O. 11.18. 
vacuo. Trituration of the residue with acetone gave the pure 0-(p-Dimethylaminocarbonyloxybenzyl)-N-(3-hydroxy-
pyridinium chloride (0.72 g) in 93% yield. m.p. 175° C. 35 1-methyl-2-pyridinemethylene) hydroxylamine chloride, 
(dee). 1 H NMR (CDClJDMSO-~) d: 8.67 (m. lH); 8.37 0-(p-propylaminocarbonylbenzyl)-N-(3-hydroxy-1-methyl-
(m. lH); 8.00-7.67 (m. lH); 7.37 (s. 4H); 5.3 (s. 2H); 4.33 2-pyridinemethylene) hydroxylamine chloride, and 0-(p-
(s, 3H). Anal. Calcd. for C14H14N20Cl2: C, 53.68; H. 4.51; ethoxycarbonyl benzyl)-N-(3-hydroxy-1-methyl-2-
N, 8.95; CI. 22.64. Found: C. 53.76; H. 4.56; N, 8.92; Cl, pyridinemethylene) hydroxylamine chloride can be made by 
22.57. 40 the same procedure replacing 0-(p-methoxybenzyl) 
O-(p-Cyanobenzyl)-N-(3-hydroxy-1-methyl-2- hydroxylamine in the above example respectively with 
pyridinemethylene) hydroxylamine chloride, 0-(2-hydroxy- O-(p-dimethylaminocarbonyloxy benzyl) hydroxylamine, 
4- nitr o be n zyl)-N-(3-hy dr ox y-1-methyl-2- 0-(p-propylaminocarbonyl benzyl) hydroxylamine, and 
pyridinemethylene) hydroxylamine chloride, and 0-(p- 0-(p-ethoxycarbonyl benzyl) hydroxylamine. 0-(p-
carb oxy ben zy 1 )-N -( 3-h y drox y- 1-methy l- 2- 45 M ethoxyben zyl)-N -(5-hy drox y-1-methyl-2-
pyridinemethylene) hydroxylamine chloride can be made by pyridinemethylene) hydroxylamine chloride, 0-(p-
the same procedure replacing 0-(p-chlorobenzyl) hydroxy- dimethylaminocarbonyloxy benzyl)-N-(5-hydroxy-1-
lamine respectively with O-(p-cyanobenzyl)-N-(3-hydroxy- methyl-2-pyridinemethylene) hydroxylamine chloride. 
2-pyridinemethylene) hydroxylamine, 0-(2-hydroxy-4- 0-(p-propylaminocarbonyl benzyl)-N-(5-hydroxy-1-
nitrobenzyl)-N-(3-hydroxy-2-pyridinemethylene) 50 methyl-2-pyridinemethylene) hydroxylamine chloride, and hydroxylamine, and O-(p-carboxybenzyl)-N-(3-hydroxy-2- 0-(p-ethoxycarbonyl benzyl)-N-(5-hydroxy-1-methyl-2-
pyridinemethylene) hydroxylamine. 0-(p-Chlorobenzyl)-N- pyrid.inemethylene) hydroxylamine chloride can be made by 
(5-hydroxy-1-methyl-2-pyridinemethylene) hydroxylamine the same procedure replacing 3-hydroxy-2-pyridine alde-
chloride, 0-(p-cyanobenzyl)-N-(5-hydroxy-1-methyl-2- hyde in the above example with 2-formyl-5-hydroxy pyri-
pyridinemethylene) hydroxylamine chloride, 0-(2-hydroxy- dine. 
4-nitro benzyl)-N-(5-hydroxy-1-methyl-2- 55 
pyridinemethylene) hydroxylamine chloride, and 0-(p-
c a r boxy benzyl )-N -( 5-hy droxy-1-me th yl-2-
pyridinemethylene) hydroxylamine chloride can be made by 
the same procedure replacing 3-hydroxy-2-pyridine alde-
hyde with 2-formyl-5-hydroxy pyridine. 
EXAMPLES 
Preparation of O-(p-Methoxybenzyl)-N-(3-hydroxy-1-
methyl-2-pyridinemethylene) hydroxylamine chloride (le). 
0-(p-M eth oxyb en zyl)-N -(3-hy droxy-2-
pyridinemethylene) hydroxylamine. 0-(p-methoxybenzyl) 
hydroxylamine (5.55 g. 29 mmol; Grochowski et at. 1976 
EXAMPI.E 6 
Preparation of 0-Benzyl-N-[3-(N' ,N'-dimethylcarbamoyl) 
hydroxy-1-methyl-2-pyridinemethylene] hydroxylamine 
chloride (2a). 
60 O-Benzyl-N-[3-(N',N'-dimethylcarbamoyl)hydroxy-2-
pyridinemethylene] hydroxylamine. Dimethylcarbamyl 
chloride (7 mL, 76 mmol) was added to a solution of 2.59 
g ( 11 mmol) of O-benzyl-N-(3-hydroxy-2-
pyrid.inemethylene] hydroxylamine (prepared as reported on 
65 previous page) in 20 mL of pyridine. The resulting mixture 
was stirred at 65° C. for 12 h and poured over 400 mL of ice 
water. The aqueous solution was extracted with ether (6x50 
5,726,314 
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mL); the ether layer was dried (N1t:iS04), filtered and hydroxylamine (3.4 g. 14.4 mmol; Grochowski et at. 1976 
concentrated to dryness to a yellow oil which was coevapo- and Schumann et al, 1964, vide supra) was added to a 
rated with H20 and with acetone to remove the remaining solution of NaOH (0.58 g. 14.4 mmol) in 7 mL of water. 
pyridine. The residue was dissolved in 10 mL acetone. and 3-Hydroxy-2-pyridine carbaldehyde (1.8 g. 14.4 mmol) was 
water was added with cooling and stirring until no more 5 added to this solution and the resulting mixture was stirred 
precipitate came out of solution. The white solid was at room temperature for 4 h. The white solid in the reaction 
filtered, washed with water and dried to yield 3.02 g (89%) mixture was filtered. washed with H20/EtOH (1:1) and 
of product; m.p. 65°-66° C. 1H NMR (CDC13) d: 8.54 (d of dried to yield 3.17 (72%) of product. m.p. 82°-83° C. 1H 
d. lH. J=4Hz. J=lHz); 8.38 (s. lH); 7.54 (d of d. lH, J=8.3 NMR (CDC13) d: 9.60 (s. lH); 8.51 (s, lH); 8.2 (d of d. lH); 
Hz. J=l.5 Hz); 7.30-7.43 (m. 6H); 5.30 (s. 2H); 3.06 (s, 3H); 
10 
7.30-7.43 (m. lOH); 7.23 (d of cl lH); 7.16 (d of d, lH); 
2.97 (s, 3H). 6.29 (s. lH). 
0-Benzyl-N-[3-(N' ,N' -dimethylcarbamoyl)hydroxy-1- 0-(Dipheny lmethyl)-N-[ 3-(N' .N' -dimethylcarbamoyl) 
methyl-2-pyridinemethylene] hydroxylamine iodide. A solu- hydroxy-2-pyridinemethylene] hydroxylamine. Dimethyl-
tion of 2.95 g (9.9 mmol) of 0-benzyl-N-[3-(N'.N'- carbamyl chloride (9 mL, 98 mmol) was added to a solution 
dimethylcarbamoyl)hydroxy-2-pyridinemethylene] 
15 of O-(diphenylmethyl)-N-(3-hydroxy-2-pyridinemethylene] hydroxylamine and 2.8 mL ( 44 mmol) of methyl iodide in 20 hydroxylamine (3.0 g. 9.9 mmol) in 30 mL of pyridine. The 
mL of acetonitrile was heated at 65° C. in a glass pressure resulting mixture was stirred at room temperature for 14 h 
bottle for 2 days. The reaction mixture was concentrated to and poured over 400 mL of crushed ice. A white solid 
dryness to a dark orange oil which was triturated with cold precipitates upon scratching the sides of the beaker. It was 
acetone to yield a bright yellow precipitate that was washed filtered. washed thoroughly with water and dried to yield 
with acetone and ether. After drying the product weighed 20 3.47 g (94%) of product, m.p. 89o_90o c. iH NMR (~-
4.02 g (92%). DMSO) d: 8.49 (dof cl lH); 837 (s. lH); 7.64 (d of cl lH); 
O-Benzyl-N-[3-(N',N'-dimethylcarbamoyl)hydroxy-1- 7.47 (d of d. lH); 7.42-7.28 (m. lOH); 6.29 (s. lH); 2.81 (s. 
methyl-2-pyridinemethylene] hydroxylamine chloride. The 3 methiodide obtained in the previous step (4.02 g. 9 mmol) 3H); 2·74 (s. H). 
was dissolved in 25 mL H20 and 20 mL acetonitrile. Freshly 25 0-(Diphenylmethyl)-N-[3-(N' .N' -dimethylcarbamoyl) preparedAgO (2.61g,18 mmol) was added to this solution hydroxy-1-methyl-2-pyridinemethylene] hydroxylamine 
and the resulting suspension was stirred at room temperature chloride. Methyl iodide (2.8 mL. 46 mmol) was added to a 
for 1 h. The reaction mixture was filtered and the filtrate was solution of 0-( diphenylmethyl)-N-[3-(N',N' -
concentrated to dryness to a white solid that was triturated dimethylcarbamoyl)hydroxy-2-pyridinemethylene] 
with warm (40° C.) acetone for 20 min and filtered. The 30 hydroxylamine (3.44 g. 9.2 mmol) in 40 mLof acetonitrile. 
white solid was washed with acetone and ether to yield 3.2 The resulting mixture was divided into two pressure glass 
g (quantitative) of the pure chloride, m.p. 150°-152° C. vessels and heated at 70° C. for 3 days. The solvent was 
(dee.); 1H NMR (DMSO-~) d: 9.09 (d. J=5.5 Hz. lH); 8.74 removed in vacuo and the residue (4.92 g) was dissolved in 
(s, lH); 8.59 (d, J=8.4 Hz. lH); 8.19(d of d, J=8.4 Hz. J=5.5 a mixture of acetonitrile/water (200 mL:200 mL). Freshly 
Hz. lH); 7.42 (m. SH); 5.33 (s, 2H); 4.39 (s, 3H); 2.98 (s. 35 madeAgCl (2 eq. washed well with H20) was added to this 
3H); 2.92 (s, 3H). Anal. Calcd. for C17H20ClN303 x 0.45 solution and the resulting suspension was stirred at room 
H20: C. 57.04; H. 5.89; N, 11.74; Cl, 9.91. Found: C. 56.99; temperature for 2 h. It was filtered through Celite and the 
H. 5.95; N. 11.69; CI. 9.91. filtrate was concentrated to dryness in vacuo to a residue that 
O-Benzyl-N-[3-(N',N'-diethylcarbamoyl)hydroxy-1- was triturated with ether. The white solid was collected by 
methyl-2-pyridinemethylene] hydroxylamine chloride and filtration and dried to yield 3.84 g (98%) of pure product. 
O-benzyl-N-[3-(N',N'-difl.uoroethylcarbamoyl)hydroxy-1- 40 m.p. 1530_1540 c. (dee.). iH NMR (~-DMSO) d: 9.06 (d, 
methyl-d2-pynb'dinehmethylene] hydroxd ylamine
1 
ch!orideNcan lH, J=6.0 Hz); 8.87 (s. lH); 8.55 (d. lH. J=8.4 Hz); 8.18 (d be ma e y t e same proce ure rep acmg .N- 10 6 44 ( 
dimethylcarbamoyl chloride respectively with N.N- old, lH, J=6.0 Hz. J=8.4 Hz); 7.45-7.30 (m. H); · s. 
diethylcarbamoyl chloride and N.N-difl.uoroethylcarbamoyl lH); 435 (s, 3H); 2.8 (s, 3H); 2.79 (s, 3H). Anal. Calcd. for 
chloride. O-Benzyl-N-[5-(N'.N'-dimethylcarbamoyl) 45 C23H24ClN303 x 1.19 H20: C. 61.76; H. 5.94; N, 9.39; Cl. 
hydroxy-1-methyl-2-pyridinemethylene] hydroxylamine 7.93. Found: C. 61.76; H. 6.02; N, 9.41; Cl, 7.97. 
chloride, 0-benzyl-N-[5-(N' .N'-diethylcarbamoyl)hydroxy- 0-(Diphenylmethyl)-N-[3-(N'-isopropylcarbamoyl) 
1-methyl-2-pyridinemethylene] hydroxylamine chloride and hydroxy-1-methyl-2-pyridinemethylene] hydroxylamine 
0-benzyl-N-[5-(N' ,N' -difl.uoroethylcarbamoyl)hydroxy-1- chloride and 0-( diphenylmethyl)-N-[3-[N'-(2 -fluoroethyl) 
methyl-2-pyridinemethylene] hydroxylamine chloride can so carbamoyl]hydroxy-1-methyl-2-pyridinemethylene) 
be made by the same procedure replacing 3-hydroxy-2- hydroxylamine chloride can be made by the same procedure 
pyridine aldehyde with 2-formyl-5-hydroxy pyridine. 0-(2- replacing N.N-dimethylcarbamyl chloride respectively with 
(l-Methyl-1-piperidinium)ethyl]-N-[3-(N'.N'- isopropyl isocyanate and 2-ftuoroethyl isocyanate. 
dime thy 1 carb am oy 1) h ydrox y-1-me th yl- 2- O-(Diphenylmethyl)-N-(5-(N'-isopropylcarbamoyl) 
pyridinemethylene) hydroxylamine dichloride. and 0-[2- 55 hydroxy-1-methyl-2-pyridinemethylene] hydroxylamine (trim et h y 1 ammo n i u m) et h Y l] - N - [ 3 - ( N' • N' - chloride and 0-( diphenylmethyl)-N-[5-[N'-(2-fluoroethyl) 
dimethyl c arb amoyl )h ydrox Y- 1-meth Y 1- 2- carbamoyl]hydroxy-1-methyl-2-pyridinemethylene] 
pyridinemethylene] hydroxylamine dichloride can be made hydroxylamine chloride can be made by the same procedure 
by the same procedure replacing 0-benzylhydroxylamine in h 2 aldeh d 'th 2 f 1 5 
the above example with 0-[2-(l-piperidine)ethyl] hydroxy- replacing 3- ydroxy- -pyridine Y e Wl - ormy - -
lamine and 0-[2-(dimethylamino)ethyl] hydroxylamine. 60 hydroxy pyridine. 
EXAMPLE7 
Preparation of 0-(Diphenylmethyl)-N-[3-(N' .N'-
dim ethyl c arb amoy 1) h y drox y-1-me thy 1-2-
pyridinemethylene] hydroxylamine chloride (2b). 
0-( Dip hen y 1 me thy 1 )- N -( 3-h ydroxy-2-
pyridinemethylene) hydroxylamine. 0-Diphenylmethyl 
EXAMPLES 
Preparation of 0-(p-Methoxybenzyl)-N-[3-(N' ,N'-
dimethylcarbamoyl) hydroxy-1-methyl-2-
65 pyridinemethylene] hydroxylamine chloride (2c). 
0-(p-Methoxybenzyl)-N-[3-(N' .N' -dimethylcarbamoyl) 
hydroxy-2-pyridine methylene) hydroxylamine. Dimethyl-
5.726,314 
39 
carbamyl chloride (10 mL. 0.11 mol) was added to a solution 
of 0-(p-methoxybenzyl)-N-(3-hydroxy-2-
pyridinemethylene) hydroxylamine (3.3 g. 12.8 mmol) in 30 
mL of pyridine. The resulting mixture was stirred at room 
temperature for 14 h and then poured over 400 mL of 5 
crushed ice. Since it was not possible to induce precipitation 
of the product, the aqueous mixture was extracted with ether 
40 
hydroxy-l-benzyl-2-pyridinemethylene] hydroxylamine 
bromide, 0-(p-methoxybenzyl)-N-[5-(N' ,N'-
dimethylcarbamoyl)hydroxy-1-( 1-naphtylmethyl)-2-
pyridinemethylene] hydroxylamine chloride, 0-(p-
methoxybenzyl)-N-[5-(N'.N'-dimethylcarbamoyl)hydroxy-
1-(2-methyl-1-oaphtylmethyl)-2-pyridinemethyleoe] 
hydroxylamine chloride, 0-(p-methoxybenzyl)-N-[5-(N' .N'-
dimethylcarbamoyl)hydroxy- l-diphenylmethyl-2-
pyridinemethylene] hydroxylamine chloride, 0-(p-(4 x 100 mL) and the organic extract was concentrated to dryness in vacuo. The oily residue was coevaporated with 
water to remove traces of pyridine and then with acetone. 
The 300 MHz 1 H NMR of the resulting yellow oil shows no 
pyridine or water and was used in the next step without 
further purification. 
10 methoxybenzyl)-N-[5-(N',N'-dimethylcarbamoyl)hydroxy-
1-( 2-hydroxy-4-nitrobenzyl)-2-pyridinemethylen e] 
hydroxylamine chloride, 0-(p-methoxybenzyl)-N-[ 5-(N' .N' -
dime thy lcarbamoy 1 )hydroxy-1-(p-carboxybe nzy 1 )-2-
pyridinemethy lene] hydroxylamine chloride, 0-(p-
methoxybenzyl)-N-[5-(N'.N'-dimethylcarbamoyl)hydroxy-0-(p-Methoxybenzyl)-N-[3-(N' ,N'-dimethylcarbamoyl) 
hydroxy-1-methyl-2-pyridinemethylene] hydroxylamioe 
chloride. Methyl iodide (2.9 mL. 46.4 mmol) was added to 
each of two pressure glass tubes containing a solution of 
0-(p-methoxybenzyl)-N-[3-(N'.N'-dimethylcarbamoyl) 
hydroxy-2-pyridinemethylene] hydroxylamine (3.82 g. 11.6 
mmol. divided into two) in 40 mL of acetonitrile. The sealed 20 
15 1-(p-cyanobenzyl)-2-pyridinemethylene] hydroxylamine 
chloride can be made by the same procedure replacing 
3-hydroxy-2-pyridine aldehyde with 2-formyl-5-hydroxy 
pyridine. 
EXAMPLE9 
reaction vessels were heated at 70° C. for 3 days and then the Preparation of N-f 5-(N' ,N'-Dimethylcarbamoyl)hydroxy-1-
solvent was removed in vacuo. The resulting oil crystallizes methyl-2-pyridine methylene] hydroxylamine chloride (2d). 
upon standing at 0°-5° C. for 14 h in a 2:1 mixture of 2-Formyl-5-hydroxypyridine. To a stirred solution of 21.8 
acetone/ether (75 mL). The yellow solid was filtered. g of 5-hydroxy-2-picoline (0.2 mol) in 200 mL of glacial 
washed with ether and dried to yield 4.94 g (90%) of crude 25 acetic acid was added 18 mL of 30% hydrogen peroxide 
methiodide. It was dissolved in 1: 1 mixture of H20/ ( 0.159 mol) in one portion. The mixture was heated in an oil 
acetonitrile (200 mL) and then freshly madeAgCl (21 mmol. bath at 80°-85° C. with stirring for 3 h. Then another 18 mL 
washed well with water) was added. The resulting suspen- of hydrogen peroxide was added and the mixture was stirred 
sion was stirred at room temperature for 2 h and filtered for 3 h at the same temperature. Excess solvent was removed 
through Celite. The filtrate was concentrated to dryness in 30 in vacuo followed by the addition of acetone. which caused 
vacuo and the residue was triturated with 1:1 acetone/ether. the pyridine N-oxide to crystallize. Without further 
The white solid that resulted was filtered. washed with ether purification. 200 mL of acetic anhydride was added to the 
and dried to yield 3.72 g (84.4%) of pure chloride. m.p. solid and the mixture was heated at 120° C. with stirring in 
145°-6° C. (dee.). Anal. Calcd. for C18H22ClN30 4 x 0.5 anoilbathfor2h.Aftercoolingtoroomtemperature,excess 
H20: C. 55.59; H. 5.96; N.10.81; Cl. 9.12. Found: C. 55.59; 35 acetic anhydride was removed by high vacuum distillation. 
H. 6.03; N. 10.76; Cl. 9.17. The oily material was again oxidized with 30% hydrogen 
0-(p-Methoxybenzyl)-N-[3-(N'.N'-dimethylcarbamoyl) peroxide twice and rearranged with acetic anhydride fol-
hydroxy-1-ethyl-2-pyridinemethylene] hydroxylamine lowing the same procedure and amounts depicted above. 
chloride, O-(p-methoxybenzyl)-N-[3-(N' ,N'- The black oily material obtained was hydrolyzed with 200 
dime th ylc arbamo y l)h y dr ox y-1-b en zy 1-2- 40 mL of lN HCl (0.2 mol) at room temperature for 3 weeks 
pyridinemethylene] hydroxylamine bromide. 0-(p- (hydrolysis at higher temperature may be harmful to the 
methoxybenzyl)-N-[3-(N'.N'-dimethylcarbamoyl)hydroxy- pyridine nucleus). The mixture was neutralized with anhy-
1-(1-naphtylmethyl)-2-pyridinemethylene] hydroxylamine drous sodium carbonate. indicated by litmus paper and then 
chloride, 0-(p-methoxybenzyl)-N-[3-(N'.N'- extracted three times with 300 mL of diethylether. The 
dimethylcarbamoyl)hydroxy-1-(2-methyl-1-naphtylmethyl) 45 combined ether extracts were dried (MgS04 ). filtered and 
-2-pyridinemethylene] hydroxylamine chloride. 0-(p- evaporated to leave a solid material in a small mount of oil. 
methoxybenzyl)-N-[3-(N'.N'-dimethylcarbamoyl)hydroxy- The pure product (7.8 g. 32%) was obtained by filtering the 
l-diphenylmethyl-2-pyridinemethylene] hydroxylamine solid. followed by washing it with a small amount of ether. 
chloride. 0-(p-methoxybenzyl)-N-[3-(N' .N'- It is yellow in color and shows a sharp melting point at 
dimethylcarbamoyl)hydroxy-1-(2-hydroxy-4-nitrobenzyl)- 50 186°-187° C. 1H NMR (~-DMSO) d: 11.iO (br. s, lH. OH); 
2-pyridinemethylene] hydroxylamine chloride, 0-(p- 9.87 (s, lH. CHO); 8.35 (d, J=2Hz. lH); 7.58 (d, J=9 Hz, 
methoxybenzyl)-N-[3-(N',N'-dimethylcarbamoyl)hydroxy- lH); 7.35 (d of d. J=2Hz. 9Hz. lH). 
1-(p-carboxybenzyl)-2-pyridinemethylene] hydroxylamine N-( 5-Hydroxy-2-pyridinemethylene) hydroxylamine. To 
chloride. and 0-(p-methoxybenzyl)-N-[3-(N' ,N'- 200 mL of 2.5% (w/w) sodium hydroxide solution was 
dimethylcarbamoyl)hydroxy-l-(p-cyanobenzyl)-2- 55 dissolved 5.5 g of 5-hydroxy-2-formylpyridine (45 mmol). 
pyridinemethylene] hydroxylamine chloride can be made by Subsequently 12.5 g of hydroxylamine HCl ( 180 mmol) was 
the same procedure replacing methyl iodide in the above added to the solution in one portion. The solution turned 
example respectively with ethyl iodide, benzyl bromide, cloudy after being stirred for IO minutes. After stirring at 
1-chloromethyl naphtalene, 1-chloromethyl-2-methyl room temperature for 3 h. the precipitate was filtered under 
naphtalene, chlorodiphenylmethane, 2-chloromethyl-4- 60 vacuum and dried in the air for several days to yield 4.8 g 
nitrophenol. 4-chloromethyl benzoic acid. and 4-cyano ben- of N-(5-hydroxy-2-pyridinemethylene) hydroxylamine 
zyl chloride. 0-(p-Methoxybenzyl)-N-[5-(N'.N'- (78%). The solid is off white and decomposes at 195° C. 1H 
dimethyl carb amo yl) h ydrox y-1-me thy 1- 2- NMR(d6-DMSO) d: 11.27 (hr. s. lH); 10.83 (br. s, lH); 8.18 
pyridinemethylene] hydroxylamine chloride. 0-(p- (d. 1=2 Hz. lH); 8.05 (s. lH. CH N); 7.72 (d. J=9Hz. lH); 
methoxybenzyl)-N-(5-(N'.N'-dimethylcarbamoyl)hydroxy- 65 7.25 (d of d. J=2Hz. 9Hz, lH). 
1-ethyl-2-pyridinemethylene] hydroxylamine chloride, N-(5-(N' .N' -Dimethylcarbamoyl)hydroxy-2-pyridine 
0-(p-methoxybenzyl)-N-f 5-(N' .N'-dimethylcarbamoyl) methylene] hydroxylarnine. Dimethylcarbamoyl chloride 
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(5.2 mL, 57 mmol) was added to a solution ofN-(5-hydroxy-
2-pyridinemethylene) hydroxylamine (6.53 g. 47 mmol) in 
42 
stirred with silver chloride precipitated from a solution of 
6.0 g (35.3 mmol) of silver nitrate with excess of aqueous 
HCl. After 40 min the reaction mixture was filtered and the 
precipitate washed with a total of 100 mL of warm water. 
40 mL of pyridine. It was stirred at room temperature 
overnight and then the solvent was removed in vacuo, 
leaving a light green paste. The paste was dissolved in a 
minimum quantity of acetone and then triturated with ethyl 
acetate and placed in the freezer overnight. Glassy needles 
formed and were filtered and washed with ethyl acetate to 
yield 3.0 g of pure product (30%), m.p. 134°-135° C. 
5 Pale yellow crystals of product melting at 230°-232° C. 
(dee.) were obtained from the combined filtrate by both 
rotoevaporation and precipitation with acetone. Yield 4.12 
grams (95.3%). 1H NMR (D20. TSP) d: 8.45 (s. lH), 8.36 
(d. lH. 1=5.8 Hz). 8.03 (d, lH. 1=8.3 Hz), 7.80 (d of d, lH). 
10 4.42 (s. Me). Anal. Calcd for CsH11N40 2Cl: C. 41.66; H. 
4.8l;N. 24.28; Cl, 15.37. FoundC. 41.59. H.4.85; N. 24.28; 
Cl, 15.44. 
N-[5-(N',N'-Dimethylcarbamoyl)hydroxy-1-methyl-2-
pyridinemethylene) hydroxylamine chloride. Methyl iodide 
(5.3 mL. 85 mmol) was added to a solution of N-[5-(N',N'-
dimethylcarbamoyl)hydroxy-2-pyridine methylene] 
hydroxylamine (2.8 g. 13.4 mmol) in 25 mL .of acetonitrile. 
The resulting mixture was put into a glass pressure vessel 15 
and heated at 80° C. for 3 days. The solvent was removed in 
vacuo and the residue was dissolved in a minimum quantity 
of acetone. triturated with ether and placed in the freezer 
overnight. A dark yellow solid resulted and was filtered 
under vacuum and washed with 1: 1 ether/acetone to yield 20 
3.25 g of the iodide salt. Freshly made AgCl (2 eq. washed 
well with water) was added to the iodide salt in acetonitrile/ 
water (60 mLJlOO mL) and stirred for several hours. After 
filtration. the residue was crystallized from acetone/ether 
and dried in the air for several days to yield 2.5 g of the 25 
chloride salt (monohydrate, 72% yield); m.p. 159°-160° C. 
1HNMR (di;-DMSO) d: 9.18 (s, lH); 8.65 (s, lH); 8.40 (d of 
2-[[(Aminothiocarbonyl)hydrazono]methyl)-3-hydroxy-
1-methyl pyridinium chloride. 2-hydrazonomethyl-3-
hydroxy-1-methyl pyridinium chloride. 1-methyl-2-(3-
hydroxy-1-methyl-2-pyridinemethylene) hydrazine 
chloride, 1-methyl-1-phenyl-2-(3-hydroxy-1-methyl-2-
pyridinemethylene) hydrazine chloride. 1.l-diphenyl-2-(3-
hydroxy-1-methyl-2-pyridinemethylene) hydrazine 
chloride, l-(2.4-dinitrophenyl)-2-(3-hydroxy-1 -methyl-2-
pyridinemethylene) hydrazine chloride. and 1-(2-naphtyl)-
2-(3-hydroxy-1-methyl-2-pyridinemethylene) hydrazine 
chloride can be made by the same procedure replacing 
semicarbazide in the above example respectively with 
thiosemicarbazide. hydrazine, methylhydrazine, 1-methyl-
1-phenylhydrazine, 1.1-diphenylhydrazine, 2.4-
dinitrophenylhydrazine, and 2-naphtylhydrazine. 2-[[ 
(Aminocarbonyl)hydrazono ]methyl)-5-hydroxy-1-methyl 
pyridinium chloride, 2-[[(aminothiocarbonyl)hydrazono] 
d. 2H. 1=2 Hz, 9 Hz); 4.36 (s. 3H); 3.3 (s. H20); 3.1(s,3H); 
2.95 (s, 3H). Anal. Calcd. for C1Jl14N30 3ClH20: C. 43.25; 
H. 5.81; N. 15.13; Cl. 12.76. Found: C. 43.42; H. 5.81; N. 
15.09; Cl. 12.87. 
N-[3-(N'.N'-Dimethylcarbamoyl)hydroxy-1-methyl-2-
pyridinemethylene] hydroxylamine chloride can be made by 
the same procedure replacing 2-formyl-5-hydroxypyridine 
with 3-hydroxy-2-pyridine carbaldehyde. 
30 methyl]-5-hydroxy-1-methyl pyridinium chloride. 
2-hydrazonomethyl-5-hydroxy-1-methyl pyridinium 
chloride, 1-methyl-2-(5-hydroxy-1-methyl-2-
pyridinemethylene) hydrazine chloride. 1-methyl-1-phenyl-
2-(5-hydroxy-1-methyl-2-pyridinemethylene) hydrazine 
EXAMPLE 10 
Preparation of 2-[[(Aminocarbonyl)hydrazono ]methyl)-3-
hydroxy-1-methyl pyridinium chloride (3a). 
35 chloride. 1, 1-diphenyl-2-(5-hydroxy-1-methyl-2-
pyridinemethylene) hydrazine chloride. 1-(2.4-
dinitroph e nyl )-2-(5 -h ydroxy-1-methyl-2-
pyridinemethylene) hydrazine chloride, and 1-naphtyl-2-(5-
hydroxy-1-methyl-2-pyridinemethylene) hydrazine chloride 
40 can be made by the same procedure replacing 3-hydroxy-
2-pyridine aldehyde with 2-formyl-5-hydroxy pyridine. 
2-Hydrazonomethyl-3-hydroxy-1.6-dimethyl pyridinium 
chloride, 1-methyl-2-( 1.6-dimethyl-3-hydroxy-2-
2-[[(Aminocarbonyl)hydrazono]methyl)-3-hydroxy pyri-
dine. Sodium acetate (2.21 g. 16 mmol) was dissolved in 25 
mL of water and then semicarbazide hydrochloride was 
added (1.81 g.16 mmol). followed by 3-hydroxy-2-pyridine 
aldehyde (2.0 g. 16 mmol). The resulting mixture was stirred 45 
at room temperature for 2 h. The solid in the reaction 
mixture was then filtered. washed with water and dried to 
yield 2. 71 g (93%) of the semicarbazone. It was used in the 
next step without further purification; m.p.: 215°-217° C. 
(dee.). 
2-[ [ ( Aminocarbonyl)hydrazono ]methyl)-3-hydroxy-1-
methyl pyridinium iodide. A glass pressure tube containing 
pyridinemethylene) hydrazine chloride, l-methyl-1-phenyl-
2-(1.6-dimethyl-3-hydroxy-2-pyridinemethylene) hydrazine 
chloride, and i, l-diphenyl-2-(1.6-dimethyl-3-hydroxy-2-
pyridinemethylene) hydrazine chloride can be made by the 
same procedure replacing 3-hydroxy-2-pyridine aldehyde in 
the above example with 3-hydroxy-6-methyl-2-pyridine 
50 aldehyde. 
EXAMPLE 11 
a stirring bar was charged with 20 grams (11.1 mmoles) of Preparation of 3-Hydroxy- l-methyl-2-( [(N-
2-[[(aminocarbonyl)hydrazono]methyl]-3-hydroxy phenylaminocarbonyl)hydrazono)methyl)pyridinium chlo-
pyridine. 2.5 g of barium carbonate. 7.0 g (49.3 mmol) of 55 ride (3b). 
methyl iodide and 30 mL of DMF. The reaction mixture was 3-Hydroxy-2-([(N-phenylaminocarbonyl)hydrazono] 
stirred for two days at 65° C. in an oil bath. After that time methyl] pyridine. 4-Phenyl semicarbazide (4.91g.33 mmol) 
the solvent was removed in vacuo. the residue shaken with. was added to a suspension of 3-hydroxy-2-pyridine carbal-
50 mL of warm water and filtered. The filtrate was then dehyde (4.0 g. 33 mmol) in a mixture of ethanol water (30 
treated with an aqueous solution of H2S04 in amount needed 60 mL:40 mL). The reaction mixture was stirred at room 
for the precipitation of Ba2+ present in the solution. After temperature for 3 h and the yellow product was collected by 
collecting BaS04 • the filtrate was concentrated and crystal- filtration. The yellow precipitate was washed with EtOW 
lized from a mixture of water and ethanol to afford 2.1 g H20 1:1 and dried under P20 5 to yield 8.22 g (99%) of (58.3%) of the methiodide salt. m.p. 180°-182° C. product. It can be recrystallized from EtOH/H20; m.p. 
2-[[(Aminocarbonyl)hydrazono]methyl]-3-hydroxy-1- 65 201°-2° C. (dee.). 1H NMR (di;-DMSO) d: 10.85 (br.s., lH); 
methyl pyridinium chloride. The preceeding iodide. 6.0 10.6 (br.s .• lH); 9.14 (s. lH); 8.27 (s. lH); 8.15 (d if d. lH); 
grams (18.6 mmol) was dissolved in 150 mL of water and 7.55 (d. 2H); 7.26-7.36 (m. 4H); 7.01 (t. lH). 
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3-Hydroxy-2- [ [ (N-phenylaminocarbonyl )hydrazono] 
methyl]-1-methyl pyridinium chloride. Methyl iodide (7.2 
mL. 0. 12 mol) was added to a suspension of 2-[[(N-
44 
obtained as a dark beige solid (12.54 g. 87%) and was used 
in the next step without further purification; m. p. 181°-182° 
c. 
phenylaminoearbonyl) hydrazono]methyl)-3-hydroxy pyri- 1-Methyl-2-[[(N-phenylaminocarbonyl) hydrazono] 
dine (3. 72 g. 15 mmol) in 50 mL of acetonitrile. The reaction 5 methyl] pyridinium chloride. 2-[[(N-Phenylaminocarbonyl) 
mixture was placed in two pressure glass vessels and heated hydrazonolmethyl] pyridine (4.47 g. 0.02 mol) was divided 
at 70° C. for 3 days. The solid which filled the reaction flasks into two pressure glass tubes and dissolved in acetonitrile 
was filtered and triturated well with warm (40° C.) acetone. (20 mL each). Methyl iodide was then added (2.6 mL each. 
The product was dried to yield 5.13 g (89%) of methiodide. 0.04 mol). the tubes were tightly closed and heated at 65° C. 
It was dissolved in a mixture of water/acetonitrile (500 10 for 3 days. The reaction flasks were cooled to 10°-15° C. 
mL.:300 mL) and then freshly made AgCl (2 eq) was added. and the solid was filtered. The yellow solid was washed with 
The suspension was stirred at room temperature for 2 hand acetone and ether and dried to yield 6.66 g (92%) of the 
then filtered through Celite. The filtrate was concentrated to iodide salt; m.p. 192°-193° C. (dee.). It was dissolved in 400 
dryness in vacuo and the residue was triturated with acetone. mL of acetonitrile/water 1: 1 and exchanged with freshly 
The yellow solid was filtered, washed with acetone and dried 15 made AgCl (from 5.92 g of AgN03 and excess cone. HCl. 
to yield 3.67 g (93%) of the pure chloride; m.p. 220°-221° washed well with water). The resulting suspension was 
C. (dee.). It can be recrystallized from EtOH. 1H NMR stirred at room temperature for 2 h. The silver iodide was 
(d6-DMSO) d: 11.74 (br.s .• lH); 9.27 (s, lH); 8.58 (d. lH. filtered off and the filtrate was concentrated to dryness in 
J=5. 7 Hz); 8.39 (s. lH); 8.17 ( d, lH. J=8.2 Hz); 7 .85 ( d of vacuo to yield a yellow solid that was triturated with acetone 
cl. lH, J=5.7 Hz. J=8.2 Hz); 7.57 (cl. 2H. J=7.6 Hz); 7.31 (t. 20 and ether. It was filtered and dried to yield 4.86 (96%) of the 
2H. J=7.6 Hz); 7.04 (t. lH. J=7.6 Hz); 4.48 (s. 3H). Anal. pure chloride salt as a yellow solid; m.p. 187°-188° C. 
Calcd. for C14H1sClN40 2 x 0.95 H20: C. 51.90; H, 5.26; N. (dee.). 1H NMR (doDMSO) o: 11.87 (s, lH); 9.45 (s. lH); 
17.29; Cl, 10.94. Found: C. 51.90; H, 5.22; N. 17.36; Cl. 8.98 (dof d. 2H); 8.56(t, 1H); 8.43 (s. lH); 8.01 (t. lH); 7.62 
10.89. (d. 2H); 7.34 (t, 2H); 7.08 (t. lH); 4.36 (s, 3H). Anal. Calcd. 
3-Hydroxy-l-methyl-2-[[(N-phenylaminothiocarbonyl) 25 for C14H1sClN40 x 0.48 H20: C. 56.15; H. 5.37; N. 18.71; 
hydrazono]methyl)pyridinium chloride. 2-[[N,N- Cl. 11.84. Found: C. 56.15; H, 5.38; N. 18.69; Cl. 11.88. 
diphenylaminocarbonyl)hydrazonolmethyl]-3-hydroxy-1-
m ethyl pyridinium chloride, 2-[[(N.N- EXAMPLE 13 
dimethylaminothiocarbonyl)hydrazono ]methyl]3-hydroxy-
30 
Preparation of 2-[ [ (Aminocarbonyl)hydrazono ]methyl )-3-
1- methyl pyridinium chloride. 2-[[(N- (N.N-dimethylcarbamoyl)hydroxy-1-methyl pyridinium 
ethylaminothiocarbonyl)hydrazono ]methyl]-3-hydroxy-1- chloride (4a). 
methyl pyridinium chloride. 3-hydroxy-1-methyl-2-[[(N-
naphtylaminocarbonyl) hydrazono]methyl] pyridinium 2-[[(Aminocarbonyl)hydrazono]methyl]-3-hydroxy pyri-
chloride, and 2-[[[N-(l-chloro-2-naphtyl)amino carbonyl] dine. Sodium acetate (2.21 g. 16 mmol) was dissolved in 25 
35 mL of water and then semicarbazide hydrochloride was hydrazono]methyl)-3-hydroxy-1-methyl pyridinium chlo- added (l.81g.16 mmol) followed by 3-hydroxy-2-pyridine 
ride can be made by the same procedure replacing 
4-phenylsemicarbazide in the above example respectively aldehyde (2.0 g. 16 mmol). The resulting mixture was stirred 
at room temperature for 2 h. The solid in the reaction 
with 4-phenyl-3-thiosemicarbazide, 4 .4- mixture was then filtered. washed with water and dried to 
diphenylsemicarbazide. 4,4-dimethyl-3-thiosemicarbazide. 
4-ethyl-3-thiosemicarbazide, 4-(2-naphtyl)semicarbazide 40 yield 2. 71 g (93%) of the semicarbazone. It was used in the 
and 4-(1-chloro-2-naphtyl)semicarbazide. 5-Hydroxy-1- next step without further purification; m.p.: 2150_2170 C. 
methyl-2-[[ (N-phenylaminocarbonyl)hydrazono] methyl] (dee.). 
pyridinium chloride. 5-hydroxy- l-methyl-2-[ [(N- 2-[[ (Aminocarbonyl)hydrazono ]methyl]-3-(N .N-
phenylaminothiocarbonyl) hydrazono]methyl] pyridinium dimethylcarbamoyl)hydroxy pyridine. The semicarbazone 
chloride, 2-[[(N,N-di phenylaminocarbonyl)hydrazono] 45 obtained in the previous step (2.71 g. 15 mmol) was sus-
methyl]-5-hydroxy-1-methyl pyridinium chloride, 2-[[(N.N- pended in 20 mL of pyridine and then N,N-
dimethylaminothiocarbonyl) hydrazonolmethyl)-5- dimethylcarbamyl chloride was added (4.2 mL, 45 mmol). 
hydroxy-1-methyl pyridinium chloride, 2-[[ (N- The reaction flask was sealed with a septum and the mixture 
ethylaminothiocarbonyl) hydrazonolmethyl]-5-hydroxy-1- was stirred at room temperature for 20 h. The reaction 
methyl pyridinium chloride. 5-hydroxy-1-methyl-2-[[(N- 50 mixture becomes a clear solution after one hour and the 
naphtylaminocarbonyl)hydrazono]methyl] pyridinium product begins to come out of solution after 2 h. When the 
chloride, and 2-[[[N-(l-chloro-2-naphtyl)amino carbonyl] reaction is complete. the mixture is cooled to 5°-10° C. in 
hydrazono)methyl]-5-hydroxy-1-methyl pyridinium chlo- ice bath and filtered. The beige solid that results is washed 
ride can be made by the same procedure replacing with acetone/ether 1: 1 and dried to yield 3.63 g (? 6%) of the 
3-hydroxy-2-pyridine aldehyde with 2-formyl-5-hydroxy 55 carbamate which is used in the next step without further 
pyridine. purification; m.p. 182°-3° C. (dee). 
EXAMPLE 12 2-[[(Aminocarbonyl) hydrazono)methyl)-3-(N.N-dimethylcarbamoyl)hydroxy-1-methyl pyridinium chloride. 
Preparation of 1-Methyl-2-L[(N-phenylaminocarbonyl) The carbamate obtained in the previous step (3.63 g. 14 
hydrazono]methyl] pyridinium chloride (3d). 60 mmol) was dissolved in 50 mL hot (90° C.) DMR When a 
2-[[(N-Phenylaminocarbonyl) hydrazono]methyl] clear solution was obtained, the reaction flask was cooled 
pyridine. Pyridine-2-Aldehyde (5.7 mL. 0.06 mol) was under running water until the inner temperature reached 26° 
added to a suspension of sodium acetate (4.92 g. 0.06 mol) C. Methyl iodide (6.3 mL. 100 mmol) was then added and 
and 4-phenyl semicarbazide (9.07 g, 0.06 mol) in 60 mL of the reaction mixture was left at 65° C. in a Parr shaker for 
water. The resulting mixture was stirred at room temperature 65 3 days. The solvent was removed in vacuo to yield a dark 
for 14 h and the solid in suspension was filtered and washed viscous residue which was triturated with acetone. The 
thoroughly with water. After drying. the semicarbazone was yellow solid that resulted was washed with acetone/ether 
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1:1. then with ether and dried to yield 5.15 g (94%) of the chloride hydrazide (2.63 g. 0.014mol)in lOmLofmethanol 
methiodide. Freshly made AgCl (from 4.45 g AgN03 and was added to a solution of 2-aldehyde-3-hydroxy pyridine 
excess cone. HCl) was washed well with water andadded to (1.72 g. 0.014 mol) in 20 mLof CH3CN. The resulting dark 
a solution of the methiodide ( 5.15 g. 13 mmol) in 200 mL yellow solution is stirred at room temperature for 2 h and at 
acetonitrile/water 1:1. The resulting suspension was stirred 5 the end of this period a beige solid filled the reaction 
at room temperature for 1.5 h. The silver iodide was filtered mixture. Ethyl ether was added (10 mL) and the reaction 
through Celite and the filtrate was concentrated to dryness in mixture was cooled to 5°-10° C. before filtering the beige 
vacuo to yield a residue which is triturated with acetone. The precipitate. The solid was washed with ethyl ether and dried 
resulting solid is filtered and recrystallized from CH3CN/ to yield 3.72 g (91%) of product; m.p. 229°-30° C. (dee). 
EtOH and acetone to yield 2.44 g (62%) of the pure chloride 10 2-(3-Hydroxy-1-methyl-2-pyridinemethylene )-1-[2-( 1-
salt; m.p. 194°-195° C. (dee.). Anal. Calcd. for pyridinium)acetyl] hydrazine dichloride. The acyl hydra-
C11H16CIN,03 x 0.96 H20: C. 41.42; H. 5.66; N. 21.96; Cl. zone obtained in the previous step (3.5 g. 0.012 mol) was 
111.12. Found: C, 41.42; H. 5.72; N. 21.81; CI. 111.20. divided into three pressure glass vessels and each portion 
2-[[(Aminocarbonyl)hydrazono]methyl]-3-(N,N- was dissolved in 20 mL of acetonitrile. Methyl iodide was 
dimethylcarbamoyl)hydroxy-1.6-dimethyl pyridinium chlo- 15 added to these solutions (1.2 mL each, 0.02 mol) and the 
ride can be made by the same procedure replacing resulting mixtures were heated at 70° C. for 3 days. The 
3-hydroxy-2-pyridine aldehyde in the above example with reaction mixtures were concentrated in vacuo to a dark 
3-hydroxy-6-methyl-2-pyridine aldehyde. 2-[[ residue which was triturated with acetone/ethanol 5: 1. The 
(Aminocarbonyl)hydrazono] methyl] -5-(N ,N- resulting yellow solid was washed with acetone/ethanol 5:1 
dimethylcarbamoyl)hydroxy-1-methyl pyridinium chloride 20 and dried to obtain 4.39 g (84%) of the iodide salt m.p. 
can be made by the same procedure replacing 3-hydroxy- 193°-94° C. (dee). Freshly made AgCI (from 3.43 g of 
2-pyridine aldehyde in the above example with 2-formyl-5- AgN03 and excess cone. HCl) was washed well with water 
hydroxy pyridine. and added to a solution of the iodide salt (4.39 g. 0.01 mol) 
in 300 mL acetonitrile/water 1:1. The resulting suspension 
25 was stirred at room temperature for 2 h. The silver iodide EXAMPLE 14 
Preparation of 3-(N,N-Dimethylcarbamoyl)hydroxy-1- was filtered through Celite and the filtrate was concentrated 
methyl-2-[[(N-phenylaminocarbonyl) hydrazonolmethyl] to dryness in vacuo to yield a solid that was triturated with 
pyridinium chloride (4b). acetone. The dark beige solid was filtered, washed with 
3-(N,N-Dimethylcarbamoyl)hydroxy-2-[[(N- acetone and dried to yield 2.89 g (84%) of pure product as 
phenylaminocarbonyl)hydrazono]methyl] pyridine was pre- 30 the chloride salt; m.p. 230°-31° C. (dee.). Anal. Calcd. for 
pared by reaction of dimethylcarbamyl chloride (16 mL. C14H16Cl2N402 x 0.96 H20: C. 46.65; H. 5.01; N, 15.55; Cl. 
0.18 mol) with 3-hydroxy-2-[[(N-phenylaminocarbonyl) 119.67. Found: C. 46.65; H. 4.95; N, 16.33; Cl, 20.66. 
hydrazono]methyl] pyridine (4.5 g, 17.5 mmol) in 30 mL of 2-(3-Hydroxy-1-methyl-2-pyridiriemethylene)-l-[2-
pyridine. The resulting mixture was stirred at room tern- (trimethylammonium)acetyl]hydrazine dichloride, 1-[2-(4-
perature for 6 hand poured over 500 mL of crashed ice. The 35 chloro-1-pyridinium)acetyl] -2-(3-hydroxy-1-methyl-2-
beige precipitate was collected, washed thoroughly with pyridinemethylene) hydrazine dichloride, 1-(2-(3-carboxy-
water and dried to yield 5.48 g (95%) of product, m.p. 1-isoquinolinium)acetyl]-2-(3-hydroxy-1-methyl-2-
1780-1800 C. The product (5.48 g, 16.7 mmol) was dis- pyridinemethylene) hydrazine dichloride, 1-[2-(2-carboxy-
solved in acetonitrile/DMF and then methyl iodide (2.78 4-methoxy-1-quinolinium) acetyl]-2-(3-hydroxy-1-methyl-
mL. 44.7 mmolx3 vessels) was added to the reaction vessel. 40 2-pyridine methylene) hydrazine dichloride, 2-(3-hydroxy-
The resulting mixture was stirred at 70° C. for 3 days and 1-methyl-2-pyridinemethylene)-1-[2-(3-hydroxy-1-
cooled in a water-ice bath for 30 min. The precipitate was pyridinium)acetyl]hydrazine dichloride, 2-(3-hydroxy-1-
collected by filtration, washed with acetone/ether 1:1 and methyl-2-pyridinemethylene)-1-[2-( 1-methyl-1-
dried to yield 6.42 g (82%) of the methiodide salt. Il was piperidinium)acetyl] hydrazine dichloride can be made by 
dissolved in 500 mL H20 and 300 mL acetonitrile and then 45 the same procedure replacing 1-(carboxymethyl) pyridinium 
freshly made AgCl (2 eq. washed well with water) was chloride hydrazide respectively with (carboxymethyl) 
added. The resulting suspension was stirred at room tern- trimethylammonium chloride hydrazide (Girard's reagent 
perature for 2h. It was filtered through Celite and the filtrate "T"), 4-chloro-1-( carboxymethyl)pyridinium chloride 
was concentrated to dryness in vacuo to a crisp yellow foam hydrazide. 3-carboxy-1-( carboxymethyl)isoquinolinium 
that becomes a yellow solid after trituration with acetone. 50 chloride hydrazide, 2-carboxy-4-methoxy-1-
The yellow solid was filtered. washed with ether and dried ( carboxymethyl)quinolinium chloride hydrazide. 
to yield 4.83g (93%) of pure product as the chloride salt; 3-hydroxy-1-(carboxymethyl)pyridinium chloride 
m.p. 176°-177° C. (dee.). Anal. Calcd. for C17H20CIN50 3 hydrazide. and 1-methyl-1-(carboxymethyl) piperidinium 
x 0.84 H20: C, 51.95; H. 5.56; N. 17.82; Cl, 9.02. Found: C. chloride hydrazide. 2-( 5-Hydroxy-1-methyl-2-
51.95; H, 5.55; N, 17.80; Cl, 19.11. 55 pyridinemethylene)-1-[2-(l-pyridinium)acetyl] hydrazine 
5-(N ,N-Dimethylcarbamoyl)hydroxy-1-methyl-2-[ [ (N- dichloride, 2-(5-hydroxy-l-methyl-2-pyridinemethylene )-1-
phenylaminocarbonyl) hydrazono ]methyl] pyridinium chlo- [2-(trimethylammonium)acetyl]hydrazine dichloride, 1-[2-
ride can be made by the same procedure replacing (4-chloro-1-pyridinium)acetyl]-2-(5-hydroxy-l-methyl-2-
3-hydroxy-2-pyridine aldehyde with 2-formyl-5-hydroxy pyridinemethylene) hydrazine dichloride. 1-[2-(3-carboxy-
pyridine. 60 1-isoquinolinium)acetyl]-2-(5-hydroxy-1-methyl-2-
pyridinemethylene) hydrazine dichloride. 1-[2-(2-carboxy-
4-methoxy-1-quinolinium)acetyl]-2-(5-hydroxy-1-methyl-
2-pyridinemethylene) hydrazine dichloride. 2-(5-hydroxy-
1-methyl-2-pyridinemethylene)-1-[2-(3-hydroxy-1-
EXAMPLE 15 
Preparation of 2-(3-Hydroxy-1-methyl-2-
pyridinemethylene )-1-[2-( 1-pyridinium)acetyl]hydrazine 
dichloride (Sa). 
2-(3-Hydroxy-2-pyridinemethylene )-1-[2-( 1-pyridinium) 
acetyl] hydrazine chloride. 1-(Carboxymethyl) pyridinium 
65 pyridinium)acetyl]hydrazine dichloride. and 2-(5-hydroxy-
1-methyl-2-pyridinemethylene )-1-[ 2-( 1-piperidinium) 
acetyl] hydrazine dichloride can be made by the same 
5,726,314 
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procedure replacing 3-hydroxy-2-pyridine aldehyde with 
2-formyl-5-hydroxy pyridine. 
EXAMPLE 16 
Preparation of 2-(1-Methyl-2-pyridinemethylene)-1-[2-(l-
pyriclinium)acetyl] hydrazine dichloride (5b). 
48 
mmol) was then added. and the tube was sealed tightly. The 
tube was heated at 69° C. in an oil bath for 20 h. The solvent 
was removed in vacuo. and the residue was triturated with 
acetone to give the product as a shiny dark yellow solid ( 1.4 
s g. 95%), m.p. 163°-16S0 C. The chloride salt can be 
obtained as described above. 
EXAMPLE 18 2-(2-pyridinemethylene )-1-12-( 1-pyridinium)acetyl] 
hydrazine chloride. 1-(Carboxymethyl) pyridinium chloride 
hydrazide (5.25 g. 28 mmol) and pyridine-2-carbaldehyde Preparation of O-Benzyl-N-(1.6-dimethyl-3-hydroxy-2-
(2.7 mL. 28 mmol) were dissolved in 25 mL acetoni- 10 pyridinemethylene) Hydroxylamine Chloride. 
trile:methanol (4: 1). The resulting mixture was stirred at 3-Hydroxy-6-methyl-2-pyridine carbaldehyde. 
room temperature for 2 h. with the product beginning to 3-Hydroxy-6-methyl-2-pyridine methanol (20.0 g, 0.14 
come out of solution after 20 min of reaction. After 2 h the mol) and selenium dioxide(8.0 g. 72 mmol) were dissolved 
white solid in the reaction mixture was filtered and washed in 140 mL of 1.4-dioxane and 280 mL of absolute ethanol. 
with acetonitrile and ether. After drying. the product was 15 The resulting mixture was heated at 80°-85° C. for 12 h. The 
obtained as a white solid (5.27 g. 68%) and was used in the selenium precipitate was removed by filtration and the 
next step without further purification; m.p. 240°-241° filtrate was concentrated to dryness in vacuo. The dark red 
C.(dec.). 1H NMR (d6-DMSO) o: 12.43 (br.s .• lH); 9.07 (d. residue was sublimed at 90° C. and 14 mmHg for 6 h to 
2H); 8.70 (t. lH); 8.66 (d. lH); 8.24 (d old. 2H); 8.19 (s. obtain 11.0 g (56%) of pure product. m.p. 101°-102° C.; 1H 
lH); 8.01-7.90 (m. 2H); 7.48-7.44 (m. lH); 6.07 (s. 2H). 20 NMR (CDC13 ) o: 10.50 (br s. lH). 10.03 (s. lH). 7.27 (s, 
2-(1-Methyl-2-pyridinemethylene)- i -[2-(1-pyridinium) 2H); 2.S3 (s. 3H). 
acetyl] hydrazine dichloride. The acyl hydrazone obtained in 0-Benzyl-N-(3-hydroxy-6-methyl-2-pyridinemethylene) 
the previous step (2.88 g. 10 mmol) was divided into two hydroxylamine. Sodium hydroxide (3.2 g. 0.08 mol) was 
pressure vessels and each portion was dissolved in 2S mL of 25 dissolved in 80 mL of a 1:1 mixture of ethanol/water and DMF. Methyl iodide was added to these solutions (l.62 mL then 0-Benzylhydroxylamine hydrochloride (12.77 g. 0.08 
each. 2S mmol) and the resulting mixtmes were heated at mol) was added. The reaction mixture was stirred at room 
70° C. for 3 days. The solvent was removed in vacuo to yield temperature and when a clear solution was obtained 11.0 g 
a dark residue which was triturated with acetone. The (0.08 mol) of 3-hydroxy-6-methyl-2-pyridine carbaldehyde 
resulting solid was filtered. washed with acetone and ether 30 was added and the resulting mixture was stirred at room 
and dried to yield 4.2S g (quantitative) of the methiodide as temperature for i 1 h. The reaction mixture was cooled in an 
a yellow solid. Freshly made AgCl (from 3. 77 g AgN03 and ice bath and filtered to yield 18.S3 g (96%) of product as a 
excess cone. HCl) was washed well with water and added to white solid, m.p. 81°-82° C. 1H NMR (Me2SO-dJ o: 9.8S 
a solution of the iodide salt (4.18 g. 10 mmol) in 200 mL (br s. lH). 8.40 (s, lH). 7.30-7.47 (m, 5H). 7.22 (d. lH). 
acetonitrile/water 1:1. The resulting suspension was stirred 35 7.13 (d, lH). S.22 (s, 2H), 2.36 (s. 3H). 
at room temperature for 1.S h. The silver iodide was filtered 0-B en zy 1-N - ( 1, 6- dimethyl- 3 - hydroxy- 2-
through Celite and the filtrate was concentrated to dryness in pyridinemethylene) hydroxylamine iodide. O-Benzyl-N-(3-
vacuo to yield 3.63 g of a yellow solid. Recrystallization hydroxy-6-methyl-2-pyridinemethylene) hydroxylamine 
from ethanol/acetone affords the pure chloride as a beige ( 10.0 g. 0.04 mol) was dissolved in 7S mL of acetonitrile and 
solid (3.0 g. 92%); m.p. 209°-210° C.(dec). 1H NMR 40 7.7 mL (0.12 mol) of methyl iodide. The reaction mixture (~-DMSO) o: 9.13 (d. 2H); 9.08 (d. lH); 8.7S-8.S9 (m. was heated in a pressure glass vessel at 90° C. for 3 days. 
4H); 8.26 (t. 2H); 8.10 (m. lH); 6.19 (br.s .. 2H); 4.42 (s, 3H). The solvent was removed in vacuo and the residue was 
Anal. Calcd. for C14H16Cl2N40 x 0.91 H20 C. 48.94; H. triturated with acetone to yield 8.1 g of a yellow solid. 
S.23; N. 16.31; CI. 20.64. Found: C. 48.94; H. S.2S; N. Recrystallization from acetone/EtOH/Et20 yields S.S g 
16.31; Cl. 20.43. 45 (3S%) of pure product as a pale yellow solid, 1H NMR 
EXAMPLE 17 
Preparation of O-Diphenylmethyl-N-(3-hydroxy-1-methyl-
2-pyridinemethylene) Hydroxylamine Iodide. 
O-Diphenylmethyl-N-(3-hydroxy-2-pyridinemethylene) so 
hydroxylamine. 0-Diphenyl methyl hydroxylamine hydro-
chloride (3.35 g. 14.2 mmol) was added to a solution of 
NaOH (0.57 g. 14.2 mmol) in 10 mL of H20. After the 
addition of 10 mL of EtOH. 3-hydroxy-2-pyridine aldehyde 
(l.7S g. 14.2 mmol) was added. The mixture was heated on 55 
a steam bath for I h. While the solution was allowed to cool 
an additional 30 mL of H20 was added. The product 
precipitated out as yellow needles. The mixture was filtered 
to isolate the pure product (3.8 g. 89%). m.p. 83°-84° C. 1H 
NMR (CDC13 ) o: 9.S7 (s. lH); 8.40 (s, lH); 7.33 (s. lOH); 60 
7.13 (m. 3H); 6.23 (s, lH).Anal. Calcd. for C1Ji1~203: C. 
74.97; H. S.31; N. 9.21. Found: C. 74.88; H. S.32; N. 9.17. 
0-Diphe nylmethyl-N-(3-hydroxy-1-methyl-2-
pyridinemethylene) hydroxylamine iodide. A solution of 
O-diphenylmethyl-N-(3-hydroxy-2-pyridinemethylene) 65 
hydroxylamine (1.0 g. 3.29 mmol) in 4S mL of EtOH was 
placed in a glass pressure tube. Methyl iodide (0.9 mL. 13.8 
(Me2SO-~) o: 8.SS (s, lH); 7.92 (d. lH); 7.87 (d, lH); 
7.30-7.48 (m. SH); S.2.5.33 (s, 2H); 3.93.4.08 (s. 3H); 2.72 
(s. 3H). 
0-B en zy 1-N -( 1, 6- dimeth yl-3-hy droxy- 2-
pyridinemethylene) hydroxylamine chloride. 0-Benzyl-N-
( 1.6-dimethyl-3-hydroxy-2-pyridinemethylene) hydroxy-
lamine iodide (S.S g. 14 mmol) were dissolved in 700 mL of 
water and 4.1 g (28 mmol) of freshly prepared AgCl (from 
silver nitrate and excess cone. HCl) was then added. The 
suspension was stirred mechanically for 2.S h at room 
temperature and the silver iodide was then removed by 
filtration. The filtrate was concentrated to dryness in vacuo 
and the residue was triturated with acetone to yield 3.6 g 
(86%) of pure product as a light beige solid. m.p. 175°-6° 
(dee.). 1H NMR (Me2SO-~) o: 8.52, 8.06 (s. lH); 8.10 (d. 
lH); 7.8S (t. lH); 7.30-7.4S (m. SH); S.30. S.20 (s, 2H); 4.1. 
3.9 (s. 3H); 2.69 (s. 3H). Anal. Calcd. for C15H17ClN2P2 x 
O.lS H20 C. 60.96; H. 5.90; N. 9.48; Cl. 12.00. Found: C, 
60.96; H. S.90; N, 9.Sl; Cl. 12.02. 
0-( 1-Naphtylmethyl)-N-( 1,6-dimethyl-3-hydroxy-2-
pyridinomethylone) hydroxylamine chloride. 0-(2-methyl-
1-naphtylmethyl )-N-( 1.6-dimethyl-3-hydroxy-2-
5,726,314 
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pyridinemethylene) hydroxylamine chloride, 0-methyl-N- 2-pyridine methylene) hydroxylamine (1.0 g, 4.4 mmol) in 
( 1.6-dimethyl-3-hydroxy-2-pyridinemethylene) 4 mL of acetonitrile. The resulting mixture was heatedat 65° 
hydroxylamine chloride, 0-(p-chlorobenzyl)-N-(l.6- C. in a pressure bottle for 3 days. The solvent was removed 
dimethyl-3-hydroxy-2-pyridinemethylene) hydroxylamine in vacuo and coevaporated with water to leave an oily 
chloride, O-(p-cyanobenzyl)-N-(l,6-dimethyl-3-hydroxy-2- s residue that was dissolved in 100 mL of water and treated 
pyridinemethylene) hydroxylamine chloride, 0-(2-hydroxy- with activated charcoal. This mixture was filtered through 
4-nitrobenzyl)-N-( 1,6-dimethyl-3-hydroxy-2- Celite and the filtrate was concentrated to dryness under 
pyridinemethylene) hydroxylamine chloride, 0-(p- high vacuum. Acetone (20 mL) was added to the residue and 
methoxybenzyl)-N-( 1.6-dimethyl-3-hydroxy-2- the product crystallized as light beige needles (1.5 g. 86%). 
pyridinemethylene) hydroxylamine chloride, 0-(p-dimethyl 10 m.p. 145°-146° C. 1H NMR (CDC13) o: 8.68 (s. lH); 8.63 
aminocarbonyloxybenzyl)-N-(l.6-dimethyl-3-hydroxy-2- (d of d, lH); 8.52 (t, lH); 7.69 (d of d, lH); 7.35 (m. 8H); 
pyridinemethylene) hydroxylamine chloride. O-(p- 7.10 (m. 2H); 6.12 (s. 2H); 5.25 (s. 2H). Anal. Calcd. for 
propylaminocarbonyl benzyl)-N-(l,6-dimethyl-3-hydroxy- C:wff1~rN202: C. 60.16; H. 4.80; N, 7.02; Br. 20.02. 
2-pyridine methylene) hydroxylamine chloride, O-benzyl- Found: C, 59.89; H. 4.86; N, 7.00; Br. 19.91. 
N-(3-(N' .N' -dimethylcarbamoy l)hydroxy- l.6-dimethyl-2- 1s 0-Benzyl-N-( 1-benzyl-5-hydroxy-2-pyridinemethylene) 
pyridinemethylene] hydroxylamine chloride. O-benzyl-N- hydroxylamine bromide can be made by the same procedure 
[3-(N'.N'-diethylcarbamoyl)hydroxy-1.6-dimethyl-2- replacing 3-hydroxy-2-pyridine aldehyde in the above 
pyridinemethylene] hydroxylamine chloride. O-benzyl-N- example with 2-formyl-5-hydroxy pyridine. 
(3-(N' .N-difiuoroethylcarbamoyl)hydroxy-1,6-dimethyl-2- GENERAL PROCEDURES 
pyridinemethylene] hydroxylamine chloride. 20 
0-( diphenylmethyl)-N-[3-(N' .N'-dimethylcarbamoyl) 2.6-Dichlorophenylsemicarbazide (General Procedure for 
hydroxy-1.6-dimethyl-2-pyridinemethylene] hydroxy- Phenylsemicarbazide Synthesis). The synthesis of phe-
lamine chloride, O-(diphenylmethyl)-N-(1.6-dimethyl _3_ nylsemicarbazides were carried out according to procedures (N'-isopropylcarbamoyl)hydroxy-2-pyridinemethylene) by Van Gelderen (1933). To a stirring solution of 10 mL 
hydroxylamine chloride, 0-(diphenylmethyl)-N-(3-(N'-(2- 25 methylene chloride and 2 g (I 1 mmol) hydrazine monohy-
fiuoroethyl)carbamoyl]hydroxy-1.6-dimethyl-2- drate at 0° C. was added dropwise a suspension of 5.5 g (110 
pyridinemethylene) hydroxylamine chloride, O-(p- mmol) of 2.6-dichlorophenyl isocyanate and 10 mL meth-
methoxybenzyl)-N-(3-(N',N'-dimethylcarbamoyl)hydroxy- ylene chloride. The semicarbazide was formed instanta-
1,6-dimethyl-2-pyridinemethylene) hydroxylamine neously and collected by suction filtration as a white solid. 
chloride, O-(p-methoxybenzyl)-N-[3-(N'.N'- 30 The product was washed with 100 mL water and 100 mL 
dimethylcarbamoyl)hydroxy-1-ethyl-6-methyl-2- methylene chloride; yield 600 mg (25%); mp 288°-290° C. 
pyridinemethylene] hydroxylamine chloride. 0-(p- 1H NMR (DMSO-~) o 8.30-8.26 (bs. lH), 7.55 (s. lH), 
methoxybenzyl)-N-[3-(N',N'-dimethylcarbamoyl)hydroxy- 7.50 (dd, 2H). 7.23 (m. lH). 4.42--4.40 (bs, 2H); FABMS 
1-benzyl-6-methyl-2-pyridinemethylene) hydroxylamine m/e (M+lr 220.1. Anal. calcd. for ~H7N30Cl2: C. 38.18; 
bromide, N-(3-(N' ,N'-dimethylcarbamoyl)hydroxy-1.6- 35 H. 3.20; N, 19.10; Cl, 132.23. Found: C, 38.04; H. 3.09; N, 
dimethyl-2-pyridinemethylene]hydroxylamine chloride. 18·93; a. 32.40. 
1.6-dimethyl-3-hydroxy-2-[[(N-phenylaminocarbonyl) 4-Methoxyphenylsemicarbazide. This compound was 
hydrazono] methyl] pyridinium chloride, l.6-dimethyl-3- prepared by the general procedure and collected as a white 
hydroxy -2-([(N-phenylaminothiocarbonyl) hydrazono] solid; yield 39%; mp 150°-152° C. 1H NMR (DMS0-'4). o: 
methyl] pyridinium chloride, 1,6-Dimethyl-2-[[(N.N- 40 8.62 (s, lH), 7.44 (d. 2H), 7.41 (s. lH). 6.87 (d. 2H). 4.33 
diphenylaminocarbonyl) hydrazono)methyl]-3-hydroxy (s. 2H). 3.69 (s, 3H);g FABMS m/e (M+lt 182. 
pyridinium chloride, 2-(1.6-dimethyl-3-hydroxy-2- 4-Chlorophenylsemicarbazide. This compound was pre-
pyridinemethylene)-1-(2-(1-pyridinium)acetyl] hydrazine pared by the general procedure and collected as a white 
dichloride. 2-( 1, 6-dimethyl-3-hydroxy-2- solid; yield 80%; mp 260°-262° C. 1H NMR (DMSO-~) o: 
pyridinemethylene)-1-[2-(trimethylammonium)acetyl] 45 8.80 (s, lH). 7.f:IJ (d. 2H). 7.50 (s. lH). 7.78 (d. 2H). 
hydrazine dichloride. and 2-( l.6-dimethyl-3-hydroxy-2- 4.39--4.30 (bs, 2H); High resolution MS, m/e (M+) calcd. for 
pyridinemethylene)-1-(2-(4-chloro-1-pyridinium)acetyl) ~HsN30Cl 185.035. Found: 185.035. Found: 185.035. 
hydrazine dichloride can be made by the same procedure 2,6-Dimethylphenylsemicarbazide. This compound was 
replacing 3-hydroxy-2-pyridine carbaldehyde with prepared by the general procedure and collected as a white 
3-hydroxy-6-methyl-2-pyridine carbaldehyde. 50 solid; yield 77%; mp 270-272° C. 1H NMR (DMSO-~) o: 
EXAMPLE 
19 
7.85 (s, lH). 7.24 (s. lH). 7.03 (m. 3H). 4.40-4.33 (bs, 2H). 
2.18 (s, 6H); High resolution MS. m/e (~ calcd. for 
Preparation of O-Benzyl-N-(l-benzyl-3-hydroxy-2- CgH13N30 179.105. Found: 179.106. 
pyridinemethylene) hydroxylamine bromide. 2,6-Difiuorophenylsemicarbazide. This compound was 
O-Benzyl-N-(3-hydroxy-2-pyridinemethylene) hydroxy- 55 prepared by the general procedure except that the product 
lamine. 0-Benzyl hydroxylamine (10.4 g. 65 mmol) was was washed with 50 mL HlO. 50 mL ethyl acetate, and 50 
added to a solution of NaOH (2.6 g, 65 mmol) in 66 mL of mL ether, and collected as a white solid· yield 73%· mp 
H20/EtOH 1:1. 3-Hydroxy-2-pyridine carbaldehyde (8.0 g, 156°-158° C. 1H NMR (DMSO-d6) o: 8.14 (s, lH). 7.S5 (s, 
65. mmol) was. added to this solution and the resulting lH), 7.28 (m. lH), 7.11 (dd. 2H). 4.42--4.39 (bs. 2H); 
1D1Xture was stirred at room temperature 3 h. The white 60 FABMS m/e (M+lt 188. 
precipitate was then filtered and dried to yield 13.3 g (90%) 2-Ethoxyphenylsemicarbazide. This compound was pre-
of pure product, m.p. 64°-65° C. 1H NMR (CDC13) o: 9.72 pared by the general procedure and collected as a white 
(s, lH); 8.37 (s, lH); 8.13 (d of d. J=2Hz. J=4 Hz, lH); 7.33 solid; yield 93%; mp 133°-135° C. 1H NMR (DMSO-~) o: 
(m. 7H); 5.17 (s, 2H). 9.00-8.90 (bs, lH), 8.18 (m. lH), 7.63 (s, lH), 6.97 (m. lH), 
O-Benzyl-4-(1-benzyl-3-hydroxy-2-pyridinemethylene) 65 6.87 (m. 2H); 4.47--4.51(bs,2H), 4.12 (q, 2H), 1.38 (t, 3H); 
hydroxylamine bromide. Benzyl bromide (0.78 mL. 6.6 MS m/e ~) 195.1. Anal. calcd. for CgH13N30 2: C, 55.37; 
mmol) was added to a solution of O-benzyl-N-(3-hydroxy- H. 6.71; N, 21.52. Found: C, 55.38; H. 6.74; N, 21.47. 
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3-Nitrophenylsemicarbazide. This compound was pre- general procedure. The product was a brown solid; yield 
pared by the general procedure and collected as a yellow 58%; mp 197°-198° C. 1H NMR (DMSO-dJ o:ll.14 (s. 
solid; yield 59%; mp 136°-138° C. 1H NMR (DMSO-dc;) o: lH). 10.70-10.90 (bs. lH), 8.73 (s. lH). 8.27 (s. lH). 8.15 
9.21 (s. lH). 8.68 (s. lH). 7.89 (d. lH). 7.76 (m. 2H). 7.5 (m. (m. 2H). 7.32 (m. 2H). 7.05 (m. 3H). 4.13 (q, 2H). 1.45 (t. 
lH). 4.44-4.38 (bs. 2H); High resolution. MS m/e (M+) 5 3H); MS m/e (M+) 300.2. 
calcd. for ~H803N4 196.059. Found: 196.058. l-(3-Hydroxy-2-pyridylmethylene)-2-(4-tlurophenyl) 
4-Bromophenylsemicarbazide. This compound was pre- diazane. This compound was prepared by the general pro-
pared by the general procedure and collected as a white cedure. The product was a red solid; yield 76%; mp 
solid; yield 85%; mp 256°-259° C. 1H NMR (DMSO-~) o: 260°-264° C. (dee). 1H NMR (DMSO-~) o: 12.15-12.23 
8.78 (s, lH). 7.48-7.55 (d and bs, 3H). 7.40 (d, 2H). 10 (bs, lH). 12.07 (s. lH). 8.24 (d, lH), 8.12 (m. 2H). 7.66 (m. 
4.40-4.37 (bs, 2H); High resolution. MS m/e (W) calcd. for lH), 7 .62 (m. 2H). 7 .20 (m. 2H); MS m/e (W) 231.1. 
~H8N30Br 228.985. Found: 228.984. 1-(3-Hy droxy-2-pyridylmethyle ne )-4-(3-
1-(3-Hydroxy-2-pyridylmethylene)-4-(2.6- nitrophenyldiaz.anecarboxamide. This compound was pre-
dichlorophenyl) diazanecarboxamide (General Procedure pared by the general procedure. The product was a brown 
for the Condensation of Phenylsemicarbazides or Phenyl- 15 solid; yield 73%; mp 223°-225° C. 1H NMR (DMSO-dc;) o: 
hydrazides with Pyridine Aldehydes). A solution of 500 mg 11.11 (s, lH), 10.50-10.30 (bs. lH), 9.68 (s. lH). 8.62 (s. 
(4 mmol) of 3-hydroxy-2-pyridinecarboxaldehyde and 876 lH). 8.33 (s. lH). 8.20 (s. lH). 8.19 (d, lH). 7.97 (d, lH). 
mg (4 mmol) of2,6-dichlorophenylsemicarbazide in 20 mL 7.88 (m. lH). 7.61 (m. 2H); MS m/e (~ 300.1. 
of ethanol was refluxed for 1 h. The mixture was cooled. l-(3-Hydroxy-2-pyridylmethylene)-4-(4-bromophenyl) 
filtered by gravity. washed several times with 25 mL por- 20 diazanecarboxamide. This compound was prepared by the 
tions of ethanol. and air dried. The product was obtained as general procedure. The product was a brown solid; yield 
a brown solid; yield 1.20 g (95%); mp 262°-265° C. 1H 91%; mp 274° C. (dee). 1H NMR (DMSO-dc;) o: 10.95 (s, 
NMR (DMSO-d6) o: 11.05 (s, lH). 10.28-10.10 (bs. lH). lH). 10.45-10.65 (bs, lH). 9.29 (s, lH), 8.30 (s. lH). 8.19 
9.05 (s. lH). 8.30 (s. lH). 8.18 (d, lH), 7.58 (dd, 2H). 7.53 (d. lH). 7.50 (dd. 4H), 7.33 (m. 2H); MS m/e (M+1r 335. 
(m, 3H); MS rn/e (W) 324.1. 25 1-(3-(N.N-Dimethylcarbamoyloxy)-2-pyridylmethylene) 
The products of these reactions can be made in purer -4-(2.6-dichlorophenyl) diazanecarboxamide (General Pro-
forms by the addition of 1 drop of H2S04 to the reaction cedure for the Synthesis of Pyridine Carbamates). The 
mixture before refluxing as in the case of 1-(3-hydroxy-2- synthesis of pyridine carbamates was carried out according 
p~dy~ylene)-4-(2,6-dimethylphenyl) diazanecarboxa- 30 to procedures by Powers et at. (1993). A solution of 500 mg IDlde gtven below. (1.5 mmol) of 1-(3-hydroxy-2-pyridylmethylene)-4-(2,6-
1-( 3- Hydroxy- 2-py rid y lme th yle ne )-4-( 4- dichlorophenyl) diaz.anecarboxamide and 1.65 g (15 mmol) 
methoxyphenyl). diazanecarboxamide. This compound was of dimethylcarbamyl chloride in 15 mL of pyridine was 
prepared by the general procedure except that the crude allowed to stir for 14 h at room temperature. The reaction 
product was dissolved in hot methanol. concentrated in 35 mixture was poured over crashed ice and the white solid 
vacuo, and collected as a brown solid; yield 47%; mp which formed was washed thoroughly with water to remove 
183°-185° C. 1H NMR (DMSO-~+D20) o: 9.05 (s. lH), the excess pyridine; yield 280 mg (47%); mp 225°-229° C. 
8.44 (s. lH). 8.20 (s, lH). 7.5 (d. 2H), 7.4 (s, lH). 7.3 (d. 1H NMR (DMSO-~) o: 11.17 (s, lH), 8.53 (d, lH), 8.16 (s, 
2H). 6.8 (d. 2H). 3.7 (s. 3H); FABMS m/e (M+lt 287. lH). 8.12 (s, lH), 7.7 (d, lH). 7.5 (d, 2H). 7.4 (dd, lH), 7.3 
1-(3-Hydroxy-2-pyridylmethylene)-2-(2.4.6, 40 (t. lH). 3.0 (s. 3H), 2.7 (s, 3H); MS m/e (W) 395.2. 
trichlorophenyl)diazane. This compound was prepared by 1-(3-(N.N-Dimethylcarbamoyloxy)-2-pyridylmethylene) 
the general procedure. After cooling the product was -4-(4-methoxyphenyl)diazinecarboxamide. This compound 
obtained as crispy white needles; yield 84%; mp 185°-187° was prepared by the general procedure and collected as a 
C. 1HNMR(DMSO-~)o: 10.59(s.1H), 10.20(s, lH).8.36 brown solid; yield 57%; mp 146°-152 ° C. 1H NMR 
(s. lH), 8.14 (d. lH), 7.7 (s. lH), 7.24 (m. 2H); MS m/e (W) 45 (DMS0-<4) o: 10.91 (s, lH), 8.52 (d. lH). 8.34 (s, lH). 8.09 
315.1. (s. lH). 7.67 (d, lH), 7.46 (m., 3H), 3.73 (s, 3H). 3.08 (s. 3H). 
1-(3-Hydroxy-2-pyridylmethylene)-4-(4-chlorophenyl) 2.85 (s, 3H); MS m/e (M +1)+ 358. 
diazanecarboxamide. This compound was prepared by the 1-(3-(N,N-Dimethylcarbamoyloxy)-2-pyridylmethylene) 
general procedure. The product was a brown solid; yield -2-(2,4,6.trichlorophenyl)diazine. This compound was pre-
33%; mp 216°-218° C. 1H NMR (DMSO-~) 5:10.96 (s, 50 pared by the general procedure. The crude product recrys-
lH). 10.60-10.50 (bs. lH). 9.28 (s. lH), 8.29 (s. lH), 8.17 tallizes from ethanol or methanol into a fluffy yellow solid; 
(d, lH). 7.62 (dd. 2H), 7.2 (m. 4H); MS m/e (M~ 290.1. yield 58%; mp 145°-147° C. 1H NMR (DMSO-d6) o: 8.62 
l-(3-Hydroxy-2-pyridylmethylene)-4-(2.6- (d. lH). 7.84 (d. lH). 7.68 (s. 2H); 7.67 (dd. lH). 7.47 (s, 
dimethylphenyl) diazanecarboxamide. This compound was lH), 3.14 (s. 3H), 2.95 (s, 3H); MS m/e (M +lr387. 
prepared by the general procedure. The product was a brown 55 1-(3-(N.N-Dimethy lcarbamoyloxy )-2-pyridylmethylene) 
solid; yield 87%; mp 243°-248° C. 1H NMR (DMSO-~) o: -4-(4-chlorophenyl)diazanecarboxamide. This compound 
10.81 (s, lH). 10.40-10.30 (bs. lH), 8.53 (s. lH), 8.27 (s. was prepared by the general procedure except that the crude 
lH). 8.16 (d, lH). 7.33 (m., 2H), 7.10 (s, 3H), 2.20 (s. 6H); product was dissolved in hot ethyl acetate. concentrated in 
FABMS m/e (M+lt 285. vacuo and collected as a brown solid; yield 36%; mp 
1-(3-Hydroxy-2-pyridylmethylene)-4-(2.6-diftuoro] 60 170°-175° C. 1H NMR (DMSO-~) o: 11.02 (s, lH). 8.82 (s, 
phenyl) diazanecarboxamide. This compound was prepared lH), 8.52 (d, lH), 8.12 (s. lH). 7.68 (m. 3H). 7.47 (dd. lH). 
by the general procedure. The product was a brown solid; 7.37 (dd, 2H). 3.14 (s, 3H). 2.96 (s. 3H); MS m/e (M +lt 
yield 56%; mp 238°-240° C. 1H NMR (DMSO-~) o: 11.06 362. 
(s. lH). 10.05-10.15 (bs. lH). 8.88 (s. lH). 8.31 (s. lH). 1-(3-(N.N-Dimethylcarbamoyloxy)-2-pyridylmethylene) 
8.18 (s. lH), 7.35 (m. 3H). 7.18 (m. 2H); MS m/e (M+) 292. 65 -4-(2.6-dimethylphenyl)diazanecarboxamide. This com-
l-(3-Hydroxy-2-pyridylmethylene)-4-(2-ethoxyphenyl) pound was prepared by the general procedure. The product 
diazanecarboxamide. This compound was prepared by the was a brown solid; yield 78%; mp 215°-217° C. 1H NMR 
5,726,314 
53 54 
(DMSO-~) o: 10.97 (s, lH), 8.52 (d, lH), 8.10 (s, lH), 7.73 ide Iodide. This compound was prepared by the general 
(s, lH), 7.66(d, 1H), 7.46(m. lH), 7.11(s.3H), 3.00(s, 3H), procedure. The crude methiodide was precipitated by the 
2.71 (s, 3H); MS m/e (~ 355.2. addition of acetone, recrystallized from acetonitrile, and 
1-(3-(N,N-Dimethylcarbamoyloxy)-2-pyridylmethylene) collected as orange prisms; yield 56%; mp 192°-194° C. 1H 
-4-(2,6-difiuorophenyl) diazanecarboxamide. This com- s NMR (DMSO:~) o: 11.58 (s, lH), 9.1 ( d. lH), 8. 79 (s. lH), 
pound was prepared by the general procedure. The product 8.55 (d; lH), 8.18 (m. 2H), 7.46 (d. 2H), 6.89 (d, 2H). 4.51 
is a white solid; yield 70%; mp 166°-169° C. 1H NMR (s, 3H). 3.73 (s, 3H), 3.09 (s. 3H), 2.92 (s, 3H); FABMS m/e 
(DMSO-~) o: 11.17 (s, lH), 8.53 (d, lH), 8.13 (d, 2H), 7.70 (M+:l 372.2. Anal. calcd. for C18H22N50 4I: C, 43.29; H, (d. lH), 7.49 (m, lH). 7.40 (m. lH). 7.21 (m, 2H), 3.07 (s, 4.44; N, 14.02. Found: c. 43.16; H, 4.47; N. 14.03. 
3H). 2.84 (s. 3H); MS rn/e (M+) 363.1. 10 
1-(3-(N ,N-Dimethylcarbamoyloxy)-2-pyridylmethylene) 
-4-(2-ethoxyphenyl) diazanecarboxamide. This compound 
was prepared by the general procedure. The product is a 
white solid; yield 70%; mp 166°-169° C. 1H NMR (DMSO-
~) o: 11.15 (s, lH), 8.89 (s, lH), 8.50 (d, lH), 8.13 (m, 2H), 
7.70 (m. lH). 7.50(m.1H), 7.00(m. 3H).4.17 (m. 2H), 3.14 
(s, 3H), 2.96 (s, 3H), 1.43 (m. 3H); MS m/e (M+tr 372. 
1-(3-(N ,N-Dimethylcarbamoyloxy )-2-pyridylmethy lene) 
-2-(4-fluorophenyl) diazane. This compound was prepared 
by the general procedure except that the crude material was 
washed three times with 50 mL of water and 50 mL of ether, 
and then dissolved in acetone. The acetone was concentrated 
in vacuo until the product crystallized in the form of brown 
prisms; yield 24%; mp 165°-167° C. 1H NMR (DMSO-d6) 
EXAMPLE22 
1-( 1-Methyl-3-(N ,N-dimethylcarbamoyloxy)-2-
pyridylmethylene)-2-(2.4.6.trichlorophenyl) diazane Iodide. 
15 This compound was prepared by the general procedure. The 
crude methiodide was precipitated by the addition of 
acetone. recrystallized from ethanol, and collected as yellow 
needles; yield 90%; mp 198°-200° C. 1H NMR (DMSO-~) 
o: 11.22 (s. lH). 8.87 (d. lH). 8.41 (d, lH). 8.39 (s, lH). 7.94 
20 (dd. lH). 7.85 (s. 2H). 4.3 (s, 3H), 2.89 (s. 3H). 2.83 (s, 3H); 
FABMS rn/e (W) 401. Anal calcd. for C16H16N40 2Cl31: C. 
36.28; H, 3.04; N, 10.57; Cl. 20.08; I. 23.96. Found: C. 
36.35; H, 3.07; N. 10.53; Cl. 20.04; L 29.91. 
o: 10.63 (s. lH), 8.45 (d. lH). 7.91 (s. lH), 7.59(d, lH), 7.33 
(m, lH), 7.13 (m. 2H). 7.01(m.2H), 3.10 (s, 3H), 2.94 (s, 25 EXAMPLE23 
3H); MS m/e (M +lr 303. l-(1-Methyl-3-(N,N-dimethylcarbamoyloxy)-2-
1-(3-(N .N-Dimethylcarbamoyloxy)-2-pyridylmethylene) pyridylmethylene)-4-( 4-chlorophenyl) diazanecarboxamide 
-4-(3-nitrophenyl), diazanecarboxamide. This compound Iodide. This compound was prepared by the general proce-
was prepared by the general procedure. The product was . . . 
washed thoroughly with 100 mL of ether and 100 mL of 30 dure ex~ that the crude methiodide was recrys~zed 
water and collected as a white solid; yield 90%; mp 1950 C. from boiling ~than,?l an~ collected as brown needles; yield 
1H NMR (DMSO-~) o: 11.21 (s, lH), 9.47 (s, lH), 8.68 (s, 75%; mp 181 -183 C. H NMR (DMSO-~) o: 10.63 (s, 
lH), 8.52 (d. lH), 8.17 (s, lH), 8.03 (d. lH), 7.89 (d. lH), lH), 8.04 (s, lH), 7.98 (d, lH), 7.55 (d, lH), 7.11(m.2H), 
7.59 (m, lH), 7.50 (m, lH), 3.11 (s, 3H), 2.90 (s, 3H); 6.57 (d. 2H). 6.34 (d. 2H), 2.02 (s, 3H), 1.87 (s, 3H). 1.45 
FABMS m/e (M+W 373. 
35 
(s, 3H); FABMS m/e (M+) 376. Anal. calcd. for 
1-(3-(N,N-Dimethylcarbamoyloxy)-2-pyridylmethylene) C11H1~s03ClI: C. 40.53; H, 3.80; N, 13.90; Cl. 17.04; L 
-4-( 4-bromophenyl) diazanecarboxamide. This compound 25.20. Found: C, 40.64: H, 3.82; N, 13.91; Cl. 7 .01; L 25.09. 
EXAMPLE24 
was prepared by the general procedure and collected as a 
white solid; yield 89%; mp 176°-179° C. 1H NMR (DMSO-
~) o: 11.03 (s, lH), 8.88 (s, lH). 8.52 (d, lH), 8.13 (s, lH), 
7.49 (m. 2H), 7.46 (m. 4H), 3.14 (s, 3H), 2.88 (s. 3H); MS 40 1-(1-Methyl-3-(N,N-dimethylcarbamoyloxy)-2-
m/e (~ 405. pyridylmethylene)-4-(2,6-dimethylphenyl) diazanecarboxa-
EXAMPLE20 
mide Iodide. This compound was prepared by the general 
procedure except that the crude methiodide was precipitated 
1-(1-Methyl-3-(N.N-dimethylcarbamoyloxy)-2- by the addition of 20 mL of ethyl acetate and 100 mL of 
pyridylmethylene)-4-(2,6-dichlorophenyl) diazanecarboxa- 45 water to the crude residue. The product was recrystallized 
mide Iodide (General Procedure for the Synthesis of Pyri- from methanol and collected as orange prisms; yield 23%; 
dine Methiodides). The synthesis of pyridine methiodides mp 214°-217° C. 1H NMR (DMSO-~) o: 11.71 (s. lH), 
wascarriedaccordingtothefollowingprocedure.Asolution 8.99 (d. lH). 8.58 (d, lH). 8.40 (s, lH), 8.31 (s, lH). 8.23 
of 3 g (9 mmol) of 1-(3-(N,N-Dimethylcarbamoyloxy)-2- (m. lH). 7.12 (s, 3H), 4.54 (s, 3H). 3.12 (s. 3H). 2.93 (s. 3H), 
pyridylmethylene)-4-(2,6-dichlorophenyl) so 2.19 (s, 6H); FABMS m/e (M+) 370. Anal. calcd. for 
diazanecarboxamide, 6.39 g (45 mmol) ofiodomethane. and C1gll24N50 3LI2 : C, 30.36; H, 3.22; N, 9.32. Found: C. 
25 mL of DMF were sealed in a glass pressure tube and 30.68; H. 3.15; N. 9.36. 
heated for 36 h at 65° C. The crude methiodide was isolated 
by evaporation of the DMF under reduced pressure and 
trituration of the residue with a 2:1 mixture of acetone and 55 
EXAMPIE25 
ether. The crude product was recrystallized from ethanol and 1-( 1-Methyl-3-(N .N-dimethylcarbamoyloxy)-2-
collected as orange prisms; yield 0.69 g (19%); mp pyridylmethylene)-4-(2.6-difiuorophenyl) diazanecarboxa-
1320-1400 c. 1H NMR (DMSO-d6) O: 11.78 (s, lH). 9.08 (cl, mide Iodide. This compound was prepared by the general 
lH). 8.86 (s, lH), 8.58 (d, lH), 8.24 (s, lH); 8.15 (dd, lH). procedure except that ice was added to the residue to 
7.60 (d. 2H), 7.50 (dd, lH), 4.54 (s, 3H). 3.13 (s. 3H); 2.95 60 precipitate the crude methiodide. The product was recrys-
(s, 3H); FABMS m/e (M+) 410. Anal. calcd. for tallizedfromethanolandcollectedasaredsolid;yield21%; 
C17H18N50 3Cl2LH20: C. 36.71; H, 3.62; N, 12.59. Found: mp 115°-118° C. 
1H NMR (DMSO-d6) o: 11.79 (s. lH). 
C, 36.67; H. 3.62; N. 12.51. 9.01 (cl, lH). 8.68 (s, lH). 8.60 (d, lH), 8.34 (s. lH). 8.22 
EXAMPLE21 
1-( 1-Methyl-3-(N .N-dimethylcarbamoyloxy)-2-
pyridylmethylene)-4-(4-methoxyphenyl) diazanecarboxam-
(m. lH), 7.50 (m. lH). 7.22 (m, 2H), 4.5 (s, 3H). 3.12 (s. 
65 3H). 2.95 (s, 3H); FABMS m/e (~ 378. Anal calcd. for 
C17H 18N50 3IF2.HI: C, 32.24; H, 3.02; N, 11.06. Found: C, 
32.07; H. 2.88; N. 10.83. 
5,726,314 
55 
EXAMPLE26 
1-( 1-Methyl-3-(N .N-dimethylcarbamoyloxy)-2-
pyridylmethylene )-4-(2-ethoxyphenyl) diazanecaiboxamide 
Iodide. This compound was prepared by the general proce- 5 
dure except that the crude methiodide was precipitated by 
the addition of ice to the residue. The product was then 
recrystallized from methanol and collected as yellow prisms; 
yield 91%;mp194°-196° C. 1H NMR (DMSO-~) o: 11.86 
(s. lH). 9.03 (d, lH), 8.61 (d. lH). 8.49 (s, lH). 8.23 (s. lH). 10 
8.13 (m. 2H). 7.05 (m. 2H). 6.98 (m. lH). 4.52 (s, 3H). 4.13 
(q. 2H). 3.07 (s, 3H). 2.92 (s, 3H). 1:35 (t. 3H); FABM S m/e 
(M+) 386. Anal. calcd. for C19H24N50 4I: C. 42.46; H. 4.50; 
N. 13.03. Found: C. 42.64; H. 4.59; N; 13.03. 
EXAMPLE27 
15 
1-( 1-Methyl-3-(N .N-dimethylcarbamoyloxy)-2-
pyridylmethylene )-2-( 4-fl.urophenyl)diazane Iodide. This 
compound was prepared by the general procedure except 
that the crude methiodide was precipitated by ice. The 20 
product was then recrystallized from ethanol and collected 
as red prisms; yield, 94%; mp 265°-267° C. 1H NMR 
(DMSO-~) o: 11.87 (s. lH), 8.92 (d, lH), 8.40 (d. lH). 8.04 
(s, lH), 7.95 (dd. lH). 7.21 (m. 4H), 4.42 (s. 3H). 3.06 (s. 
3H). 2.98 (s. 3H); FABMS m/e (M+) 317. Anal calcd. for 25 
C 16H180;iN4Fl.0.5H20: C. 42.39; H. 4.22; N, 12.36. Found: 
C. 42.25; H. 4.22; N. 12.32. 
EXAMPLE28 
30 
1-( 1-Methyl-B-(N .N-dimethylcarbamoyloxy)-2-
pyridylmethylene)-4-(3-nitrophenyl) diazanecarboxamide 
Iodide. This compound was prepared by the general proce-
dure except that ice was used to precipitate the crude 
methiodide. The crude product was then dissolved in hot 35 
acetone. filtered and refrigerated. The analytically pure 
product was collected as a yellow solid; yield 25%; mp 
200°-202° C. 1H NMR (DMSO-~) o: 11.84 (s. lH), 9.52 (s, 
lH). 9.07 (d, lH). 8.64 (d ands, 2H). 8.22 (m. 2H). 8.05 (d, 
lH). 7.94 (d, lH). 7.63 (dd lH). 4.54 (s. 3H), 3.09 (s. 3H). 40 
2.94 (s. 3H); FABMS m/e 387. Anal. calcd for 
C17H190 5NJ:: C. 39.70; H. 3.72; N. 16.34. Found: C. 39.92; 
H. 3.80; N, 16.13. 
EXAMPLE29 45 
1-( 1-Methyl-3-(N .N-dimethylcarbamoyloxy)-2-
pyridylmethylene )4-( 4-bromophenyl) diazanecarboxamide 
Iodide. This compound was prepared by the general proce-
dure except that ice was added to the residue to precipitate 50 
the crude methiodide. The crude product was recrystallized 
from hot methanol and collected red prisms; yield 86%; mp 
202° C. 1H NMR (DMSO-d6) o: 11.70 (s, lH). 9.05 (s, lH). 
9.03 (d. lH), 8.62 (d. lH). 8.15 (m. 2H). 7.58 (m. 4H). 4.52 
(s. 3H). 3.16 (s, 3H), 2.93 (s, 3H); FABMS m/e (M+) 420. 55 
Anal calcd for C17H 1~50~rI: C, 37.24; H, 3.49; N. 12.77. 
Found: C, 37.42; H. 3.59; 12.60. 
TABLE I 
60 
Kinetic Constants for the Reversible Inhibition of electric Eel and Human 
compd 
la 
lb 
Erythrocyte Acetyk:holinesterase. 
K1 (eel) 
µM 
40 
500 
K1 (hwnan) IC50 (eel) IC50 (hwnan) 
µM µM µM 
100 
>600 
100 175 65 
56 
TABLE I-continued 
Kinetic Constants for the ReveISible Inhibition of electric Eel and Human 
Erythrocyte Acetvk:IDlinesterase. 
K1 (eel) 
compd µM 
le 
ld 
le 
1f 
3a 
3b 30, 3401' 
4b 85 
5a 
5b 
10 
c 
K1 (hwnan) IC50 (eel) 
µM µM 
m· 
400 
400 
m• 
325 
100 
20 
c 40 
•NI, no inhibition at cow:entrations up to 1 mM. 
IC50 (hwnan) 
µM 
m• 
>500 
>500 
m• 
300 
240 
40 
"two distinct K1 's with eel ACbE, multiple binding with both enzymes. 
0 Multiple binding observed, only IC50 values detennined. 
TABLE II 
Kinetic Constants for the Irreversible Inhibition of Electric Eel and Human 
Erythrocyte Acetyk:IDlinesterase. 
compd 
2a 
2b 
2c 
4a 
Pyrb 
Phy• 
1700 68000 
870 1100 
5000 >110000 
25 2200 
580° 13000 
1400.)" 19000 
K1 (eel) 
(µM) 
NT' 
NT' 
NT' 
100 
NT' 
NT' 
•NT, not tested (inhibition half-life is too short to measure accmately); 
"I>yrioostigmine; 
0 K..J[I] = 843 M-1.-1 (Forsberg, A. and Puu, G., Eur. J. Biocbem. 1984, 140, 
153.); 
•Physosti.gmine; 
"k,,.,/[I] = 18500 ~1s-• (Forsberg, A. and Puu, G., Eur. J. Biochem. 1984, 
140, 153.). 
TABLE ID 
In Vivo Evaluation of Pyridiniwn Derivatives as Intramuscular 
Pretreatment Agents Against GD in Mice. 
LD50 time• doseb 
compd (mmoVkg) (min) (mmollkg) 
la 
lb 
ld 
le 
1f 
lg 
2a 
2b 
2c 
2d 
3b 
3c 
3d 
4a 
4b 
4b 
180 
>880 
>320 
>760 
>610 
>514 
0.5 
22 
84 
600 
>40 
>560 
>430 
>1240 
42 
15/60 3.~5 
15/60 22 
15/60 9.6 
15/60 320/81 
15/60 31on1 
15/60 16'260 
15/60 0.009--0.14 
15 0.30 
1.4 
5.4 
(£1 0.30-5.4 
15/60 0.005-0.11 
15/(£1 9.0 
37 
150 
15/60 1.3/5.2 
15/(£1 0.017-0.28 
15/60 0.013-0.215 
15/60 0.2 
0.6 
2.3 
15 0.65 
2.7 
11 
(£1 0.65-11 
% survival 
10-20 
0110 
10/20 
40/10 
30120 
10/20 
80/90 
90 
60 
30 
60-70 
50-70 
90190 
90/70 
50/0 
01'1D 
40-70/30-40 
20-40/10-30 
50/90 
80/100 
80/80 
90 
90 
40 
70-80 
5,726,314 
57 58 
TABLE ill-continued TABLE VI 
In Vivo Evaluation of Pyridinium Derivatives as Intramuscular 
Pretreatment Agents Against GD in Mice. 
5 
In Vivo Evaluation of Pyridinium Derivatives as Reactivatois Against 
GA in Mice. 
LD50 time• doseb LDso dose 
compd (mmol/kg) (min) (mmollkg) % survival compel (nunol/kg) (mmol/kg) % survival• 
Sa >670 15160 18-290 70-100/20-70 le >1970 30 0 
Sb 380 15/60 0.6 40/20 1f 2100 33 0 
24 100/30 10 lg >SlO 16 0 
96 100/100 2a 0.5 0.009 30 
2c 84 o.oos 20 
"Compounds were tested at two different time intervals to allow for differ- 4a 9.6 0.60 20 
ences in bioavailability; 4b 670 2.70 30 
"Three different ooses were tested, only one oose is recorded fur inactive 5a >670 18 10 
compounds. 15 73 80 
290 90 
5b 380 6 10 
TABLE IV 24 0 
96 80 
In Vivo Evaluation of Pyridinium Derivatives as Oral Pretreatmenl Agents 
Agaimt GD in Mice. 20 "Three different ooses were tested, only one dose is recorded for inactive 
compouruls. 
LD"° time• ooseb 
compd (mmollkg) (min) (mmollkg) % survival What is claimed is: 
lb 3600 30/120 60 3CV70 1. A compound of the group consisting of the formulas: 
le >3200 30/120 200 CY50 
25 2a 220 30/120 3.4 9CY80 
2b 490 30/120 120 9CY100 
2c 140 30/120 2.2 lOG'lOO 
4b 670 30/120 10 7CY100 
5a 2900 30/120 730 4CY50 
xlfu 
Ne CH=NN'R5Rts 
"Compounds were tested at two different time intervals to allow for differ- 30 
I 
z 
ences in bioavailability; 
"Three different doses were tested, only one oose is recorded for inactive and 
compounds. 
TABLE V 35 
JOXX 
Jn Vivo Evaluation of Pyridinium Derivatives as Reactivators Against 
GD in Mice. 
B Ne CH=NN'R5Rts 
I 
z 
LD50 dose0 
__ com __ pd ____ <mmo--l/k-g) __ <mm_o_l/kg_) ____ %_surv_i_val__ 40 and any counterion to make pharmaceutically acceptable 
la 
lb 
ld 
le 
lf 
lg 
2a 
2b 
2c 
3a 
3b 
3c 
3d 
4a 
4b 
Sa 
5b 
2-PAMCI 
JD-6 
180 2.8 20 salts, wherein 
>880 S.6 20 
>320 40 20 Rs is selected from the group consisting of 
>760 20 o pentafluorophenyl, phenyl monosubstituted with K. 
~!~ :; g 4S phenyl disubstituted with K. phenyl trisubstituted with 
o.s o.~.14 30-50 K. and naphthyl. 
22 o.33 20 wherein ~ is selected from the group consisting of H. 1.4 70 
84 
>1100 
>40 
>560 
>430 
9.6 
42 
>670 
380 
853 
4500 
5.4 60 CH1~ alkyl, phenyl, pentafluorophenyl, phenyl mono. 
1.3 20 
50 
di, or trisubstituted with K. CH1-6 alkyl with an 27• 50 
uo" 90 attached phenyl group, and C1-6 alkyl with an attached 
430b 90 phenyl group mono, di, or trisubstituted with K. 
~-8 2g wherein K is selected from the group consisting of 
430 10 halogen. COOH, OH, CN, N02 • NH2, C1-6 alkyl. C1~ 
1.3 10 ss fluorinated alkyl. C1~ alkoxy, C1~ alkyl-0-CO-, g:;~s ~ C1~ alkyl-0-CO-NH-, C1~ alkyl-NH--C0-
0.2-2.3 0-50 NH-, C1-6 alkyl-NH--C0-0-, C1-6 alkyl-
0.65-11 30-50 NH-CO-, and (C1-6 alkylhN--C0-18-290 70-90 
6 20 wherein X is selected from the group consisting of OH. 
24 40 
60 C1-6 alkyl-NH-C0-0-, (C 1_ 6 alkylh-N-59; ~ C0-0-, C1-6 fluoroalkyl-NH--C0-0-, and 
280-1125 90-100 (C1~ fluoroalkylh-NH--C~. 
"Three different ooses were tested, only one dose is recorded fur inactive 
compounds; 65 
wherein B is selected from the group consisting of H, and 
c1~ alkyl. 
badjWJCt efficacy test, sec text fur details. 
* * * * * 
